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ABSTRACT 
 The SRC gene encodes pp60c-Src, a 60 kDa non-receptor tyrosine kinase that is 
frequently activated and/or overexpressed in many cancers including colon cancer. In a 
subset of colon cancer cell lines, it has been shown, that the overexpression of c-Src can 
be explained, in part, by the transcriptional activation of the SRC gene. As a result, the 
general goal of this thesis was to further characterize how SRC is transcriptionally 
regulated in human cancer cell lines. Two highly dissimilar promoters, the 
housekeeping-like SRC1A promoter, as well as the HIF-1α regulated tissue-specific 
SRC1α promoter, regulate SRC expression. hnRNP K and the Sp family of factors 
regulate the SRC1A promoter; however, the true impact of Sp3 on SRC1A activity was 
not understood. In this thesis, a comprehensive analysis of the effect of Sp3 on SRC1A 
activity was performed. Physiologically, Sp3 exists as four translational isoforms that, 
in part, dictate the activation potential of Sp3. In general, the longer forms of Sp3 were 
modest transcriptional activators of the SRC1A promoter whereas the shorter forms 
were unable to activate the SRC1A promoter. An analysis of all Sp3 isoforms identified 
that the shorter Sp3 isoforms could be converted into transcriptional activators of 
SRC1A if the SUMOylation of a critical lysine residue within the inhibitory domain 
was prevented. Conversely, SUMOylation of the same isoform had little effect on the 
activation potential of the longer Sp3 isoforms at the SRC1A promoter. These results 
suggest that transcriptional activation by Sp3 is promoter context-, isoform- and 
modification-dependent. 
 SRC is transcriptionally repressed by histone deacetylase inhibitors (HDIs) and 
despite unsuccessful studies attempting to identify HDI-responsive elements within the 
SRC promoter regions none could be identified. This finding also suggests that histone 
deacetylases (HDACs) may be required for SRC expression. Historically, it was 
believed that HDIs act at the histone level to alter chromatin dynamics through the 
inactivation of HDACs to result in histone hyperacetylation and increased 
transcriptional activation. As such, a systematic investigation of the changes in histone 
H3 and H4 acetylation status at the transcriptionally repressed SRC promoter regions 
and the transcriptionally activated p21WAF1 promoter region was performed. The 
p21WAF1 promoter was used as control in this study as p21WAF1 is a classical example of 
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a gene transcriptionally activated by HDIs.  Interestingly, similar changes in histone 
acetylation at the p21WAF1 promoter and both SRC promoter regions were observed. 
Upon closer examination of acetylation changes at discreet histone residues, it was 
observed that in the rare case that a particular residue was differentially acetylated upon 
treatment at the promoter regions analyzed, the SRC1α and  p21WAF1 promoter regions 
demonstrated more similar changes in acetylation as compared to SRC1A. Taken 
together, these results suggest that histone acetylation status is not an accurate indicator 
of transcriptional activity following HDI treatment. To further investigate HDI-
mediated SRC repression, RNA Pol. II occupancy at the promoter and regions 
downstream of the promoter were assessed. Despite the continued occupancy of RNA 
Pol. II at the promoter regions, RNA Pol. II was lost from the 3’ UTR upon treatment 
with HDIs. These findings suggest that RNA Pol. II . may be sequestered at the 
promoter regions upon treatment with HDIs possibly as a result of impeded 
transcription initiation and/or elongation. Further analysis of the phosphorylation status 
of RNA Pol. II identified that transcriptional initiation was indeed occurring despite 
HDI treatment; however, productive transcriptional elongation could not be confirmed 
thus suggesting a role for abrogated elongation in HDI mediated SRC repression. 
Complimentary analysis of the effects of HDACs on SRC expression suggested that 
while class I HDACs abrogated SRC expression, class II HDACs were required for the 
maintenance of SRC transcript levels in a promoter-independent fashion. Together, 
these results provide the basis for a model whereby HDIs repress SRC transcriptional 
expression through the inhibition of class II HDAC activity to eventually result in 
curtailed SRC transcriptional elongation.       
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1. REVIEW OF LITERATURE 
1.1. Introduction 
 Eukaryotic transcription is a multifactoral process subject to many levels of 
regulation. The regulation of chromatin, by a host of pleiotropic enzymes, combined 
with the tight regulation of transcriptional initiation, elongation and activation leads to 
the ultimate expression of unique transcripts. The products of the transcripts eventually 
mediate an array of physiological consequences. The expression of SRC, a proto-
oncogene, is subject to regulation by all of these processes. SRC transcriptional 
regulation is of particular significance as the activation and/or overexpression of  
pp60c-Src has been implicated in the development of numerous neoplasms. Furthermore, 
SRC activity is repressed by a potent class of chemotherapeutic agents, histone 
deacetylase inhibitors (HDIs), by an unknown mechanism. Therefore, the general goal 
of this thesis is to investigate the transcriptional regulation of SRC in human cancer 
cells and to determine the mechanism by which SRC is repressed by this 
chemotherapeutic class. The following review will summarize the current literature 
describing transcriptional regulation in a chromatin context, as well as introduce the 
human SRC gene and the cellular effects -mediated by pp60c-Src.    
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1.2. Dynamic Chromatin 
1.2.1. Chromatin Structure  
The organization of the eukaryotic genome has evolved to accommodate the 
packaging of more than one metre of DNA into the narrow confines of the nucleus. 
Furthermore, DNA accessibility is maintained such that, replication, transcription and 
repair occur in a timely fashion (Peterson and Laniel, 2004; Horn and Peterson, 2006). 
To allow such processes to occur in eukaryotes, a unique packaging system evolved 
whereby both the structural and functional requirements of DNA packaging are met 
through a DNA-nucleoprotein complex referred to as chromatin (Horn and Peterson, 
2006).    
Historically, eukaryotic genomes have been categorized into two distinct 
cytological classes based on the degree of chromatin compaction exhibited. Nearly 80 
years ago, Emil Heitz observed a portion of compact chromatin that persisted throughout 
the cell cycle in stained moss samples (Zacharias, 1995). Heitz described this condensed 
chromatin as heterochromatin to contrast with the euchromatin, or “true” chromatin, that 
underwent repeated phases of decondensation throughout the cell cycle (Dillon, 2004). It 
is now well established that euchromatin is gene rich, contains the majority of 
transcribed genes, and replicates early in the cell cycle (Santos-Rosa and Caldas, 2005). 
In contrast, heterochromatin is considered transcriptionally silent, rich in repetitive 
sequences, essential for the formation of chromosomal structures, such as centromeres 
and telomeres, and typically replicates late in the cell cycle (Santos-Rosa and Caldas, 
2005; Horn and Peterson, 2006). 
1.2.1.1. The Nucleosome 
 The fundamental unit of chromatin is the nucleosome core particle (NCP). Each 
NCP subunit is composed of an octamer of highly basic core histone proteins consisting 
of two of each of the histone proteins: H2A, H2B, H3 and H4. The NCP has a molecular 
weight of 210 KDa that also includes 147 bp of DNA looped in 1.7 left-handed 
superhelical turns around the nucleosome core (Arents, et al., 1991, Luger, et al., 1997).
The binding of DNA to the NCP is achieved through the interaction of the histone 
proteins and DNA at fourteen unique sites (Luger and Richmond, 1998). Histone 
proteins are highly conserved and contain a globular C-terminal domain that functions 
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in histone-histone and DNA-histone interactions as well as a critical protruding N-
terminal tail (White, et al., 2001) (Figure 1.1). The N-terminal tail is prone to a variety 
of post-translational modifications, including acetylation, methylation, ubiquitynation, 
SUMOylation and phosphorylation. These modifications are instrumental in multiple 
key protein-protein interactions. Importantly, the interaction of the NCP and DNA can 
also be easily altered through the introduction of modified histone proteins into the 
octamer that differ from the archetypal histone protein described above. These histones 
are known as histone variants and are suggested to have specific roles in DNA damage 
response, gene activation and DNA replication (Kober, et al., 2004; Kush, et al, 2004; 
Tagami, et al., 2004) 
Each NCP is separated by 10-60 bp of DNA that interacts with histone H1 
(Hansen, et al., 1998). Histone H1 is structurally dissimilar to the NCP histone proteins 
as it is composed of unstructured C- and N-terminal domains linked via a globular helix 
domain (Wolffe, 1997). Importantly, both histone H1 and the N-terminal tails of the 
NCP histones are absolutely crucial for the formation of higher order chromatin 
structures (Woodcock and Dimitrov, 2001).  
1.2.1.2. Higher order chromatin structure 
 The interaction of several NCPs, DNA and histone H1s results in the highly 
recognizable “beads on a string” 10 nm fibre. However, this secondary structure is often 
associated and in dynamic equilibrium with the further condensed 30 nm solenoid fibre 
in vitro (McBryant, et al., 2006).  Studies using model systems with histones lacking the 
N-terminal domains have highlighted the critical nature of core histones in 30 nm fibre 
formation (Carruthers and Hansen, 2000). In particular, the histone H4 N-terminal 
domain is key in this process due to interactions between this domain and histones H2A 
and H2B from neighbouring nucleosomes, which aid in chromatin condensation 
(Dorigo, et al., 2004). The 30 nm solenoid fibre is structurally characterized as  
containing 6 nucleosomes per 11nm, which is approximately 6 nucleosomes per turn, 
and has been deemed the primary helix of chromatin (Woodcock and Dimitrov, 2001). 
 There are many models of how chromatin compaction continues after the 
formation of the solenoid and an exhaustive review of all models is beyond the scope of 
this thesis. However, it is worth noting that in all of the models, histone H1 is required  
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Figure 1.1. The nucleosome core particle (NCP). (A) Schematic representation of
a histone octamer. H2A and H2B form dimers that interacts with a H3 and H4
tetramer to form the histone octamer. (B) Several histone octamers connected by DNA
(green). Yellow lines represent protruding amino-terminal tails of histones which are
host to a variety of post-translational modifications (adapted from Hess-Strump,
2005; ).Workman, 2006
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(Daban, 2003; McBryant, et al., 2006). Histone H1 stabilizes oligomeric tertiary 
chromatin complexes, through electrostatic neutralization of linker DNA segments, 
including the formation of the intermediate fibres formed from the looped solenoid 30 
nm fibres (200-300) (Carruthers and Hansen, 2000; Daban, 2003). The coiled chromatid 
is subsequently formed from the intermediate fibre (Daban, 2003). Despite years of 
research, the final steps in the formation of the chromosome are still not well 
understood. However, recent advances utilizing Xenopus eggs and fission yeast have 
identified that chromatin condensation requires the co-operation of many multi-protein 
complexes. One such example is the condensin complex, which implicates ATP-
dependent enzymes in both chromosome condensation and segregation (Hirano, 2000). 
 
1.2.2. ATP--dependent Chromatin Remodeling Enzymes 
 The basic requirements for chromatin structure are outlined above. However, for 
chromatin to be both dynamic and functional a great deal of DNA must be 
compartmentalized and yet necessary genetic information must remain available for 
replication, repair and transcription (Horn and Peterson, 2006).  For this to be achieved, 
euchromatin must be able to decondense to allow repair enzymes, transcription and 
replication factors access to DNA target sequences. ATP--dependent chromatin 
remodelling enzymes are essential in altering and maintaining the properties of 
functional chromatin as they are able to physically eject and re-locate nucleosomes from 
their cognate DNA locations. 
 Eukaryotes have five classes of nucleosomal remodelling enzymes. The classes 
include: the switching/sucrose non-fermenting (SWI/SNF) family, the imitation switch 
(ISWI) family, the inositol biosynthesis 80 containing (INO80) family, the SWI/SNF 
related factor (SWR1) family and the nucleosome remodelling histone deacetylase/ 
chromodomain3 for Mi2alpha/ chromodomain (NURD/Mi-2/CHD) family. These 
enzymes are grouped together by the presence of an ATPase domain and due to their 
role in mobilizing nucleosomes to different locations along the DNA. The remodelling 
enzymes are responsible for the spacing of nucleosomes throughout chromatin 
assembly, as well as allowing transcription factor access to specific sites during 
transcriptional regulation and the regulated access of DNA-repair factors to damaged 
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DNA within the chromatin (Becker and Horz, 2002; Saha, et al., 2006). The three 
classes most pertinent to this thesis will be briefly reviewed.  
 The human SWI/SNF class of chromatin remodellers is involved in a variety of 
essential cellular processes including transcriptional elongation, cellular signalling and 
alternative splicing (Zhao, et al., 1998; Corey, et al., 2003; Batsche, et al., 2006). Aside 
from the ubiquitous ATP-ase domain, the SWI/SNF family contains a unique C-
terminal domain and at least one bromodomain that is (are) capable of recognizing 
acetylated histone residues (Winston and Allis, 1999; Hassan, et al., 2001). The 
presence of the bromodomain, which recognizes acetylated residues, suggests that 
remodellers within the SWI/SNF family function primarily to re-organize nucleosomal 
position to promote transcriptional activation (Martens and Winston, 2003). 
Interestingly, both the SWI/SNF and ISWI family of remodellers re-organize 
nucleosomes in a 3’-5’ direction despite inherent differences in both the mechanism of 
nucleosomal translocation along the DNA strand and the effect of the translocation 
(Saha, et al., 2006). However, the precise mechanisms of the nucleosomal remodelling 
are beyond the scope of this thesis. 
 The ISWI family of nucleosome remodellers contain an ATPase domain and C-
terminal SANT and SLIDE domains. The SANT domain is important for both DNA and 
histone-tail binding, whereas the SLIDE domain exclusively binds DNA. The ISWI 
remodellers are typically associated with transcriptional repression (Goldmark, et al., 
2000), X-chromosome regulation (Deuring, et al., 2000) and most significantly, 
chromatin assembly following replication (Bozhenok, et al., 2002).   
 The NURD family of ATP--dependent chromatin remodellers is also frequently 
associated with transcriptional repression and gene silencing (Wade, et al., 1999).  The 
human NURD complex was originally isolated from HeLa nuclear extracts and was 
subsequently characterized as having multiple methylation recognizing chromodomains, 
histone deacetylase (HDAC) domains and a metastasis-associated antigen domain 
(MTA-2), as well as being ATP -dependent (Becker and Horz, 2002). ATP-dependent 
chromatin remodellers within the NURD family are excellent examples of nucleosome 
remodelling proteins capable of not only mobilizing nucleosomes, but also recognizing 
methylated histone residues and deacetylating histone targets. The functional 
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consequences of these pertinent domains are essential for chromatin function and will 
be discussed further in the next section.   
 
1.2.3. Histone Modifying Enzymes  
 In the previous section, a critical component of the chromatin machinery was 
reviewed. Other major components of chromatin metabolism, which function in concert 
with the ATP-dependent chromatin remodellers, are histone acetyltransferases (HATs), 
and histone deacetylases (HDACs). These complimentary classes of enzymes 
covalently modify lysine residues within histones and other proteins in a manner that 
directs the action of the ATP-dependent chromatin remodellers. 
1.2.3.1. Histone Acetyltransferases (HATs) 
 The acetylation of core histones by HATs is frequently associated with 
transcriptional activation. In fact, the first HAT isolated, from Tetrahymena, was 
homologous to the previously characterized yeast transcriptional co-activator Gcn5 
(general control nonderepressible-5) (Brownell, et al., 1996). Subsequently, many 
transcriptional co-activators have been discovered to contain HAT activity (Peterson 
and Laniel, 2004). HATs frequently exist in large multi-protein complexes critical for 
locus targeting. These multi-protein complexes expand HAT specificity such that 
particular residues are acetylated at particular genomic loci. Historically, models have 
suggested that HAT activity mediates transcriptional activation by modifying the innate 
lysine charge on histone nucleosome tails through acetylation. It was hypothesized that 
the acetylation of these residues disrupted histone tail-DNA interactions, resulting in an 
open or “active” chromatin conformation that was permissive to the binding of 
transcriptional activators (Santos-Rosa and Caldas, 2005). A lack of evidence has since 
discredited this idea; even the lysine residue rich histone H3 tail would only have a 10-
30 % decrease in positive charge if all 13 available lysine residues were acetylated 
(Peterson and Laniel, 2004). Current dogma now suggests that HATs are frequently 
associated with transcriptional activation due to their ability to both acetylate lysine 
residues and recognize acetylated lysine residues via the presence of one or more 
bromodomains (Mellor, 2006).    
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    Human HATs have been organised into several superfamilies based on 
sequence similarity and mechanisms of histone substrate binding and catalysis. Human 
HAT characterization has identified that these HAT complexes share similar 
composition to known yeast complexes (Sterner and Berger, 2000). The GNAT (Gcn5-
related N-acetyltransferase) superfamily includes the potent co-activators GCN5L and 
PCAF (p300/CBP associated factor). These co-activators share similar carboxyl 
terminal ends, with each containing a 160 residue HAT domain and conserved 
bromodomains (Kuo and Allis, 1998). Studies from yeast suggest the GNAT 
superfamily uses acetyl CoA to specifically acetylate lys13 of histone H3 (H3K9 and 14 
in humans) and lys8 and lys16 of histone H4 (H4K8 and 16 in humans) in vitro (Kuo, et 
al., 1996) However, in vivo, the overexpression of yeast Gcn5p results in the 
hyperacetylation of all four core histones (Kuo, et al., 1998). This disparity can be 
explained by the observation that HAT involvement in transcriptional activation is 
context-dependent and other complex components influence how a HAT will affect a 
particular substrate (Sterner and Berger, 2000). Therefore, it should be noted that the 
majority of studies have examined the activity of HATs as complex components rather 
than the activity of the HAT enzyme itself. In the case of the GNAT superfamily, GCN5 
is frequently associated with the potent co-activator SAGA (Spt-Ada-Gcn5-
acetylatransferase) complex in yeast (STAGA in humans) and has been implicated in 
the transcriptional activation of numerous genes (Brownell, et al., 1996). In a further 
example, PCAF interacts with the p300/CBP HAT superfamily and is required for the 
transcriptional activation of a variety of genes including p73, p53, and ETS responsive 
genes (Goel and Janknecht, 2003; Zhao, et al., 2003).   
 HATs within the nuclear p300/CBP (E1A binding protein p300/CREB-binding 
protein) family contain a large 500 amino acid residue HAT domain, a bromodomain 
and three key cysteine-histidine rich domains (TAZ, PHD, ZZ) that are required for 
protein-protein interactions (Santos-Rosa and Caldas, 2005). p300/CBP HATs are 
global modulators of transcription that use acetyl CoA to specifically acetylate histones 
H3/H4 and histones H2A/H2B (Kuo and Allis, 1998). More specifically, in mammals, 
histone residues H2AK5, H2BK12, H2BK15, H3K14, H3K18, H3K23, H4K5 and 
H4K8 are acetylated by one or both of these powerful HATs (Peterson and Laniel, 
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2004). HATs in this versatile superfamily have also been reported as acetylating non-
histone targets such as: p53, viral oncoprotein E1A, androgen receptors and other 
transcription factors. The effect of this acetylation frequently results in the stabilization 
of the protein target (Zhang, et al., 2000; An, et al., 2004; Santos-Rosa and Caldas, 
2005). Interestingly, PCAF is often in complex with p300 and/or CBP and is also 
associated with the acetylation of the above non-histone targets.  
 Finally, the MYST superfamily is unique from the other HAT superfamilies in 
that it contains a conserved 370 residue MYST domain that acetylates target lysine 
residues through an acetyl-cysteine intermediate. This unique catalytic mechanism is 
common to all MYST members, including Tip60 (Tat-interactive protein 60 kDa), 
MOZ (monocytic leukemia zinc finger protein), MORF (MOZ-related factor) and 
HBO1 (histone acetyltransferase bound to ORC). Members of this family also contain a 
cysteine-rich zinc binding domain within the MYST HAT domain and a chromodomain 
that recognizes methylated residues (Yang, 2004; Santos-Rosa and Caldas, 2005). 
MYST HATs specifically acetylate histone H2AK5, H3K14, H4K5, H4K8, H4K12 and 
H4K16 (Peterson and Laniel, 2004). Furthermore, MYST HATs have been implicated 
in both transcriptional activation and silencing (Yang, 2004). In particular, Tip60 has a 
role in the transcriptional repression of signal transducer and activator of transcription-3 
(STAT3) but also functions as a co-activator for nuclear factor kappa beta (NF-κβ) and 
c-myc (Baek, et al., 2002; Frank, et al., 2003; Xiao, et al., 2003). 
 Notably, aside from the specific HATs mentioned above, many proteins contain 
HAT domains but are not categorized within the HAT superfamilies. Such examples 
include the transcription factors TAF1 (acetylates H3K14), ATF2 (acetylates H4K5, K8 
and K16), and Elp3 (acetylates H3K14 and H4K8) and the nuclear hormone related 
SRC-1 (acetylates H3K9, K14) (Peterson and Laniel, 2004; Yang, 2004). It is also 
important that many HATs or HAT containing proteins have the intrinsic ability to 
auto-acetylate (Yang, 2004). Specifically, PCAF autoacetylation is required for nuclear 
localization and TFIIB autoacetylation is required for the formation of the pre-initiation 
complex responsible for transcriptional activation (Choi, et al., 2003; Santos-Rosa, et 
al. 2003).     
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1.2.3.2. Histone Deacetylases (HDACs) 
 The reversible deacetylation of core histone residues is frequently associated 
with transcriptional repression. This is not surprising considering that HATs are often 
associated with transcriptional activation and HATs and HDACs have contrary 
functions. In fact, these enzymes exist in dynamic equilibrium within the cell and the 
acetylation status of histones and non-histone proteins is governed by the opposing 
actions of these enzymes. Similar to HATs, historically, it was hypothesized that 
HDACs functioned by relieving the positively charged lysine residues of the negatively 
charged acetyl moiety. The restoration of positively charged lysine residues within the 
histone tails was thought to result in increased nucleosome-nucleosome and 
nucleosome-DNA interactions thus “closing” the chromatin and preventing access to 
co-activators (Santos-Rosa and Caldas, 2005). This theory has since been replaced by 
the idea that a reduction in acetylation reduces the binding of bromodomain containing 
co-activators, thereby discouraging transcriptional activation. Indeed, it has been 
demonstrated that non-acetylated histone residues promote the association of repressors 
(Yang and Seto, 2003).  
 The four classes of mammalian HDACs are characterized based on homology to 
yeast HDACs. Class I HDACs possess homology to yeast Rpd3 (reduced potassium 
dependency 3) and include HDACs 1, 2, 3 and 8. These HDACs are ubiquitously 
expressed, primarily nuclear and all contain a zinc-dependent HDAC domain.  HDAC 
enzymatic activity is mediated via a charge-relay system whereby nucleophilic attack of 
the acetyl moiety is mediated by a critical Zn2+ ion found in the tubular active site of the 
enzyme (DeRuijter, et al., 2003; Hildmann, et al., 2006). HDAC1 and 2 are highly 
similar enzymes that only display activity within protein complexes in vivo. These 
complexes modulate the intrinsic HDAC activity and are required for binding to DNA 
and histone targets. HDAC1 and 2 are found in complex with Sin3, the ATP-dependent 
remodeller NuRD and co-repressor to RE1 silencing transcription factor (CoREST). 
Conversely, HDAC3 requires the co-repressors silencing mediator for retinoic acid and 
thyroid hormone receptor (SMRT) and nuclear receptor co-repressor (N-CoR) for 
repressive activity, as both of these co-repressors contain conserved deacetylase-
activating domains. HDAC3 also contains a nuclear localization signal (NLS) and 
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nuclear export signal (NES); thus HDAC3 is the only class I HDAC capable of shuttling 
in and out of the nucleus (Khochbin, et al., 2001; DeRuijter, et al., 2003). In fact, recent 
reports have suggested that HDAC3 localizes to the plasma membrane where it is a 
substrate for c-Src (Longworth and Laimins, 2006). HDAC8 is most similar to HDAC3 
but is not as well characterized and is generally present in low abundance within the cell 
(Khochbin, et al., 2001; DeRuijter, et al., 2003). As hinted at above, class I HDACs can 
be regulated by post-translational modifications. HDAC1, 2 and 3 are all 
phosphorylated by casein kinase 2 (CK2). However, only HDAC3 is phosphorylated by 
c-Src. HDAC1 phosphorylation results in the disruption of complex formation and loss 
of enzymatic activity. Conversely, HDAC2 and HDAC3 activity is upregulated by 
phosphorylation (Pflum, et al., 2001; Galanski, et al., 2002; Tsai and Seto, 2002; 
Zhang, et al., 2005) Similar to HDAC1, HDAC8 is negatively regulated by cAMP-
dependent protein kinase A (Lee, et al., 2004).   
 Class II HDACs include HDAC4, 5, 6, 7, 9 and 10. These HDACs are 
characterized as being larger in size, more tissue specific than class I HDACs, and can 
be either nuclear or cytoplasmic. This class is homologous to yeast histone deacetylase 
1 (HDA1). Like class I HDACs, the deacetylation activity of class II HDACs is 
dependent on a Zn2+ ion present in the tubular-shaped active site of the enzyme 
(DeRuijter, et al., 2003). Unlike class I HDACs, however, the nature and activity of a 
particular class II HDAC is -dependent on it’s intracellular localization (Khochbin, et 
al., 2001). As such, the catalytic activity of this class of HDAC is often characterized by 
the presence of a NLS and/or NES domain. HDAC4, 5 and 7, which contain a C-
terminal catalytic domain and N-terminal NLS, are the most similar class II HDACs. 
Notably, HDAC5 also contains an NES within the catalytic domain and therefore can 
shuttle in and out of the nucleus. Furthermore, all three of these HDACs contain N-
terminal binding domains for the co-repressor C-terminal binding protein (CtBP), 
transcription factor myocyte enhancer factor 2 (MEF2) as well as 14-3-3 proteins and it 
is through interactions with these factors that cellular localization is determined (Bertos, 
et al., 2001; DeRuijter, et al., 2003). For example, it is through the repressive 
interaction with MEF2 that HDAC4, 5 and 7 are localized to the nucleus where they 
appear to have a role in muscle differentiation (Lu, et al., 2000). Similarly, HDAC4, 5 
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and 7 are further implicated in transcriptional repression due to complex formation with 
the co-repressor SMRT/N-CoR. It is through this interaction that these class II HDACs 
are found in complex with HDAC3 (Bertos, et al., 2001).  
Evolutionary analysis suggests that HDAC6 and HDAC10 are the next most 
similar class II HDACs. However, HDAC6 is unique in that it contains two catalytic 
domains, a zinc finger motif and a unique SE14-repeat domain that is exclusive to 
human HDAC6 and essential for cytoplasmic retention (Yang and Gregoire, 2005). 
HDAC 6 functions primarily as a tubulin deacetylase, involved in microtubule-
dependent cell motility. Despite this primary function, HDAC6 is also found within the 
nucleus in complex with other HDACs (DeRuijter, et al., 2003). HDAC10 contains a N-
terminal catalytic domain similar to that of HDAC6. The C-terminal half of HDAC10 
contains an NES and putative lysine-rich second catalytic domain. HDAC10 is the least 
characterized of the HDAC enzymes so very little is known concerning the function of 
this HDAC. However, HDAC10 has been shown to exist in complex with HDAC1, 2, 3, 
4, 5, and 7 thereby suggesting a role for HDAC10 in transcriptional repression 
(DeRuijter, et al., 2003; Yang and Gregoire, 2005). Finally, HDAC9 exists as at least 
three splice variants and contains a N-terminal catalytic domain. HDAC9 appears to be 
expressed primarily in muscle tissue where it also interacts with MEF2 in a repressive 
fashion similar to that observed with HDAC5 (Chang, et al., 2004; Yang and Gregoire, 
2005).  
Similar to class I HDACs, class II HDACs are also susceptible to post-
translational modifications such as phosphorylation. Calmodulin-dependent protein 
kinases (CaMKs) phosphorylate HDAC4, 5 and 7 to promote nuclear export 
(McKinsey, et al., 2000; Yang and Gregoire, 2005). Moreover, HDAC4 can be 
phosphorylated by extracellular signal regulated kinase (ERK1) and ERK2 in vitro 
suggesting a role for HDAC4 in signalling pathways (Gray and Teh, 2001). HDAC4, 5 
and 9 are subject to ubiquitination and SUMOylation, which do not affect nuclear 
localization (Yang and Gregoire, 2005).  
Most significantly, class I and class II HDACs are not always associated with 
transcriptional repression. HDAC1 is required for the transcriptional activation of 
STAT5 target genes (Rascle, et al., 2003; Xu, et al., 2003). HDAC1, 2 and 3 enhance 
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expression of STAT1-dependent genes (Klampfer, et al., 2004). HDAC7 has been 
implicated in transcriptional activation through its interaction with HIF-1α (hypoxia 
inducing factor 1α) (Kato, et al., 2004). Moreover, select interferon response genes 
require HDAC activity to activate transcription (Chang, et al., 2004; Sakamoto, et al., 
2004). Furthermore, yeast HDACs have also been frequently associated with 
transcriptional activation. For example, Rpd1 has been reported as being required for 
maximal transcriptional activation, as well as repression, of a subset of genes in 
Saccharomyces cerevisiae (Vidal, et al., 1991). In addition, yeast HDACs Rpd3 and 
Hos2 are required for the activation of DNA-damage inducible genes RNR3 and HUG1 
(De Nadal, et al., 2004; Sharma, et al., 2007). Rpd3 has also been implicated in the 
transcriptional activation of osmoresponsive genes (De Nadal, et al., 2004). 
The third class of HDACs, the Sir2-like (silent information regulator 2-like) 
class, is structurally and catalytically different from the first two classes of HDACs. 
Unlike the Zn2+ ion dependency exhibited by the first two HDAC classes, class II 
HDACs require nicotinamide adenine dinucleotide (NAD+) as a co-factor for 
deacetylase enzymatic activity. During the deacetylation reaction, NAD+ breaks down 
to produce in O-acetyl-ADP-ribose and nicatinanide (NAM) (Santos-Rosa and Caldas, 
2005). There are seven human class III HDACs (SIRT1-7) and despite the relatively 
recent discovery of this class of HDACs it appears that they are functionally distinct 
from the first two HDAC classes. For example, the NAD+ requirement suggests a 
susceptibility to cellular energy requirements/redox states (Khochbin, et al., 2001). 
Furthermore, in S. cerevisiae and C. elegans, this class of HDAC has been implicated in 
the ageing process whereby overexpression of the sirtuens leads to an increase in 
lifespan (Trapp and Jung, 2005). A comprehensive survey of all class III HDAC family 
members is beyond the scope of this thesis. 
The fourth class of HDACs contains only one member. The function of 
HDAC11 is relatively unknown. However, this HDAC is nuclear, like class I HDACs, 
tissue specific, like class II HDACs, and contains an enzymatic domain similar to that 
seen in both class I and II HDACs. Due to the similarities and differences between 
HDAC11 and both class I and II HDACs, HDAC11 is considered in a class by itself 
(Minucci and Pelicci, 2006).     
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1.2.3.3. Other Covalent Histone Modifying Enzymes 
 Histone tail residues may also be post-translationally modified by methylation, 
phosphorylation, SUMOylation and/or ubiquitination.  Similar to acetylation, these 
modifications are frequently associated with a particular chromatin state. These 
modifications, the enzymes that elicit them and associated functions will be briefly 
reviewed. 
 Histone methylation/demethylation occurs at the side chain nitrogen atoms of 
lysine or arginine residues through the donation of a methyl group from S-adenosyl-L-
methionine (SAM) (Gary and Clark, 1998). Histone arginine residues are mono- or di-
methylated; the latter in a symmetrical or asymmetrical manner. The degree and manner 
of histone methylation is -dependent on the methyltransferase involved in the reaction. 
Generally, histone arginine methylation correlates with transcriptionally active genes. 
Methylated arginines are susceptible to a deimination reaction thus resulting in the 
modified residue being converted into a citrulline (Santos-Rosa and Caldas, 2005). 
Histone lysine residues may be mono, di- or tri-methylated and, like arginine 
methylation, the lysine residue and degree of methylation is -dependent on the 
methyltransferase employed. Lysine methylation is associated with a variety of 
functions including transcriptional activation, chromatin condensation, constitutive 
heterochromatin formation and transcriptional silencing/repression. Recently, the lysine 
specific demethylase 1 (LSD1) and jumonji C-domain-containing histone demethylase 2 
(JMJD2) families of lysine demethylases, were identified as being capable of reversing 
lysine methylation (Santos-Rosa and Caldas, 2005; Cloos, et al. 2006).  
 Specific serine and threonine residues on the histone tails are subject to 
phosphorylation. This type of post-translational modification is reversible and mediated 
by the interplay of kinases, such as the Aurora-B kinase, and phosphatases, such as 
protein phosphatase 1 (PP1). Phosphorylation of histone residue targets is frequently 
associated with the condensation of chromatin to form heterochromatin and yet, 
conversely, also with the transcriptional activation of select eukaryotic genes (Santos-
Rosa and Caldas, 2005; Johansen and Johansen, 2006). 
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 Both ubiquitin and small ubiquitin-related modifier, SUMO, can also modify 
histone lysine residues. Histone lysine mono-ubiquitination is -mediated primarily 
through the ubiquitin conjugating enzyme homologous to RAD6 A (HR6A) and, 
depending on the residue affected, has been associated with euchromatic regions, 
transcriptional activation, spermatogenesis and meiosis (Osley, 2004). The 
SUMOylation of histone lysine residues is, however, not as well characterized, although 
this modification is usually associated with transcriptional repression. The SUMO 
conjugating enzyme Ubc-9 is required for the SUMOylation of histone lysine residues 
(Shiio and Eisenman, 2004). 
 
1.2.4. Histone Code 
 Chromatin is a dynamic environment. The last few sections have outlined 
several key processes involved in chromatin dynamics. The following section serves to 
bring these critical components together under the guise of the histone code. The 
histone code is the cooperation of distinct histone modifications to result in 
transcriptionally active or inactive chromatin states (Mellor, 2006).  
 Covalent histone residue modifications have been suggested to be required for 
the recruitment of essential ATP-dependent chromatin remodelling enzymes and 
transcriptional regulators to DNA promoter regions (Winston and Allis, 1999; Hassan, 
et al., 2001). Therefore, these modifications are suggested to act as a type of scaffold for 
the assembly of large multi-protein complexes that direct or mediate the remodelling of 
chromatin. Significantly, many of these modifying enzymes, such as HDACs, are 
actually in complex with the ATP-dependent remodelling enzymes and in some cases 
require complex formation to be functional (Khochbin, et al., 2001; DeRuijter, et al., 
2003). If this is indeed the case, then covalent histone modifications themselves do not 
occur prior to remodelling events but may actually occur during or after chromatin 
reshuffling. Interestingly, many co-activators and co-repressors contain bromo- and 
chromodomains required to recognise methylated and acetylated residues, suggesting 
that some degree of modification is likely to occur prior to complex binding. Regardless 
of the order that these events occur, there appears to be a synergy amongst histone  
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modifications that can be suggestive of a transcriptionally active or repressive state 
(Jenuwein and Allis, 2001). A particular modification may indicate a transcriptionally 
active genomic region or may serve to influence other modifications to exact alternate 
effects (Figure 1.2.).  
For example, the combination of H4K8, H3K14 acetylation and H3S10 
phosphorylation is frequently associated with a transcriptionally active chromatin  
region. Conversely, H3K9 trimethylation prevents H3K9 acetylation and is associated 
with a repressive chromatin state (Peterson and Laniel, 2004). Methylation on H4R3 is 
suggested to facilitate acetylation of H4K8 and H4K12, modifications often associated 
with active chromatin (Zhang and Reinberg, 2001). Significantly, H4K16 acetylation is 
credited with transforming a repressive genomic region into an active region because 
this modification precludes the binding and remodelling activities of ISWF, thus 
providing an example that the effect -mediated by one modification is not always reliant 
on other histone modifications (Saha, et al., 2006; Shia, et al., 2006). Finally and most 
importantly, it should be noted that a particular modification or combination of 
modifications is(are) not always predictive of a particular gene-specific outcome.    
 
1.2.5. Histone Deacetylase Inhibitors 
 Many of the studies involving chromatin remodelling and the histone code have 
been aided by the use of a particular new class of promising anti-neoplastic agent, 
known as histone deacetylase inhibitors (HDIs). As the name suggests, these drugs 
specifically inhibit class I, II and IV HDACs. The treatment of cells with these drugs 
has far-reaching cellular consequences.  
 Of primary importance to this thesis, inhibition of HDACs upsets the dynamic 
equilibrium of acetylation and deacetylation within the cell. Because HDACs, and 
deacetylation, are frequently associated with transcriptional repression, it was expected 
that there would be an overall increase in transcriptional activation post treatment. This 
was not the case. Data from microarray studies suggest that anywhere between 2% and 
22% of all genes are affected by HDIs (Van Lindt, et al., 1996; Glaser, et al., 2003; 
Mitsiades, et al., 2003; Gray, et al., 2004; Peart, et al., 2005). While discrepancies 
obviously exist in the reported numbers of affected genes, most significantly, equal 
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numbers of affected genes appear to be up or down -regulated in these studies. Such 
findings support the now pervading sentiment, that genes are both activated and 
repressed by HDIs.   
 The differential transcriptional regulation caused by HDIs has a significant 
impact on the cell. The HDI -mediated, p53 -independent, transcriptional upregulation 
of p21WAF1, and/or the simultaneous downregulation of cyclins A and D, can induce cell 
cycle arrest at the G1/S boundary (Richon, et al., 2000; Sandor, et al., 2000). HDIs also 
transcriptionally activate TNF-related apoptosis-inducing ligand (TRAIL) and FAS 
resulting in apoptosis through the death-receptor pathway. Similarly, HDIs may also 
induce apoptosis via the upregulation of pro-apoptotic BCL2 proteins (BAK/BAX) and 
the downregulation of anti-apoptotic BCL2 family members (BCL2/BCL-XL), thereby 
facilitating the activation of the caspase -dependent mitochondrial apoptotic pathway 
(Green, 2000; Johnstone, 2002).  
More recent findings indicate that HDIs are capable of interfering with existing 
phosphatase complexes. Specifically, it has been demonstrated that HDIs are capable of 
blocking PP1/HDAC1/6/10 complex formation (Brush, et al., 2004). The abrogated 
interaction of PP1 and HDAC1/6 results in increased interaction between Akt and PP1, 
thus decreasing Akt phosphorylation and lowering the apoptosis threshold (Chen, et al., 
2005). Subsequent studies have identified that in breast cancer cells the decreased Akt 
activity leads to increased susceptibility to apoptosis due to heightened glycogen 
synthase kinase 3 beta (GSK3beta) activity (Alao, et al., 2006).  The interaction of 
HDAC3 and A-Kinase-Anchoring Proteins AKAP95 and HA95 (AKAp95/HA95), 
which is required to alter histone tail residues for aurora B kinase recognition at the 
onset of mitosis, is also impeded by HDIs. HDI treatment, by preventing aurora kinase 
B association with histone tails, therefore results in a delay in mitotic progression (Li, et 
al., 2006).  
1.2.5.1. HDIs as cancer therapeutics 
Strikingly, although both normal and tumour cells accumulate hyperacetylated 
histone residues, normal cells are ten times more resistant to HDIs than tumour cells 
(Dokmanovic and Marks, 2005; Minucci and Pelicci, 2006). This difference provides 
these agents with the powerful ability to specifically target cancer cells. The utility of 
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HDIs as anticancer agents is therefore not difficult to imagine, given that these drugs 
can induce cell-cycle arrest, apoptosis and terminal differentiation in neoplasms 
(Dokmanovic and Marks, 2005). Moreover, HDIs are particularly attractive as cancer 
therapeutics due to their anti-angiogenic, anti-metastatic and enhanced anti-tumour 
immunological qualities in vivo and in vitro. 
HDIs suppress angiogenesis through the decreased expression of vascular 
endothelial growth factor (VEGF), HIF-1α and chemokine receptor 4 (CXCR4) as well 
as other pro-angiogenic genes (Kim, et al., 2001; Qian, et al., 2006). The down 
regulation of CXCR4 is of particular interest due to the role of CXCR4 in circulating 
endothelial cells to active sites of angiogenesis (Qian, et al., 2006). Moreover, the 
decreased accessibility in nutrient supply to a primary tumour in itself could be 
perceived as anti-metastatic. However, down regulation of matrix metalloproteinases 
(MMPs) or upregulation of MMP negative regulators, such as RECK (reversion-
inducing cysteine-rich protein with Kazal motifs), by HDIs also inhibit metastasis. 
Importantly, an in vivo study involving hepatocarcinoma cell lines suggested that a 
modified HDI was able to specifically target the membrane protein CD44 and reduce 
the metastatic potential of these cell lines (Coradini, et al., 2004; Bolden, et al., 2006).   
Enhancement of anti-tumour immunity by HDIs can be modulated through the 
alteration of immune cell activity and/or cytokine production. Indeed, HDIs are capable 
of making tumour cells more attractive immune targets. One way in which this occurs is 
through HDI -mediated induction of major histocompatibility complex (MHC) class I 
and II protein expression. Specifically, the expression of the MHC class I proteins 
MICA and MICB is induced in response to HDIs. These proteins are localized to the 
surface of tumour cells and are targets for the immunoreceptor of natural killer cell 
protein group 2D (NKG2D) found on the surface of natural killer and select T cells 
(Bolden, et al., 2006). The targeted binding of NKG2D to the tumour cell can result in 
cellular cytotoxicity, as demonstrated by HDI treated Hep3B and HepG2 
hepatocarcinoma cell lines (Armeanu, et al., 2005; Bolden, et al., 2006).  
Notably, HDIs can also act with other chemotherapeutic agents in a synergistic 
manner. Treatment of cells derived from both hematological and solid tumours with the 
DNA-demethylating agent 5-aza-cytidine followed by treatment with HDIs results in 
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the transcriptional activation of previously silenced genes (Bolden, et al., 2006).  The 
treatment of non-small-cell lung cancer cell lines with an HDI and anti-metabolite 
gencitabine resulted in synergistic cell death (Loprevite, et al., 2005; Bolden, et al., 
2006). Finally, the treatment of chronic myeloid leukemia (CML) cells with both HDIs 
and imatinib was effective against even imatinib-refractory CML (Nimmanapalli, et al., 
2003).    
Significantly, HDAC overexpression is observed in many types of cancer. 
HDAC1 has been reported to be overexpressed in hormone refractory prostate, gastric, 
colon and breast cancers, as well as oesophageal squamous cell carcinomas. Similarly, 
HDAC2 overexpression is observed in colorectal, cervical and gastric cancers. 
Increased HDAC3 expression is seen in colon cancer and overexpression of HDAC6 
has been observed in breast cancer. Furthermore, siRNA-mediated knockdowns of 
HDACs have resulted in suppressed cellular growth and survival (Glaser, et al., 2003; 
Wilson, et al., 2006). Taken together, these findings suggest an important role for 
HDACs in cancer and HDIs in cancer therapies.  
1.2.5.2. HDI Families 
There are several families of HDIs grouped into classes based on their structure: 
(1) short-chain fatty acids (carboxylic acids), (2) Hydroxamates, (3) Benzamides, (4) 
Cyclic tetrapeptides, and (5) Electrophilic ketones (Bolden, et al., 2006). Representative 
structures from each of the HDI families can be seen in Figure 1.3. 
    The first class of HDI is the short-chain fatty acid group; examples of this 
class include: sodium butyrate (SB) as well as the anti-epileptic valporic acid (VPA). 
The mechanism of action of these inhibitors is unknown. However, these agents are 
considered weak inhibitors of HDACs due to their short side chains, which limit their 
interaction with the tubular catalytic site of HDACs. As a result, the requirement of 
millimolar concentrations of this type of HDI makes this class a poor candidate for 
clinical development as a chemotherapeutic agent (Acharya, et al., 2005). However, 
despite the relatively weak activity of these drugs several members of this class are 
currently undergoing clinical trials. VPA can inhibit all of the class I HDACs and  
HDAC4, 5, 7 and 9 and is implicated in the inhibition of angiogenesis and the induction 
of apoptosis in multi-drug resistant acute myeloid leukemia cells (AML). SB is a  
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naturally occurring HDI commonly present in colonic mucosa that selectively inhibits 
class I and II HDACs (Bolden, et al., 2006). SB can cause cell cycle arrest and 
apoptosis in AML and acute T-lymphoblastic cells. The butanoic acid prodrug pivaloyl 
oxymethyl butyrate (AN-9) is, however, the most clinically promising short chain fatty 
acid HDI as it has been shown that AN-9 is ten-fold more potent than SB in leukemia 
tumour cell lines (Acharya, et al., 2005). 
 The hydroxamic acids are the broadest class of HDIs and have been studied 
most extensively. This class includes many potent HDIs in particular Trichostatin A 
(TSA), Suberoylanilide hydroxamic acid (SAHA) and Tubacin. This family is 
characterized as having a general structure consisting of a polar cap linked to a 
hydroxamic acid moiety via a bulky, hydrophobic linker region (Hess-Strump, 2005). 
The mechanism of inhibition by this class has been elucidated and the crystal stucture of  
HDAC8 interacting with TSA solved. The hydroxamic acid residues bind with high 
affinity to the tubular HDAC active site thereby preventing the access of the substrate to 
the enzymatically critical Zn2+ ion. The polar, bulky portion of the inhibitor acts as a 
cap to further discourage substrate-enzyme interaction (Somoza, et al., 2004; Vannini, 
et al., 2004). The majority of hydroxamic acid inhibitors are potent enough to function 
at nanomolar to micromolar concentrations in vitro. TSA was initially isolated as an 
anti-fungal agent (Bolden, et al., 2006). While, TSA is widely used in research it is 
unstable, relatively toxic and exhibits a lack of specificity towards particular HDACs, 
which makes it a poor candidate for clinical studies. However, TSA has been shown to 
be successful at inhibiting solid and hematological tumours in animal bearing models 
(Dukmanovic and Marks, 2005). Moreover, the potency of TSA has led to the creation 
of similar hydroxamic inhibitors that have demonstrated clinical success. SAHA is 
structurally similar to TSA and has activity at submicromolar concentrations. Although 
SAHA also inhibits all of the class I and class II HDACs, this HDI has been successful 
in phase I, II and III clinical trials and has been approved by the Federal Drug 
Administration (FDA) for use in the treatment of cutaneous T cell lymphomas (Bolden, 
et al., 2006; Marks and Breslow, 2007). The success of this particular hydroxamic acid 
is due to acceptable oral bioavailability, favourable pharmokinetic profile and the ability 
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to exert anti-cancer effects, at tolerable doses, in a wide variety of tumours 
(Dukmanovic and Marks, 2005). Tubacin is not currently undergoing clinical trials but 
is worth mentioning due its specificity towards HDAC6 activity. However, while 
Tubacin has been shown to elicit hyperacetylation of α-tubulin it has no effect on 
histone acetylation (Bolden, et al., 2006). 
 The benzamide class of HDIs is exemplified by two inhibitors: MS-275 and Cl-
994. MS-275 is interesting due to the specificity this HDI exhibits towards HDAC1, 2, 
3 although it has also been reported to marginally reduce HDAC8 activity. Thus this 
inhibitor has been reported to be specific only for class I HDACs and has entered phase 
II clinical trials (Bolden, et al., 2006). CI-994, however, has greater clinical potential 
than MS-275 as it is currently in phase III clinical trials. Both of these inhibitors are 
functional at micromolar concentrations and have been successful in the treatment of 
hematological and solid tumours in vivo (Minucci and Pellicci, 2006; Bolden, et al., 
2006). 
 Depsipeptide is the most promising member of the cyclic tetrapeptides class of 
HDIs. Like MS-275, depsipeptide specifically targets class I HDACs and is currently in 
phase II clinical trials. Also, it is relatively potent as it is effective at nanomolar 
concentrations (Bolden, et al., 2006). While the mechanism of action of this particular 
class of HDI is not known, it is hypothesized that the epoxyketone contained within the 
tetrapeptide may chemically modify the active site of the HDAC thus preventing 
enzyme-substrate formation (Acharya, et al., 2005). Depsipeptide can induce apoptosis 
in cells obtained from patients with chronic lymphocytic leukemia and has also 
demonstrated anti-angiogenic properties in vivo and in vitro (Kwon, et al., 2002; 
Acharya, et al., 2005).     
 The electrophilic ketones are a small and relatively poorly defined class of 
HDIs. Trifluoromethylketone is functional at micromolar concentrations but HDAC 
specificity and clinical utility is currently unknown (Bolden, et al., 2006). Depudecin is 
an example from the miscellaneous class of HDIs and was originally isolated as a 
fungal metabolite. This particular HDI was identified due to the ability of depudecin to 
morphologically reverse transformed NIH 3T3 cells (Monneret, 2005). Subsequently, it 
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has been observed that depudecin hyperacetylates histones at micromolar concentrations 
by a currently unknown mechanism (Bolden, et al., 2006).    
 These diverse families of drugs are proving to be powerful chemotherapeutics. 
However, the mechanisms by which these drugs exert their effects remain largely 
unknown. While it is clear that apoptosis may be induced through the deregulation of 
genes leading either to the death receptor pathway or the mitochondrial pathway, it is 
not clear how these genes are deregulated. Similarly, it is known that HDIs stimulate G1 
arrest through the transcriptional upregulation of p21WAF1; however, the mechanism of 
transcriptional activation has not been satisfactorily explained. A great deal of study is 
still required to fully elucidate the mechanism of action of these pleiotropic drugs. 
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1.3. Eukaryotic transcriptional regulation 
1.3.1. Requirements for basal transcription 
 Eukaryotic transcription is a complex process that begins with the sequential 
binding of essential factors to the DNA core promoter to ultimately produce mature 
messenger RNA (mRNA) transcripts designed to convert genetic information into the 
template for cellular protein synthesis. However, this simplified description of 
transcription fails to address the regulatory gauntlet required to produce a single peptide 
protein. The following sections will summarize pertinent checkpoints in mRNA 
maturation including promoter architecture and pre-initiation complex (PIC) assembly, 
promoter escape, transcriptional elongation and, finally, essential co-transcriptional 
processes and transcriptional termination. 
1.3.1.1. RNA polymerase II -dependent transcription  
 Four discreet RNA Polymerases have been isolated and characterized. RNA 
Polymerase I is primarily involved in transcribing 18S and 28S ribosomal RNAs, while 
RNA Polymerase II transcribes mRNAs and RNA Polymerase III transcribes 5S 
ribosomal RNA, transfer RNAs and adenovirus VA RNAs. A fourth RNA Polymerase 
that appears to solely transcribe small interfering RNA (siRNA) was also recently 
identified in plants (Thomas and Chiang, 2006). The focus of this review will be the 
DNA-dependent RNA Polymerase II, as this polymerase is key in transcribing protein-
encoding genes.  
 The eukaryotic core promoter is defined as the 40-50 bp region encompassing 
the transcriptional start site. Several cis acting elements have been identified at the core 
promoter region existing in variations of at least four basic forms: (1) the TATA-box, 
(2) Initiator element (Inr), (3) downstream activator element (DPE), and (4) TFIIB 
recognition element (BRE). These cis acting elements are the very first points of 
regulation for basal transcription as they are responsible for regulating the orientation of 
RNA Polymerase II and are required for transcriptional initiation (Smale and Kadonaga, 
2003; Juven-Gershon, et al., 2006).  
 The TATA box was first identified in 1979 following a comparison of viral, 
Drosophila and mammalian RNA Polymerase II (RNA Pol. II) transcribed genes 
(Breathnach and Chambon, 1981). Although at one time the TATA-box was touted as 
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being almost ubiquitous at metazoan core promoter regions, it is now known that the 
TATA box is present at only ~24% of human promoter regions (Shi and Zhou, 2006). 
The characteristic TATA box consists of a TATA(A/T)AA(G/A) motif that appears -25 
to -30 bp upstream of the transcriptional start site (Figure 1.4.)  (Smale, 2001). This 
motif functions by acting as a point of recognition and docking site for the TATA-
binding protein (TBP), which is necessary for transcriptional activation -mediated by 
RNA Pol. II. As TATA box sequence fidelity is directly related to TBP binding, the 
TATA box is involved in transcriptional regulation (Gross and Oelgeschlager, 2006). 
Although, the TATA box alone is sufficient for the recruitment of the PIC to the 
promoter region for basal transcription, the TATA box can co-exist with other core 
promoter elements, such as Inr elements, BREs and, occasionally, DPEs (Smale and 
Kadonaga, 2003). 
 Inr elements are relatively abundant core promoter elements reported to be 
present at ~46% of human genes. Significantly, the canonical 
(T/C)(T/C)AC(T/A)(T/C)(T/C) Inr elements exist at ~30% of human genes in the 
absence of a TATA box (Yang, et al. 2007). Clearly, these elements, which span the 
transcriptional start site (-2 to +4), do not require a TATA box to contribute to accurate 
transcription (Figure 1.4.). Despite the presence of these Inr elements at core promoters, 
little is understood concerning how these elements actually initiate transcription. While, 
it has been reported that the binding of TBP alone is insufficient to initiate transcription 
via this element, the binding of the general transcription factor (GTF) TFIID 
(transcription factor II D), which contains TBP, does initiate transcription. Significantly, 
two components of TFIID, TAF1 and TAF2 (TATA-binding protein associated factors 
1, 2), have been suggested as being important in mediating TFIID binding to the Inr 
element; moreover, their involvement has been identified as being essential for Inr 
element promoter activity in both human and yeast cell extracts (Smale and Kadonaga, 
2003). Furthermore, GTF TFIIA binding to the Inr element is essential for subsequent 
TFIID binding to this core promoter element although the binding site domain of TFIIA 
remains undetermined. Similarly, RNA Pol. II can itself recognize Inr elements, 
however, transcription initiated in the absence of other GTFs is inefficient (Smale and  
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Kadonaga, 2003). Taken together, these findings suggest that the Inr element requires 
the binding of all GTFs to successfully initiate transcription. Interestingly, Inr elements 
and TATA box elements can mediate synergistic transcriptional initiation whereby 
TFIID co-operatively binds both the TATA box and Inr element. However, this synergy 
is maintained only when the TATA box and Inr elements are within 30 bp of each other 
(Smale and Kadonaga, 2003; Juven-Gershon, et al., 2006). Inr elements and DPEs also 
act co-operatively to initiate transcription, although, in contrast to the TATA box, DPEs 
rely on Inr elements to mediate transcriptional initiation (Juven-Gershon, et al., 2006).  
 As the name suggests, downstream promoter elements (DPEs) are found +28 to 
+32 bp downstream of the Inr element and have the consensus sequence 
(A/G)G(A/T)(C/T)(G/A/C) that is conserved from yeast to humans (Figure 1.4.) (Smale 
and Kadonaga, 2003). This core promoter element is relatively under-represented in the 
human genome; it has been estimated that only ~12% of human core promoters contain 
this element (Jin, et al., 2006). Core promoters containing an Inr element and a DPE 
bind TFIID via both of these elements and, as stated above, DPEs require Inr elements 
to initiate transcription. Significantly, in vitro studies have demonstrated that a single 
nucleotide change in distance between the Inr element and DPE results in fold decreases 
in TFIID binding and dramatically decreases transcriptional initiation (Smale and 
Kadonaga, 2003).  
 In contrast to the TATA box, Inr elements or DPEs, BREs are located and are 
recognized by the GTF TFIIB whether upstream and/or downstream of the TATA box 
(-37 to -32 bp upstream and -25 to -19 bp downstream of the transcriptional start site). 
The upstream BRE, which mediates the interaction of TFIIB in the major groove 
upstream of the TATA box has a (G/C)(G/C)(G/C)CGCC recognition motif. The 
interaction of TFIIB with the minor groove downstream of the TATA box is, however, 
facilitated by the inexact motif (G/A)(T)(T/G/A)(T/G)(G/T)(T/G)(T/G) (Figure 1.4.)     
(Smale and Kadonaga, 2003). Interestingly, although BREs flank the TATA box, recent 
evidence suggests that a TATA box is not required for BRE -mediated TFIID binding. 
In fact, BREs may act as a substitute for the TATA box in transcriptional initiation 
(Deng and Roberts, 2006). Despite the presence of these elements in ~22% of human 
promoter regions the function of the BRE is poorly understood, as in vitro experiments 
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have described this promoter element as both increasing and decreasing transcriptional 
initiation (Smale and Kadonaga, 2003; Jin, et al., 2006).   
 Notably, not all core promoter regions contain the above mentioned core 
promoter elements. Generally, these promoter regions are CpG islands, which are 
composed of 0.5 Kb-2 Kb stretches of DNA possessing a relatively high density of CpG 
dinucleotides. It has been suggested that CpG islands account for nearly 50% of  
promoters of protein coding genes and generally, transcription is initiated via multiple 
transcription start sites that span ~100 bp or more (Smale and Kadonaga, 2003). 
Significantly, CpG islands and core promoter elements are not mutually exclusive. 
1.3.1.2. Pre-initiation Complex Formation  
 As suggested in the previous section, transcriptional initiation -mediated by 
RNA Pol. II requires the co-operation of many essential components known collectively 
as general transcription factors (GTFs). The co-ordinated binding of GTFs and RNA 
Pol. II is referred to as the assembly of the pre-initiation complex (PIC) and is achieved 
through the stepwise and timely recruitment of all critical factors to the DNA core 
promoter. The GTFs governing PIC assembly include: transcription factor II A (TFIIA), 
TFIIB, TFIID, TFIIE, TFIIF, TFIIH and RNA Pol. II (Thomas and Chiang, 2006). Once 
the PIC has been assembled, the co-ordinated efforts of the PIC components initiate 
RNA Pol. II -mediated transcription (Figure 1.5.).  
The TFIID is a large multi-protein complex consisting of TBP and at least 14 
TATA-binding protein associated factors (TAFs) that include a wide range of molecular 
weights (250 KDa to 15 KDa) (Thomas and Chiang, 2006). As suggested above, human 
TFIID is capable of recognizing discreet core promoter elements such as the TATA-
box, Inr element, and DPE in vitro. Upon binding these core promoter elements, TFIID 
can mediate the interaction between distal promoter elements and the general 
transcription machinery to promote PIC assembly. Also, TFIID acts to post-
translationally modify chromatin and surrounding factors involved in the regulation of 
transcriptional initiation (Thomas and Chiang, 2006). An essential component of TFIID 
is TBP, which is responsible for TATA box recognition and binding. Upon binding the 
core promoter, crystal structures have demonstrated that the “saddle-like” TBP 
manipulates the promoter DNA by widening the minor groove and narrowing the major  
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groove. The manipulation of the core promoter in such a way is important for the 
recruitment of the PIC (Thomas and Chiang, 2006). Similarly, the 250 KDa TAF1 and 
150 KDa TAF2 components of TFIID play critical roles in promoter recognition via Inr 
elements, as well as in facilitating the effects of upstream activators on PIC assembly. 
TAF1 also modifies histone H1 by mono-ubiquitination and acetylates lysine residues 
on histone H2B/H3/H4 N-terminal tails, thus mediating structural chromatin changes 
required for transcriptional initiation. Furthermore, TAF1 contains two bromodomains 
that recognize acetylated histone H4K5 and H4K12 residues, as well as acetylated 
H3K9 and H3K14 residues, suggesting that TAF1 may aid in the recruitment of TFIID 
and chromatin remodelling enzymes to chromatin-packaged promoters (Green, 2000b; 
Wassarman and Sauer, 2001; Agalioti, et al., 2002).     
TFIIA and TFIIB are the next PIC components to congregate at the core 
promoter following TFIID. Both TFIIA and TFIIB are reported to be involved in the 
stabilization of TBP binding to the TATA-box. Interestingly, work performed with a 
purified in vitro transcription system demonstrated that TFIIA is not strictly required for 
PIC assembly and initiation (Aoyagi and Wassarman, 2000). Conversely, TFIIB is 
absolutely required for TFIID/TBP core promoter stabilization, whether it be by 
stabilizing TATA box-TBP interactions or the manipulation of core promoter DNA 
through binding to both flanking BREs, TFIIB is essential for PIC assembly. 
Furthermore, the highly conserved TFIIB is also reported to have an essential role in the 
recruitment of RNA Pol. II/TFIIF to the partially assembled pre-initiation complex, as 
well as in transcriptional start site selection through the positioning of promoter DNA in 
the catalytic cleft of RNA Pol. II in vivo (Choi, et al., 2003; Thomas and Chiang, 2006). 
TFIIF is responsible for the recruitment of RNA Pol. II to the partially 
assembled pre-initiation complex through pre-promoter binding interactions between 
TFIIF and RNA Pol. II (Svejstrup, 2003). Furthermore, TFIIF stabilizes the interactions 
between RNA Pol. II and promoter DNA by altering DNA topography such that the 
DNA is ensconced by RNA Pol. II and a stable TFIID-TFIIB-Pol. II-TFIIF complex is 
formed. The stabilization of RNA Pol. II by TFIIF aids in the prevention of spontaneous 
initiation by inhibiting the interaction between RNA Pol. II and non-promoter DNA 
sequences. TFIIF is also critical for the recruitment of both TFIIE and TFIIH, which are 
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responsible for facilitating RNA Pol. II promoter escape following transcriptional 
initiation and the enhancement of RNA Pol. II elongation (Thomas and Chiang, 2006).  
RNA Pol. II is a 12 subunit, highly conserved, key enzymatic complex that 
facilitates every step of transcription. Structurally, human RNA pol. II is comprised of a 
N-terminal core domain that physically interacts with the promoter DNA, an 80-residue 
linker domain and a C- terminal domain (CTD) that is largely responsible for co-
ordinating all phases of mRNA biogenesis. The human RNA Pol. II CTD is composed 
of 52 heptapeptide repeats of the consensus sequence Y1-S2-P3-T4-S5-P6-S7 
(Meinhart, et al 2005). This heptapeptide is conserved across species; however, the 
number of repeats varies. In yeast, for example, a minimum of eight heptapeptide 
repeats are required for viability (West and Corden, 1995).  The CTD is post-
translationally modified at serine 2 (S2) and/or serine 5 (S5) by phosphorylation. 
Typically, while, the phosphorylation of CTD S5 is associated with the 5’ region of the 
gene, CTD S2 phosphorylation is more common downstream of the promoter 
(Svejstrup, 2003). As a result of these findings, the phosporylation status of the CTD is 
often indicative of early or late stages of transcription (Komarnitski, et al. 2000). Upon 
entry into PIC assembly, however, the RNA pol. II CTD, in complex with TFIIF, is 
hypophosphorylated (Svejstrup, 2003; Thomas and Chiang, 2006). The modification 
status of the CTD plays an integral role in the formation of the CTD scaffold 
responsible for the binding of factors involved in initiation, elongation, mRNA 5’ 
methyl-guanine capping, mRNA splicing, transcriptional termination and 
polyadenylation (Meinhart, et al 2005). In light of the numerous processes -dependent 
on the phosphorylation status of the CTD, the term “CTD code” has been coined 
(Buratowski, 2003) The N-terminal domain of RNA pol. II, based on crystal structures 
of RNA pol. II interaction with DNA, has been suggested to form a “jaw” that closes 
around the DNA upon RNA pol. II/TFIIF- DNA interaction. The N-terminal “jaw” 
domain is the RNA pol. II active site from which the nascent mRNA transcript extends 
upon transcription initiation. Importantly, it is at the RNA pol. II-DNA “jaw” 
interaction that TFIIE binds to the core promoter, 10 bp upstream of the transcriptional 
start site, to eventually be involved in mediating promoter melting and transcriptional  
initiation (Svejstrup, 2003; Thomas and Chiang, 2006). 
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As well as binding to RNA Pol. II, TFIIE physically interacts with TFIIF, 
TFIIB, promoter DNA and is responsible for the recruitment of TFIIH. The interaction 
between TFIIE and TFIIH is critical for initiation, as TFIIE is responsible for 
stimulating the DNA -dependent ATPase, CTD kinase and the DNA helicase activities 
of TFIIH. TFIIH is also associated with the cell cycle, as the CTD kinase domain of 
TFIIH is comprised of cyclin H and cyclin -dependent kinase 7 (CDK7), which is 
responsible for the phosphorylation of serine 5 within the CTD of RNA pol. II. 
(Svejstrup, 2003). TFIIH ATPase activity is required for stable promoter opening and 
the formation of the first phosphodiester bond, thereby signalling transcription 
initiation. Furthermore, without TFIIH, RNA Pol. II stalls at the promoter regions, 
which leads to abortive transcription products in vitro. Significantly, TFIIH is a 
bidirectional helicase, capable of unwinding DNA in both a 5’-3’ and 3’-5’ direction 
thus providing a transcription bubble comprised of single stranded promoter DNA that 
will act as the template for RNA Pol. II -mediated transcription (Svejstrup, 2003; 
Thomas and Chiang, 2006). Upon binding of TFIIH, the step-wise assembly of the PIC 
is complete (Figure 1.5.). Notably, it has been suggested that the PIC is not ‘built” upon 
the core promoter elements, as described above, but rather binds to the core promoter 
elements as a pre-assembled holoenzyme. However, this theory has been mostly 
discounted as in vitro and in vivo studies have demonstrated that TFIID, TFIIA and 
TFIIB remain at the promoter region upon RNA Pol. II promoter clearance to usher in 
the assembly of a new PIC (Svejstrup, 2003).  
1.3.1.3. RNA Polymerase II Promoter Escape      
 TFIIH is involved in transcriptional initiation as it phosphorylates serine 5 
residues contained within the CTD of RNA Pol. II, mediates the formation of the first 
phosphodiester bond in mRNA biosynthesis, and further unwinds DNA downstream of 
the start site via helicase activity (Dvir, et al., 2001). However, initiation does not 
guarantee the production of a mature mRNA transcript; the RNA Pol. II must “escape” 
from the core promoter region with the nascent mRNA transcript intact. This rate-
limiting step is characterized by the formation of the first 8 nucleotides of mRNA and is 
mediated through the actions of TFIIB in vivo and in vitro (Saunders, et al., 2006). 
Following the formation of a 4-5 nucleotide nascent mRNA transcript, the N-terminal 
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“B-finger” domain of TFIIB protrudes into the RNA Pol. II active site to stabilize the 
association of mRNA with RNA Pol. II (Chen and Hampsey, 2004; Saunders, et al., 
2006). The translocation of the RNA Pol. II active site to the ninth position after the 
start site marks the conversion from promoter escape into early elongation complex 
(EEC). The lengthening of the nascent mRNA transcript to 9 nucleotides also signifies 
the end of the TFIIH -mediated ATPase requirement for transcription and the collapse 
of the transcription bubble. Transcription bubble collapse also provides the required 
energy for the remodelling of the transcription complex. The EEC differs from the 
initiation complex in that it no longer contains TFIIA, TFIIB or TFIID and at least three 
proteins stabilize the nascent mRNA transcript to prevent DNA-RNA hybrid formation 
(Westover, et al., 2004; Saunders, et al., 2006).  
1.3.1.4. Co-transcriptional Processes  
Upon promoter escape, the EEC does not become a fully competent, mature 
elongation complex until after the transcription of ~30 nucleotides. At this stage, the 
EEC is paused or stalled on the DNA template by the binding of DRB sensitivity-
inducing factor (DSIF) and negative elongation factor (NELF) to await the binding of 
pertinent factors to the RNA Pol. II S5 phosphorylated CTD. The capping enzyme (CE) 
and RNA (guanine-7) methyltranserase bind to the stalled RNA Pol. II S5 
phosphorylated CTD to add a methylated guanosine “cap” to the 5’end of the RNA, 
thus protecting the nascent mRNA transcript from nuclease degradation (Sims III, et al., 
2004). After capping, positive transcription-elongation factor-b (P-TEFb) binds the 
CTD and phosphorylates DSIF, NELF, and S2 of the CTD, which relieves the negative 
pressure imposed by DSIF and NELF on elongation (Saunders, et al., 2006). 
Concurrently, S5 CTD phosphorylation is abrogated by the activity of the small CTD 
phosphates (SCPs) and TFIIS binds to the elongation complex to mediate the transition 
between promoter-proximal pausing and productive transcription elongation. Taken 
together, these findings highlight the importance of 5’ mRNA capping on the 
production of a mature mRNA transcript. Without the interactions between the capping 
enzymes and P-TEFb, productive elongation would not occur and mRNA synthesis 
would be stalled 30 nucleotides into production. Furthermore, without a methyl-guanine 
cap nascent mRNAs may be degraded prior to being fully transcribed or exported into 
 35
the cytoplasm. Subsequent in vitro studies have identified components of the elongation 
complex to include: RNA pol. II, TFIIF, TFIIS, SCPs, P-TEFb, the elongation 
stimulating elongins and ELL (eleven-nineteen lysine-rich in leukemia), as well as 
Elongator and FACT (facilitates chromatin transcription), which are involved in 
facilitating transcription elongation in a chromatin environment (Sims III, et al., 2004).  
Interestingly, the progression from the early elongation complex to productive 
elongation underscores the value of differential RNA Pol. II CTD phosphorylation. The 
deregulation of CTD phosphorylation stalls transcription initiation and elongation 
possibly due to aberrant enzymatic activity, be it through the loss of TFIIH kinase 
activity, the loss of SCP activity, or the loss of P-TEFb activity. Abnormal behaviour by 
any of these factors prohibits the production of a mature mRNA transcript.  
 5’ capping is not the only RNA processing occurring in unison with initiation 
and/or elongation. mRNA splicing, -mediated by U1-U6 small nuclear RNAs 
(snRNAs), in association with transcription is essential for the production of a nuclear 
export-ready mature mRNA species. Recent reports suggest that snRNA U1 is a 
component of TFIIH and required for transcription initiation. Furthermore, transcription 
rates are reduced by the elimination of intronic sequences, while proximal pausing sites 
actually enhance transcription (Neugebauer, 2002). Similarly, 3’ end formation and 
transcription have been linked through the observation that termination depends on the 
production of a transcript that includes a polyadenylation signal (AAUAAA), which can 
be as far as 1500 bp upstream of the termination site in humans. The polyadenylation of 
immature mRNA occurs in a region between the polyadenylation signal, which binds 
the cleavage and polyadenylation factor (CPSF), and a downstream G/U rich region 
reported to bind cleavage stimulatory factor (CstF). Cleavage factors I and II cut the 
mRNA and nuclear polyadenylation is achieved through the action of poly(A) 
polymerase (PAP) that binds to CPSF. Moreover, polyadenylation is considered a co-
transcriptional process due to the findings that CPSF is bound to TFIID at the core 
promoter and the phosphorylated S2 CTD of RNA pol. II downstream of the core 
promoter. (Neugebauer, 2002; Orphanides and Reinberg, 2002).  
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1.3.1.5. Transcription through histones 
 In the previous sections, basal transcription from initiation to termination was 
described. The movement of the RNA Pol. II and associated complexes through a 
chromatin environment will now be discussed. In vitro studies with yeast cell free 
extracts have shown the ATP-dependent remodeller SWI/SNF to play a critical role in 
encouraging transcriptional initiation by altering the chromatin landscape at core 
promoter regions (Carey, et al., 2006). SWI/SNF works in concert with TFIIS to 
stimulate elongation after promoter-proximal pausing in vivo (Svejstrup, 2003). In 
yeast, the Paf1 complex associates with the S5 phosphorylated CTD to mediate the 
recruitment of methyltransferases required for histone modifications essential for 
transcriptional initiation, and is also implicated in elongation through the mediation of 
histone H3 and H4 eviction in vitro (Sims III, et al., 2004; Schwabish and Struhl, 2006). 
Alternatively, human Paf1 is associated with transcription dependent histone H3 
acetylation, potentially providing the modifications necessary to attract the FACT 
complex to nucleosomes at transcriptionally active genes (Zhu, et al., 2005). As one of 
the components of the mature elongation complex, the FACT complex is intimately 
involved in facilitating transcriptional elongation through nucleosomes both in vitro and 
in vivo. Chromatin manipulation by FACT is achieved through nucleosomal disorder 
following the eviction of histone H2A-H2B dimers; furthermore, FACT histone 
chaperone activity reassembles the nucleosomes in the wake of RNA Pol. II (Workman, 
2006). Although there is no evidence to support a physical interaction between FACT 
and RNA Pol. II, the FACT complex is consistently identified as being involved in the 
clearing of chromatin, thus allowing RNA Pol II transcription to proceed (Sims III, et 
al., 2004). The binding of FACT to histones may be associated with the elongation 
factor Elongator, the HAT activity of which may modify histone residues to recruit 
FACT to actively elongating transcripts. Interestingly, Elongator was first isolated as a 
component of the hyperphosphorylated form of RNA Pol. II. In vitro studies have 
demonstrated that Elongator is acetyl-CoA-dependent, further confirming an essential 
role for Elongator in either histone or protein acetylation (Svejstrup, 2003).  
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1.3.2. Proximal promoter sequences and activated transcription     
 The previous sections described the factors required for basal transcription. This 
section will integrate the effects of gene-specific upstream transcriptional regulators on 
activated transcription, as well as the factors and complexes mediating these effects. 
1.3.2.1. Gene-specific proximal promoter elements 
   In yeast the region upstream of the DNA core promoter is known as the 
upstream activator sequence. In humans these gene-specific regulatory regions are 
frequently referred to as enhancers or proximal promoter sequences that are able to 
influence gene expression through the input of cellular cues such as growth, 
developmental and homeostatic signals (Malik and Roeder, 2005). The existence of 
these cis -acting components of transcriptional regulation in eukaryotes enables the 
rapid exchange of information to influence the genetic program in response to the 
cellular environment. There are numerous families of transcription factors that bind to 
cognate upstream promoter DNA sequences. However, the Sp family provides an 
excellent example of gene-specific transcription factors because they are frequently 
associated with the transcriptional regulation of housekeeping, tissue specific and 
inducible genes (Li, et al., 2004). 
 The Sp family of transcription factors binds the cis-acting GC box DNA 
regulator elements containing the canonical 5’-GGGGCGGGG-3’ sequence (Suske, et 
al., 2005). There are at least nine Sp family members, although Sp1 and Sp3 are the 
only family members that are ubiquitously expressed. Sp1 is a powerful transactivator 
capable of synergistic activation of promoters containing multiple Sp binding sites. The 
synergistic activation by Sp1 is even more remarkable as Sp1 binding to sites as far 
away as 2 kb can be looped together to enhance Sp1-mediated transcriptional activation. 
Consistent with the role of Sp1 in activation, Sp1 is reported to recruit SWI/SNF 
chromatin-remodelling factors to promoter regions to increase the accessibility of 
promoter regions to other transcription factors (Li, et al., 2004). Furthermore, Sp1 is 
capable of binding the GC box target sequence at promoter regions in assembled 
nucleosomes and further enhances transcription through CRSP (co-activator required 
for Sp1 activation) mediated RNA pol. II interaction in vitro (Ryu, et al., 1999; Suske, 
1999).  
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 Sp3 is similar to Sp1 in that Sp3 is able to mediate the activation of 
transcription. However, Sp3 can also act as an inhibitor of transcription. This 
phenomenon can be partially explained by the existence of four Sp3 translational 
isoforms. The two longest forms of Sp3 have only recently been characterized and are 
reported to function as activators. Previous studies had isolated a Sp3 isoform that was 
considered full length, although the N-terminal region present in the physiologically 
relevant forms of Sp3 was missing. Despite the absence of the N-terminal region, this 
putative long Sp3 isoform contained two glutamine rich activation domains and was 
also a transcriptional activator (Sapetschnig, et al., 2004). The two shortest isoforms of 
Sp3, however, contain only one activation domain and, as a result, are frequently 
associated with transcriptional repression. Moreover, previous studies have suggested 
that these smaller isoforms could inhibit Sp1-mediated activation through competition 
for binding sites (Kennett, et al.,, 1997). As a result, the role exacted by Sp3 has been 
suggested to be defined by the sheer number of a particular Sp3 isoform present within 
the cell at a particular time (Li, et al., 2004).  Conversely, other groups have reported 
that the number of Sp binding sites within a particular promoter dictates the effect 
mediated by Sp3 in that system (Birnbaum, et al., 1995). Unlike Sp1, Sp3 does not bind 
to promoter regions as a multimer and as such is not capable of synergistic promoter 
activation. However, although Sp1 is involved in basal activation of the PKR gene 
(protein kinase regulated by RNA) Sp3 is the factor responsible for interferon-mediated 
inducible activation (Ward and Samuel, 2003; Li, et al, 2004). Subsequent experiments 
with Sp1 and Sp3 and this promoter system have suggested that Sp1-mediated basal 
activation of PKR was dominant over basal activation mediated by the longest Sp3 
isoforms in vivo (Das, et al., 2006). Clearly the activation and/or repression mediated by 
these factors are governed by mechanisms other than which factor is present in the 
greatest cellular abundance. 
 In order to rapidly alter gene expression, these factors must be amenable to a 
constantly shifting cellular environment. The post-translational modification of both 
Sp1 and Sp3 is an efficient mechanism to rapidly alter gene expression mediated by 
these factors. For example, in lung epithelial cells PP1-mediated dephosphorylation of 
Sp1 and Sp3 decreases the binding of these factors to the alpha-ENaC2 (alpha-epithelial 
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Na channel 2), thereby decreasing Sp1/Sp3-mediated activation at this promoter (Chu, 
et al., 2003). However, it is likely that the effect mediated by a particular modification 
is dependent on the system affected. Indeed, in vitro studies using extracts isolated from 
human chronic mylogenous leukemia cells suggest that the phosphorylation of Sp1/Sp3 
impedes the binding of these factors to the human Galpha(i2) gene promoter and thus 
reduces transcriptional activation mediated by these factors (Arinze and Kawai, 2003).  
Similarly, both Sp1 and Sp3 are acetylated and this modification influences the 
ability of each of these factors to activate transcription. In a recent study it was 
suggested that the acetylation status of Sp1 determines which co-activators/co-
repressors are recruited to the promoter of the 12(S)-lipoxygenase gene and therefore 
determines if the gene is repressed or activated (Hung, et al., 2006). Similarly, the 
acetylation of Sp3 is frequently associated with enhanced Sp3 -mediated activation 
(Ammanamanchi, et al., 2003; Wooten and Ogretmen, 2006). However, Sp3 acetylation 
has also been shown to decrease Sp3-mediated activitation (Braun, et al, 2001). Sp3 
acetylation is slightly more complicated than Sp1 acetylation, however, because the 
lysine residue within the inhibitory domain of Sp3 susceptible to acetylation can also be 
SUMOylated (Braun, et al, 2001; Ross, et al, 2002; Ammanamanchi, et al., 2003; 
Splenger, et al, 2005; Ehlting, et al., 2006). Sp3 is SUMOylated via the protein inhibitor 
of activated STAT1 (PIAS) E3 ligase (Sapetschnig, et al., 2002). Without exception, all 
reports of Sp3 SUMOylation are associated with decreased Sp3-mediated activation 
(Ross, et al., 2002; Sapetschnig, et al., 2002; Sapetschnig, et al., 2004; Splenger, et al., 
2005). The mechanism of SUMO-1 -mediated inhibition of Sp3 activation is currently 
unknown. However, some suggest that SUMOylation alters the nuclear localization of 
Sp3 in murine cells, whereas, others claim that Sp3 nuclear localization is unaltered 
upon SUMO-1 modification (Ross, et al., 2002; Sapetschnig, et al., 2002). Moreover, 
transient transfection assays performed with Drosophila SL2 cells, which lack 
endogenous Sp factors, indicate that the SUMOylation of the shortest Sp3 isoforms was 
particularly crippling to the ability of these isoforms to activate the dihydrofolate 
reductase (DHFR) promoter (Splenger, et al., 2005). Regardless of the mechanism, the 
modification of Sp3 by SUMO-1 remains a pertinent topic in transcriptional regulation 
by gene-specific transcription factors.       
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1.3.2.2. Activated Transcription 
  Gene-specific transcriptional regulators bind regions upstream of the core 
promoter. In order for these factors to influence the assembly of the PIC and the 
recruitment of other factors required for transcription, therefore, co-activators and co-
repressors are required to communicate the effects imposed by the binding of gene-
specific transcription factors to the core promoter. The Mediator complex is one of the 
best-characterized examples of a co-activator, or co-repressor, required for activated 
transcription in metazoans (Roeder, 2005).  
 Studies performed in yeast have characterized the yeast Mediator as being 
composed of ~20 subunits that form four distinct Mediator subdomains known as the 
“head”, “middle”, “tail” and kinase modules (Conaway, et al., 2005).  Functional 
characterization has demonstrated that yeast Mediator is important in activator-
dependent transcription as Mediator associates with both the transcriptional activation 
domain of gene-specific transcription factors and also with the hypophosphorylated 
form of the RNA Pol. II CTD. However, Mediator is not just an adapter protein 
complex linking upstream transcription factors and PIC components. In vitro 
transcription assays indicate that the binding of yeast Mediator to RNA Pol. II 
stimulated the CTD-kinase activity of TFIIH, resulting in the phosphorylation of S5 on 
the CTD, which is critical in initiation (Conaway, et al., 2005). Moreover, the 
Mediator/RNA Pol. II interaction may be important only at initiation because Mediator 
is absent from elongator complexes containing hyperphosphorylated forms of the RNA 
Pol. II CTD, thus suggesting that CTD phosphorylation may disrupt Mediator binding 
(Svejstrup, 2003). Furthermore, yeast Mediator can also function as a HAT thereby 
providing a connection between chromatin remodelling and activated transcription 
(Conaway, et al., 2005). Taken together, these results indicate that yeast Mediator has 
essential functions at many levels of activated transcription.   
The human Mediator complex was first isolated through association with the 
liganded thyroid receptor (TR) and was named TRAP for thyroid hormone receptor-
associated proteins. The TRAP complex contained subunits that were homologous to 
yeast Mediator subunits and was shown to be required for TR-dependent transcription 
from DNA templates by RNA Pol. II (Roeder, 2005). Subsequent isolation of other 
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human Mediator complexes have identified at least 30 subunits that contribute to 
activated transcription in human cells in vitro and have identified a role for discreet 
Mediator (MED) subunits in directing transcription in cooperation with specific 
activators both in vivo and in vitro (Malik and Roeder, 2005; Zhang, et al., 2005). As 
observed with yeast cell free extracts, human MED subunits associate with the 
hypophosphorylated CTD of RNA pol. II in vitro (Näär, et al., 2002). While the 
functional consequences of this interaction have not yet been delineated, in vivo ChIP 
studies have indicated that during hormone-induced target gene activation MED 
subunits are recruited to the core promoter region before the recruitment of RNA Pol. II 
(Sharma and Fondell, 2002; Malik and Roeder, 2005). These studies suggest that, like 
yeast Mediator, human Mediator may have a role in the formation of the PIC at the 
promoters of activated genes.  
Interestingly, many human co-activator complexes contain a heterogeneous 
assortment of MED subunits, which may be involved in dictating what role Mediator 
imparts on activated transcription. For example, the Sp1 associated CRSP complex 
contains MED components with homology to the “head”, “middle” and “tail” regions of 
the yeast MED. However, it has been reported that the CRSP complex lacks the MED 
subunits responsible for Mediator kinase activity that are required for Mediator 
facilitated co-repression in yeast. In vitro transcription studies using both naked DNA 
and chromatin templates have also identified a role for CRSP in activator -dependent 
transcription activation. Conversely, the much larger TRAP Mediator complex contains 
components of all four modules and is involved in both the stimulation and inhibition of 
activator-dependent transcription in vitro, suggesting that the kinase module may be 
required for co-repressor MED activity (Conaway, et al., 2005). As a result, it has been 
suggested that the repressive nature of the kinase module may be the result of 
interference in MED/ RNA Pol. II binding, and/or due to the phosphorylation and 
resulting deactivation of TFIIH by the MED kinase module (Malik and Roeder, 2005). 
Presumably, the alternative composition of human MED containing complexes may be 
explained by the interaction of specific MED subunits with the activation domains of 
different gene-specific transcriptional activators to elicit alternative regulatory programs 
(Conaway, et al., 2005). Taken together, human and yeast Mediator studies have 
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suggested a requirement for MED subunit containing complexes in exerting the effects 
of gene-specific transcription factors. Furthermore, the high degree of evolutionary 
conservation existing between human and yeast Mediator subunits suggests that human 
Mediator may prove to be functionally equivalent to its yeast counterpart.   
 As described in the previous sections, transcriptional regulation of mammalian 
genes requires the input of a variety of diverse factors. Basal transcription requires the 
interplay of core promoter sequences, GTFs and RNA Polymerase II. However, gene-
specific transcriptional activation involves the inter-relation of diverse cellular signals 
manifested through the modifications of gene-specific transcription factors, co-
activators and co-repressors, such as Mediator, and all of the components of the basal 
transcription apparatus. The high level of regulation of these interactions has been 
developed to co-ordinate the adaptive nature of the mammalian genetic program.  
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1.4. c-Src 
1.4.1. Src 
 Nearly a century ago Peyton Rous first suggested that a chicken tumour could be 
transfered to another chicken of the same species using cell-free filtrates or a “filterable 
agent” (Rous, 1911). At this time it was not known that “filterable agents”, or viruses as 
we know them now, contained genetic information. Continued work by Rous and that 
of at least two other groups in-dependently demonstrated that a virus could indeed 
induce tumours in healthy specimens. Despite considerable resistance from the 
scientific community, this controversial finding was eventually rewarded when Peyton 
Rous received the Nobel Prize in 1966 (Martin, 2004).  
 Since these initial findings, a wealth of information concerning the Rous 
sarcoma virus (RSV) has emerged. In 1955, a landmark study pioneered by Harry Rubin 
demonstrated that every cell in a RSV-induced tumour was capable of disseminating the 
virus thus suggesting that the virus had become a permanent component of the tumour 
and was actually necessary to maintain the tumour’s malignant state (Rubin, 1955). In 
the 1960s, several laboratories in-dependently identified that transforming and 
replication qualities could be separated in a particular strain of RSV. These findings, 
and those of others, led to the observation that the RNA genome of transforming, 
replication positive RSV strains were larger than their non-transforming counterparts.  
The transforming strain of RSV was identified as containing unique oligonucleotides, 
through the use of oligonucleotide fingerprinting and chromatography, in this manner 
viral Src (v-Src) was identified (Wang, et al., 1976). Concurrently, the concept that viral 
genomes might contain captured cellular genes was gaining ground, and the findings 
that transformation negative strains of RSV could still replicate suggested that the 
mutated transforming gene (v-Src) from the RSV might actually be a mutated 
endogenous gene (Martin, 2004). A v-Src specific probe was annealed to normal avian 
DNA and a cellular component for v-SRC, aptly named cellular Src (c-Src), was 
identified (Stehelin, et al., 1976). Moreover, the cDNA probe was also able to bind 
higher vertebrate DNA, thus confirming the existence of a cellular component to v-Src 
that is conserved through evolution. v-Src had already been dubbed an oncogene due to 
its ability to transform normal cells. As such, the term proto-oncogene was introduced 
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to distinguish between the transforming v-Src gene and the c-Src gene that is non-
transforming unless overexpressed and/or mutated (Martin, 2004). Src has been 
implicated in tumourgenesis in one capacity or another for nearly a century. It is 
therefore not surprising that the roles of c-Src in tumour formation continue to be a 
popular topic in tumour biology. The structure and function of Src are essential to 
understanding the role of Src in the oncogenic process.  
 
1.4.2. c-Src Protein Structure and Regulation  
 Studies initially performed with v-Src identified Src as a 60 kDa, non-receptor 
tyrosine kinase. Interestingly, it was originally thought that v-Src was a threonine kinase 
as tyrosine kinases were unheard of at that time. However, in 1980 a group was able to 
prove that not only did v-Src specifically phosphorylate tyrosine residues but that v-Src 
itself was tyrosine phosphorylated (Hunter and Sefton, 1980). These observations hinted 
at a role for phosphorylation in Src activity and function. v-Src autophosphorylation 
was subsequently shown to occur at tyrosine residue 416 (Tyr416) (Tyr419 in humans). 
However, while this site in c-Src was not found to be phosphorylated in vivo, tyrosine 
residue 527 (Tyr530 in humans), a residue that is absent in v-Src, was phosphorylated, 
furthermore, the phosphorylation of c-Src at Tyr527 was shown to be repressive to c-
Src tyrosine kinase activity, while dephosphorylation activated c-Src kinase. 
Significantly, Tyr527 phosphorylation of c-Src was found to be due to the action of Csk 
(carboxy-terminal Src kinase), rather than a product of auto-phosphorylation (Martin, 
2001). Eventually it was ascertained that c-Src was also autophosphorylated at Tyr 416; 
however, dephosphorylation of Tyr527 was a prerequisite to Tyr 416 
autophosphorylation (Parsons and Weber, 1989). These results suggested that v-Src was 
a constitutively activated form of c-Src, as the negative regulatory C-terminal was not 
present in v-Src. Already it was clear that structural differences between v-Src and c-Src 
were involved in mediating their alternate effects. 
 In the course of delineating c-Src structure, the existence of cellular homologues 
bearing significant similarity to c-Src were described and given the name of Src family 
kinases (SFKs). Currently there are nine members in this structurally related family of 
non-receptor tyrosine kinases; however, while structurally similar, expression patterns 
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differ dramatically between family members (Lowell and Soriano, 1996). For example, 
Fyn and Yes are the two SFKs most closely related to Src and, like Src, demonstrate an 
almost ubiquitous distribution. Conversely, the other SFKs are more tissue specific and 
as a consequence their expression is primarily restricted to haematopoietic and neuronal 
cells (Lowell and Soriano, 1996; Martin, 2001).    
 All of the Src family members share a similar structure consisting of six discreet 
functional domains (Figure 1.6.). These domains include:  a short regulatory C-terminal 
tail domain, the 250-residue Src homology 1 (SH1) catalytic domain, the 100-residue 
SH2 domain, the 50-residue SH3 domain, the 40-70-residue unique region and finally, 
the 15-residue SH4 domain (Thomas and Brugge, 1997). The regulatory C-terminal 
domain contains the hallmark Tyr530 residue common to all SFK. As described earlier, 
the phosphorylation of this residue by Csk has a negative impact on Src kinase activity 
(Sicheri and Kuriyan, 1997). The catalytic SH1 domain contains Tyr419, which is 
autophosphorylated to activate Src. The SH2 domain binds phosphotyrosine; however, 
binding specificity is determined by the presence of a second binding pocket. This 
second binding pocket recognizes residues immediately C-terminal to the 
phosphotyrosine residue. In vitro experiments have suggested that the phosphopeptides 
optimal for binding contain a YEEI motif (Y = tyrosine, E = glutamic acid, I = 
isoleucine) (Pawson, 2004). The SH3 domain interacts specifically with proline-rich 
sequences containing a PXXP (P = proline, X = any amino acid residue) consensus 
sequence to form a left-handed polyproline helix (polyproline type II) (Li, 2005). As the 
name suggests, the unique domain is a region poorly conserved between Src family 
members. This region is responsible for interactions between discreet Src family 
members and effectors (Sicheri and Kuriyan, 1997). Finally, the SH4 domain is required 
for cotranslational attachment of myristic acid by the action of N-myristoyl transferase 
(NMT). Myristylation of this domain is key in Src function as it results in the 
localization of c-Src to membranes including: the rough endoplasmic reticulum, 
endosomes, secretory vesicles and the plasma membrane (Silverman and Resh, 1992). 
Other SFK members are also modified at the N-terminal region, however, palmitic acid  
is more commonly the lipid modifier (Lowell and Soriano, 1996; Thomas and Brugge, 
1997).   
NN
C
C
SH4
SH4
SH3
SH3
SH2
SH2
SH1(kinase)
SH1(kinase)
Y419
Y416
Y530Human c-Src
Chicken v-Src
U
U
Figure 1.6. Structure of Src proteins. Comparison of protein structures of
human c-Src and chicken v-Src. Both proteins contain four Src homology
domains (SH). SH1 is the catalytic domain which contains the conserved
tyrosine residue required for autophosphorylation and activation (Tyr419 in
human c-Src and Tyr416 in chicken v-Src). The SH2 domain is required for
the recognition of phosphotyrosine residues. The SH3 domain binds proline-
rich sequences. The unique domain is a region exhibiting very little
conservation between Src family members. The SH4 domain is required for
myristylation which aids in the localization of Src to cellular membranes.
c-Src and v-Src differ primarily at the C-terminal domain. v-Src lacks the
negative regulatory Tyr530 residue which allows v-Src to be constitutively
activated (Yeatman, 2004).
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Src structure is critical in understanding c-Src regulation. Crystallographic and 
structure-function studies have confirmed that Src is regulated through interactions 
involving the SH2, SH3 and C-terminal domains (Frame, 2001). In particular, as 
mentioned previously, Tyr530 within the C-terminal domain is phosphorylated by Csk 
(Martin, 2001). The resulting phosphotyrosine and associated residues interact with the 
SH2 domain to result in a closed or “inactive” conformation. Subsequently, or 
concurrently, the proximity between SH3 and the region linking the kinase and SH2 
domains increases to allow the binding of SH3 to proline rich sequences within the 
linker region. These interactions further confine c-Src and render the Tyr419 residue 
within the kinase domain incapable of autophosphorylation thus hindering c-Src kinase 
activity (Figure 1.7.). The preclusion of c-Src autophosphorylation is not the only 
interaction preventing kinase activity. The interactions between the SH2 and the C-
terminal domain, as well as SH3 and the linker region, prohibit associations between 
these domains and other proteins, including receptor tyrosine kinases (Frame, 2001; 
Yeatman, 2004). Appropriately, the dephosphorylation of Tyr530 relieves the “closed”, 
inactive c-Src conformation to again allow the autophosphorylation of Tyr419 and 
intramolecular interactions between the SH2/SH3 domains with downstream targets 
such as focal-adhesion kinase (FAK) (Frame, 2001). Dephosphorylation of Tyr530 is 
accomplished through the activities of phosphatases such as: Protein Tyrosine 
Phosphatase-α (PTP-α), PTP1, PTP2, SH2 containing phosphatase 1 (SHP1) and SHP2 
(Yeatman, 2004).  
 
1.4.3. c-Src Signalling 
 c-Src activation is associated with numerous cellular processes -mediated 
through interactions with proteins and signalling molecules. Two of the most commonly 
studied c-Src interactions will be briefly reviewed: the interaction with members of the 
epidermal growth factor (EGF) family of receptors to mediate cellular proliferation and 
the association with focal adhesion kinase (FAK) to mediate cellular migration, motility 
and invasion.  
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Figure 4.7. c-Src activation. Csk phophorylates Y530 resulting in an
interaction between phosphotyrosine 530 and the SH2 domain. Concurrently,
SH3 interacts with the linker region of Src thus closing c-Src off from
interactions with RTKs and resulting in an inactive, closed enzymatic
conformation. Dephosphorylation of Y530 relieves the closed, inactive
conformation of c-Src to allow for the autophosphorylation of Y419 and
SH2/SH3 domains the opportunity to interact with downstream targets
(Yeatman, 2004).
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The interactions between c-Src and transmembrane receptor tyrosine kinases 
(RTKs) are well documented and are fundamental in mediating c-Src activity (Parsons 
and Parsons, 1997). The effects of these interactions involve the autophosphorylation of 
c-Src, the association of c-Src and RTKs to mediate downstream events, and the 
phosphorylation of the RTK itself (Thomas and Brugge, 1997).  The interactions 
between c-Src and EGFR characterize the properties of c-Src and RTK associations and 
provide excellent examples of the processes pivotal to c-Src participation. Pioneering 
studies in murine cells have demonstrated that c-Src physically associates with activated 
EGFR via the SH2 domain, which prompts the transient activation of c-Src through the 
auto-phosphorylation of Tyr419 and results in the phosphorylation of downstream 
targets. Similarly, c-Src overexpression in murine fibroblasts enhances the 
phosphorylation of EGFR downstream effectors such as p190 Rho-Gap (p190 Rho 
GTPase activating proteins). Taken together, these experiments suggest that c-Src and 
EGFR function in a synergistic manner. Moreover, the overexpression of c-Src in 
quiescent murine cells enhances DNA synthesis in response to EGF, thereby suggesting 
a role for c-Src in EGFR -mediated G0 to G1 cell cycle progression (Parsons and 
Parsons, 1997). More recent experiments have suggested that EGFR is itself a target for 
c-Src kinase activity at multiple residues. In particular, c-Src directly or indirectly 
mediates Tyr845 phosphorylation of EGFR, which is required for cyclooxegenase (Cox) 
II -mediated enhanced cell survival and EGF-induced cell proliferation through 
STAT5b. c-Src also negatively regulates EGFR degradation by facilitating the 
ubiquitination and proteosomal degradation of CBL (Casitas B-lineage Lymphoma), an 
E3 ligase that promotes receptor endocytosis and degradation (Ishizawar and Parsons, 
2004). Interestingly, c-Src is itself a target for CBL proteosomal degradation which 
suppresses v-Src transformation in NIH 3T3 cells (Kim, et al., 2004).    
 FAK and c-Src transiently associate following ligand stimulation of the EGF 
receptors (see previous section) or integrin/extracellular matrix (ECM) complex 
formation. This association potentiates the autophosphorylation of FAK, which results 
in FAK engagement with a variety of downstream effectors, including c-Src. FAK/c-Src 
association activates c-Src, consequently causing the phosphorylation of tyrosine 
residues to enhance FAK kinase activity and provide the docking sites required for 
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interactions with other signalling molecules (Ishizawar and Parsons, 2004). The 
significance of this interaction has consequences to cellular adhesion, motility and 
invasion through the destabilization of focal adhesions and adheren junctions. For 
example, focal adhesions are formed at the sites where the actin cytoskeleton is linked 
to the ECM by integrins. Focal adhesions are highly dynamic and can consist of over 50 
different proteins, including both c-Src and FAK, which are involved in mediating both 
cell-matrix attachment and cell-matrix detachment to induce cellular migration and 
motility. c-Src and FAK are primarily involved in detachment through the disruption of 
focal adhesions and actin stress fibres, which results in cellular migration. Specifically, 
c-Src -mediated activation of FAK causes the phosphorylation of downstream targets 
including integrin associated CAS (CRK-associated substrate) and the integrin-actin 
cytoskeleton connector paxillin to alter the cytoskeleton to promote focal-adhesion 
turnover and allow motility (Yeatman, 2004). Significantly, Fak-/- cells transfected with 
dominant-negative c-Src display larger than average focal adhesions and reduced 
motility, further confirming the value of c-Src-FAK interactions in cellular migration 
(Ilic, et al., 1995). Moreover, c-Src activated FAK stimulates the JNK (c-JUN amino 
terminal kinase) pathway to ultimately result in the increased expression of 
MMP2/MMP9, which promote the breakdown of the ECM. The disintegration of the 
ECM is required for the invasion of tumour cells to surrounding tissues, thereby directly 
linking c-Src/FAK interactions to tumour progression (Yeatman, 2004).  
 
1.4.4. c-Src and Cancer 
 The previous section described only a few cellular processes involving c-Src. 
Given the breadth of critical interactions requiring c-Src and the effects -mediated by 
these interactions, including proliferation, cellular migration, motility and invasiveness, 
it comes as no surprise that the constitutively activated v-Src is an oncogene. However, 
c-Src activation and/or overexpression have also been implicated in tumour progression.     
 In-dependent groups have reported the presence of an activating mutation of c-
Src in  ~12% of advanced colon cancers and very small portion of endometrial 
carcinomas (less than 2%) (Irby, et al., 1999; Sugimura, et al., 2000). This activating 
mutation results from the premature truncation of the c-Src C-terminal domain at 
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glutamine residue 531, which prevents the negative regulation of c-Src by 
phosphorylation at Tyr530. Moreover this change was demonstrated to be activating, 
transforming, tumourgenic and metastasis promoting (Irby, et al., 1999). Subsequent 
studies with colon cancer patients have not been able to confirm the presence of this 
activating mutation in advanced colon carcinomas; as such it has been suggested that 
these mutations may be present in only a very small subset of colon cancers (Daigo, et 
al., 1999; Nilbert and Fernebro, 2000). Significantly, these activating mutations are not 
the only studies reporting a correlation between increased c-Src kinase activity and 
cancer. 
  Several groups have reported increased c-Src expression and activity in colonic 
polyps and adenomas as compared to normal mucosa (Talamonti, et al., 1993; Iravani, 
et al., 1998). Specifically, it appears that both c-Src expression and c-Src activity are 
increasing during adenoma formation, whereas only c-Src activity continues to increase 
as the cells become tumourous and possibly metastatic (Yeatman, 2004). Similarly, high 
c-Src kinase activity has been correlated with a poor clinical prognosis in all stages of 
human colon carcinomas (Aligayer, et al., 2002).  To further examine the role of c-Src 
activity in colon cancer cells, several groups have studied the effects of downregulating 
c-Src activity on cellular phenotypes. In one such study, Csk or a dominant-negative 
form of c-Src was overexpressed in a rat carcinoma cell line. Although these cells were 
still able to form primary tumours, they could no longer metastasize to secondary sites 
when injected into rats (Boyer, et al., 2002). Along a similar vein, a c-Src anti-sense cell 
line was developed using the colon cancer cell line, HT29. These cells grew far more 
slowly than their parental counterparts, further suggesting a role for c-Src in 
proliferation. Furthermore, when these anti-sense cells were injected into nude mice, the 
anti-sense producing cells formed tumours at a greatly reduced rate as compared to wild 
type counterparts (Staley, et al., 1997). The mechanisms behind these effects are 
complex and likely involve the co-ordination of many signalling pathways. 
   As reviewed in the previous section, Src and EGFR activity are intimately 
related and their association results in synergistic activation of downstream targets that 
encourage cellular proliferation. To underscore the importance of this interaction in 
regard to cancer, c-Src and members of the EGFR family are co-overexpressed in 70% 
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of breast cancer tumours (Ishizawar and Parsons, 2004). Increased c-Src activity, 
mediated by RTKs, results in the STAT3 -mediated induction of VEGF (Yeatman, 
2004; Yu and Jove, 2004). Significantly, c-Src is required for hypoxia-induced VEGF 
expression to mediate angiogenesis in vivo (Kilarski, et al., 2003). Furthermore, through 
the use of in vivo models of angiogenesis it has been shown that Src inhibition is an 
effective mechanism in blocking neovascularization, thus confirming an angiogenic role 
for Src (Summy and Gallick, 2006).  
  The interactions between FAK and c-Src also deserve attention with respect to 
cancer progression. These two kinases interact to mediate cellular migration, motility 
and invasion. The assembly and disassembly of focal adhesions, mediated by Src and 
FAK, is a normal cellular occurrence during mitosis and normal cellular migration. 
However, focal adhesion disassembly also occurs during transformation to allow for 
increased migration (Yeatman, 2004). This provides another example of how a normal 
cellular process can become potentially tumourgenic if enhanced through the 
heightened activity of a key kinase, such as c-Src.   
 Increased c-Src activity can be achieved through a variety of mechanisms. As 
described earlier, an activating mutation is able to convert c-Src into a potent 
oncoprotein. However, this particular mutation appears to exist only in a very small 
subset of tumour samples. Another way in which an increase in c-Src activity may occur 
is through the downregulation of Csk levels, which would result in decreased 
phosphorylation of the C-terminal Tyr residue of c-Src. This is the case in both colon 
cancer carcinomas and hepatocellular cancers, in which Csk is underexpressed and c-
Src is overexpressed, resulting in higher levels of c-Src activated protein (Yeatman, 
2004). Significantly, Src overexpression achieved through transcriptional activation also 
results in increased c-Src protein levels accompanied by elevated kinase activity in a 
variety of colon cancer cell lines (Dehm, et al., 2001). However, future studies into the 
mechanism of c-Src deregulation will be necessary to fully elucidate the role of Src in 
cancer.   
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1.5. SRC Transcriptional Regulation 
 The SRC gene consists of 15 exons spanning over 60 Kb (Figure 1.8.) (Bonham 
and Fujita, 1993; Bonham, et al., 2000). Exons 2-12 encode the open reading frame and 
3’ untranslated region (3’UTR). Exons 1B and 1C encode a portion of the 5’UTR while 
the remainder of the 5’UTR and the alternative SRC promoter regions are encoded by 
exon 1α and exon 1A. The SRC1α promoter is ~1 Kb upstream of SRC1A promoter, 
however, transcripts initiated from either promoter are alternatively spliced to exon 1B 
to yield mRNA products with differing 5’UTRs that encode identical protein products 
(Figure 1.8.).  Interestingly, relative SRC promoter usage was measured in several colon 
cancer and hepatocellular carcinoma cell lines, and while the SRC1A and SRC1α 
promoters each contribute equally to mRNA transcribed in the colon cancer cell lines 
HT29, COLO 201 and COLO205, in the hepatocellular carcinoma HepG2 cells a 
greater number of transcripts were initiated from the SRC1α promoter (Bonham, et al., 
2000). 
1.5.1. SRC1A Promoter 
 The SRC1A promoter is a housekeeping-like promoter; it is GC rich, 
ubiquitously expressed and transcription is initiated via an Inr element (Bonham and 
Fujita, 1993; Dehm, et al., 2004). This well characterized promoter is regulated by two 
critical Sp1/Sp3 binding sites (GC1 and GA2) and three perfect 
polypurine/polypyrimidine tracts that bind heterogeneous nuclear ribonucleoprotein K 
(hnRNP K) (TC tracts 1, 2 and 3) (Ritchie, et al., 2000; Ritchie, et al., 2003).  
The Sp family of transcription factors has been reviewed in a previous section but the 
interactions between SRC1A and Sp family of transcription factors will be described 
here. In vitro experiments have demonstrated that both Sp1 and at least two forms of 
Sp3 (a longer and shorter form) bind to the GC1 and GA2 sites upstream of the SRC1A 
core promoter region. Furthermore, initial transient transfection experiments indicated 
that Sp1 is a strong activator of SRC1A activity whereas Sp3 has little effect on SRC1A 
activation in the Sp factor deficient Drosophila SL2 cell line. Upon co-transfection with 
both Sp1 and Sp3 factors, Sp3 was able to impede Sp1-mediated activation, presumably 
through competition for binding sites (Ritchie, et al., 2000). To further  
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Figure 1.8. Architecture of SRC. The SRC exons are represented by the green or
black rectangles (1 exon -exon 12). The black exons are untranslated regions and
the grey exons are coding regions. The lines connecting exon 1 and exon 1B, as
well as exon 1A and exon 1B, indicate alternative splicing based on promoter usage.
The SRC1 and SRC1A exons are as indicated. The SRC1 promoter is regulated by
HNF-1 . The SRC 1A promoter is regulated by the Sp family of factors, which bind
to the GC1 and GA2 sites, as well as by hnRNP K which binds to TC1, TC2 and TC3.
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complicate the issue, more recent transient transfection experiments have revealed that 
Sp3 is able to activate the SRC1A promoter, suggesting that further study into the role 
of Sp3 at the SRC1A promoter is required (Dehm, et al., 2004). Despite the confusion 
surrounding the role of Sp3 in SRC1A activation, it is clear that the interactions 
between the Sp family of transcription factors and SRC1A are essential to promoter 
activity as mutations abrogating binding of Sp factors to GC1 and GA2 reduced SRC1A 
activity by 70% (Ritchie, et al., 2000). Similarly, individual deletions of the SRC1A 
TC1, TC2 and TC3 tracts also diminished SRC1A activity by 65%, 45% and 34% 
respectively indicating an essential role for hnRNP K binding in SRC1A activation 
(Ritchie, et al., 2000).  
hnRNP K is a complex protein with pleiotropic functions including: RNA 
splicing, transcriptional activation, chromatin remodeling, mRNA stability, and cellular 
signalling (Bomsztyk, et al., 2004). Specifically, hnRNP K has been reported to 
separate the double stranded DNA of a perfect polypyrimidine/ polypurine tract within 
the c-myc promoter to promote the formation of a single-stranded transcriptional bubble 
and contribute to transcriptional initiation (Michelotti, et al., 1996). At the SRC1A 
promoter, hnRNP K binds to double stranded TC1 and TC2 and to single-stranded TC1, 
2 and 3 in vitro. Through mutation analysis, it has been observed that hnRNP K will 
only bind to the double-stranded tracts if the putative consensus sequence CTTCC is 
maintained. In addition, hnRNP K binds to the single-stranded tracts with greater 
affinity than to the double-stranded tracts and mutations that abolish single-stranded 
binding also abolish double-stranded binding in vitro. As a consequence of these 
findings, it has been suggested that hnRNP K participates in SRC1A transcriptional 
activation in a manner similar to that observed at the c-myc promoter. Specifically, 
binding of hnRNP K to the double-stranded TC1 and TC2 strands facilitates the 
separation of the double-stranded DNA as hnRNP K has a higher affinity for single- 
stranded TC1 and TC2. As a consequence of the strand separation, TC3 becomes single- 
stranded thus providing an additional hnRNP K binding target to mediate the movement 
of the transcription bubble towards the core promoter region and facilitate 
transcriptional initiation (Ritchie, et al., 2003). Furthermore, through the 
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characterization of the SRC1A promoter, it is clear that both the binding of Sp factors 
and hnRNP K are required for maximal SRC1A transcriptional activation.  
1.5.2. SRC1α promoter 
 The SRC1α promoter was originally identified due to the observation that many 
SRC transcripts did not contain a 5’UTR originating from the SRC1A promoter. 
Subsequent experiments identified the SRC1α promoter as an alternative to the SRC1A 
promoter. Similar to the SRC1A promoter, SRC1α -mediated transcription is initiated 
through an Inr element. However, unlike SRC1A, the SRC1alpha promoter is regulated 
by the tissue specific, liver enriched transcription factor, Hepatocyte Nuclear Factor-1 
alpha (HNF-1α) and, as a result, is characteristically active in stomach, kidney and 
pancreas (Bonham, et al., 2000). HNF-1α is a homeodomain transcription factor that 
binds to the GGTTAATNATTAAC(A/C) consensus sequence. The HNF-1α activation 
domain is located at the C-terminus of the protein and is comprised of three isolated 
regions that are absolutely essential for the role of HNF-1α in the activation of 
particular genes (Cereghini, 1996). In addition, HNF-1α can form homodimers or 
heterodimers with the related HNF-1β via a common dimerization domain, although, 
HNF-1α is a stronger transactivator than HNF-1β. In addition, the two family members 
differ structurally in activation domain components, thus suggesting a possible 
mechanism for differential activation by these two related factors (Cereghini, 1996; 
Hayashi, et al., 1999). At the SRC1α promoter, mutations that abolished HNF-1α 
binding resulted in a very dramatic decrease in SRC1α activity, further confirming a 
role for HNF-1α in SRC transcriptional activation (Bonham, et al., 2000). Significantly, 
while the SRC1α promoter contributes equally to mRNA transcribed from a variety of 
colon cancer cell lines and contributes a greater number of transcripts in HepG2 cells, 
the SRC1α promoter is consistently weaker than the SRC1A promoter in transient 
transfection analysis. This observation has led to the suggestion that the activity of the 
SRC1α promoter may be reliant on distal promoter elements such as enhancers (Dehm 
and Bonham, 2004b).  
 
 
 57
1.5.3. HDI -mediated transcriptional repression 
 Increased SRC expression has been observed in a variety of colon cancer and 
breast cell lines. Moreover, this increased expression was the result of transcriptional 
activation and correlated well with increased protein and kinase levels in these cell lines 
(Dehm, et al., 2001; Dehm and Bonham, 2004a). As described in a previous section, 
HDIs are potent chemotherapeutic drugs that are capable of deregulating transcription 
and influencing the activity of many genes. SRC is transcriptionally repressed by the 
HDIs, TSA and Sodium Butyrate. Moreover, although treatment with these drugs does 
not abrogate transcription factor binding to either SRC promoter, this repression does 
not require new protein synthesis and both the SRC1A and SRC1α promoters were 
repressed in a dose -dependent manner (Kostyniuk, et al., 2002). Attempts to identify an 
HDI responsive element common to both highly dissimilar promoters were fruitless. 
However, one common feature exists between the two SRC promoters. Both core 
promoters contain an Inr element and, as such, transcription is TAF1 -dependent. To 
further delve into the relationship between TAF1 dependency and HDI -mediated 
repression, a series of chimera constructs were produced. These constructs were 
chimeras of the SRC core promoter elements and the HDI inducible p21WAF1 distal 
promoter elements and vice versa. Interestingly, all of the SRC/p21WAF1 chimeric 
constructs were repressed by HDIs and -dependent on TAF1 (Dehm, et al., 2004). 
These results suggest a role for core promoter elements, and associated DNA specific 
transcription factors, in HDI -mediated repression.       
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2. SPECIFIC AIMS AND HYPOTHESIS 
 A consistent finding in a variety of cancers, including colon cancer, is an 
increase in c-Src protein levels followed by a corresponding increase in c-Src kinase 
activity. Members of the Bonham laboratory have demonstrated that the increased c-Src 
protein levels often correlate with increased SRC mRNA expression. As a result, the 
transcriptional regulation of SRC in human cancer cells is a source of significant 
interest to those attempting to elucidate the causative mechanisms of cancer. 
Interestingly, SRC expression is inhibited by the promising chemotherapeutic agents, 
known as histone deacetylase inhibitors. The mechanisms underlying this repression are 
unknown but could provide critical clues in determining how SRC expression is 
deregulated in cancer. Previous studies have suggested that these agents repress SRC by 
a mechanism involving both the core promoter and general promoter architecture. The 
basis for the hypothesis and specific aims of this thesis are drawn from the above 
observations. 
 
HYPOTHESIS: Sp1 and Sp3 have contrary roles in SRC activation. Histone 
deacetylase inhibitor treatment results in decreased histone acetylation at SRC 
promoter regions. Histone deacetylases are required for SRC transcriptional 
activity. 
 
SPECIFIC AIMS: 
Specific Aim #1: To characterize the role of the SP family of transcription factors in 
SRC expression in human cancer cell lines. 
Specific Aim #2: To determine the effect of histone deacetylase inhibitors on histone 
acetylation at the promoter regions of genes alternatively affected by histone 
deacetylase inhibitors. To characterize the impact of histone deacetylase inhibitors on 
transcriptional activation at the SRC promoter regions. 
Specific Aim #3: To evaluate the role of histone deacetylases in SRC expression. 
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3. Materials and Methods 
3.1. Reagents and Suppliers 
 The materials and reagents involved in this study are listed in Table 3.1 and are 
molecular biology or reagent grade. The commercially available kits used in this study 
are listed in Table 3.2. The equipment and software used in this study are listed in Table 
3.3. The names and addresses of distributors are listed in Table 3.4.
 
Table 3.1. Materials and Reagent
 
Reagent  Distributor Name 
Acetic acid (glacial) BDH  
Actinomycin D Sigma-Aldrich Co. 
Agarose EMD Chemicals Inc. 
Ampicillin EMD Chemicals Inc. 
β-Mercaptoethanol EMD Chemicals Inc. 
Bacto Agar BD Biosciences 
Boric acid EMD Chemicals Inc. 
Bromophenol blue BDH  
Calcium chloride dihydrate BDH  
Calf Intestinal Alkaline Phosphatase New England Biolabs Ltd.  
Chloroform EMD Chemicals Inc. 
Cycloheximide Sigma-Aldrich Co. 
Diethyl pyrocarbonate  Sigma-Aldrich Co. 
Disodium hydrogen phosphate  EMD Chemicals Inc. 
DMEM Invitrogen – Gibco Cell Culture Systems 
DMEM-F12 Invitrogen – Gibco Cell Culture Systems 
DMSO Sigma-Aldrich Co. 
dNTPs New England Biolabs Ltd.  
EDTA EMD Chemicals Inc. 
Ethidium bromide BDH  
Fetal Bovine Serum HyClone  
Formaldehyde EMD Chemicals Inc. 
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Formamide BDH  
GeneScreen Plus Hybridization Transfer 
Membrane  PerkinElmer Life Sciences, Inc.  
Glycerol EMD Chemicals Inc. 
Glycine EMD Chemicals Inc. 
Guanidinium thiocyanate BDH  
Humulin Eli Lilly Canada Inc. 
Hydrochloric acid EMD Chemicals Inc. 
Isoamyl alcohol BDH  
Isopropanol EMD Chemicals Inc. 
Kanamycin EMD Chemicals Inc. 
Klenow Fragment  Fermentas Canada Inc.  
Lambda DNA GE Healthcare Bio-Sciences Inc.  
Manganese chloride tetrahydrate  BDH  
Magnesium chloride BDH  
Morpholinopropanesulfonic acid (MOPS) Sigma-Aldrich Co. 
N-Lauroyl sarcosine Sigma-Aldrich Co. 
O’GeneRuler 50 bp DNA Ladder  Fermentas Canada Inc.  
O’GeneRuler 1 kb DNA Ladder  Fermentas Canada Inc.  
o-nitrophenyl-β-D-galactopyranoside Sigma-Aldrich Co. 
pBluescript KS + Stratagene 
pCAT3-Basic Promega 
penicillin-streptomycin  Invitrogen – Gibco Cell Culture Systems 
Pfu DNA Polymerase Fermentas Canada Inc.  
Phenol (water saturated) EMD Chemicals Inc. 
Potassium Acetate BDH  
Potassium Chloride EMD Chemicals Inc. 
Potassium dihydrogen phosphate EMD Chemicals Inc. 
Protein Assay Dye Reagent Concentrate Bio-Rad Laboratories Ltd. 
Rubidium Chloride EMD Chemicals Inc. 
Restriction endonucleases New England Biolabs Ltd.  
RPMI–1640 Invitrogen – Gibco Cell Culture Systems 
Shrimp Alkaline Phosphatase Fermentas Canada Inc.  
Sodium acetate  BDH  
Sodium butytrate Sigma-Aldrich Co. 
Sodium bicarbonate EMD Chemicals Inc. 
Sodium carbonate EMD Chemicals Inc. 
Sodium chloride EMD Chemicals Inc. 
 61
Sodium citrate BDH  
Sodium dihydrogen phosphate  BDH  
Sodium hydroxide BDH  
Sodium phosphate (monobasic) EMD Chemicals Inc. 
Sodium phosphate (dibasic) EMD Chemicals Inc. 
SuperFect Transfection Reagent Qiagen Inc.  
T4 DNA Polymerase GE Healthcare Bio-Sciences Inc.  
Taq DNA Polymerase Qiagen Inc.  
Trichostatin A  Sigma-Aldrich Co. 
Tris EMD Chemicals Inc. 
Trypsin-EDTA 1X Invitrogen – Gibco Cell Culture Systems 
Xylene Cyanol FF BDH 
 
Table 3.2. Commercially available kits 
Commercial Kit Distributor Name 
CAT ELISA Kit Roche Diagnostics 
EndoFree Plasmid Maxi Kit Qiagen Inc.  
FastPlasmid Mini Kit Eppendorf AG 
QIAfilter Plasmid Midi Kit  Qiagen Inc.  
QIAprep Miniprep Kit Qiagen Inc.  
QIAquick Gel Extraction Kit Qiagen Inc.  
Quick Ligation Kit  New England Biolabs, Ltd.  
Zero Blunt TOPO PCR Cloning Kit Invitrogen 
 
Table 3.3. Equipment and Software 
Equipment and Software Distributor Name 
Biofuge 13 microcentrifuge Thermo Electron Corporation - Heraeus  
CO2 Incubator 3326 Forma Scientific, Inc.  
Coulter Counter ZM  Coulter Electronics, Ltd. 
Gel Doc 2000 Bio-Rad Laboratories Ltd. 
Gene Amp PCR System 2700 Applied Biosystems Canada 
Horizontal Gel Electrophoresis System Owl Separation Systems 
Isotemp Incubator 230D Fisher Scientific Company 
JA-10 rotor Beckman Coulter Canada, Inc. 
J2-MI highspeed centrifuge Beckman Coulter Canada, Inc. 
MacVector 7.2.3 Accelrys Inc. 
Microplate Reader Model 3550 Bio-Rad Laboratories Ltd. 
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Molecular Imager FX Bio-Rad Laboratories Ltd. 
ORBIT Incubator Shaker  Lab-Line 
SmartSpec 3000 Spectrophotometer  Bio-Rad Laboratories Ltd. 
Sorvall RT6000D Du Pont Canada, Inc. 
Quantity One Software, Version 4 Bio-Rad Laboratories Ltd. 
UV Stratalinker 2400 Stratagene 
 
Table 3.4. Names and Addresses of Distributors 
Distributor Name Address 
Accelrys Inc.  Accelrys Inc., San Diego, CA, USA 
Applied Biosystems Canada 
Applied Biosystems Canada, Streetsville, 
ON, Canada 
BarnsteadIThermolyne Corp. 
International  
BarnsteadIThermolyne Corp., Dubuque, 
Iowa, USA 
BD Biosciences BD Biosciences, Mississauga, ON, Canada
BDH Inc. BDH Inc., Toronto, ON, Canada 
Beckman Coulter Canada, Inc.  
Beckman Coulter Canada, Inc., 
Mississauga, ON, Canada  
Bio-Rad Laboratories Ltd.  
Bio-Rad Laboratories Ltd., Mississauga, 
ON, Canada 
Coulter Electronics Ltd.  
Coulter Electronics Ltd. Luton, Beds., 
England 
Du Pont Canada, Inc. 
Du Pont Canada, Inc., Mississauga, ON, 
Canada 
Eli Lilly Canada Inc. 
Eli Lilly Canada Inc., Scarborough, ON, 
Canada 
EMD Chemicals Inc. 
EMD Chemicals Inc., Gibbstown, NJ, 
USA 
Eppendorf AG Eppendorf AG, Hamberg, Germany 
Fermentas Canada Inc.  
Fermentas Canada Inc., Burlington, ON, 
Canada 
Fisher Scientific Company 
Fisher Scientific Company, Nepean, ON, 
Canada 
Forma Scientific, Inc.  Forma Scientific, Inc., Marietta, OH, USA
GE Healthcare Bio-Sciences Inc. 
GE Healthcare Bio-Sciences Inc., Baie 
d'Urfe, QC, Canada 
HyClone HyClone, Logan, UT, USA 
Integrated DNA Technologies, Inc. 
Integrated DNA Technologies, Inc., 
Coralville, IA, USA 
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Invitrogen Canada Inc. 
Invitrogen Canada Inc., Burlington, ON, 
Canada 
New England Biolabs, Ltd.  
New England Biolabs, Ltd., Pickering, 
ON, Canada 
Owl Separation Systems 
Owl Separation Systems, Portsmouth, NH, 
USA 
PerkinElmer Life Sciences, Inc.  
PerkinElmer Life Sciences, Inc., Boston, 
MA, USA 
Promega  Promega, Madison, WI, USA 
Qiagen Inc.  Qiagen Inc., Mississauga, ON, Canada 
Roche Diagnostics Roche Diagnostics, Laval, QC, Canada 
Sigma-Aldrich Co. Sigma-Aldrich Co., Oakville, ON, Canada
Stratagene Stratagene, La Jolla, CA, USA 
Thermo Electron Corporation - Heraeus  
Thermo Electron Corporation, Waltham, 
MA, USA  
 
 
3.2. Tissue Culture and Cell lines 
3.2.1. Cell lines and Standard Tissue Culture conditions 
 All cell lines utilized in this study were obtained from the American Type 
Culture Collection (ATCC). Tissue culture media required for these studies was 
obtained from Invitrogen. HT29 and SW480 cells were grown in DMEM supplemented 
with 10% fetal calf serum (FCS, HyClone). HepG2 cells were grown in DMEM F12 
supplemented with 10% FCS. The Drosophila SL2 cell line was grown in Schneider’s 
media (GibcoBRL) supplemented with 10% FCS. All cells were maintained at 37°C 
and 5% CO2, except for SL2 cells, which were maintained at room temperature and 
approximately 0.05% CO2. 
3.2.2. Histone Deacetylase Inhibitor Treatment 
 Exponentially growing cells were trypsinized and seeded such that they were 
between 50-70% confluent at time of treatment. Twenty-four hours post-seeding cells 
were treated with 1µM trichostatin A (TSA, Sigma) and harvested at various time 
points.  
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3.2.3. ChIP Tissue Culture 
 Exponentially growing HepG2 and HT29 cells were trypsinized and seeded such 
that they were between 50-70% confluent at time of treatment. Twenty-four hours post-
seeding, cells were treated with 1µM TSA. At set time points, formaldehyde was
added directly to growth media to a final concentration of 1% and cells were incubated 
at 37°C for 10 minutes. Cells were washed twice in ice cold Phosphate buffered saline 
(PBS, 0.15 M NaCl, 20 mM sodium phosphate, pH 7.4) containing freshly added 
protease inhibitor mix (PIM, Sigma), 1 µM pepstatin A, 1 M sodium vanadate and 1 M 
Sodium Fluoride. Cells were scraped off the plate, pelleted and flash frozen to be stored 
at -80°C until use. Generally, 5x106 or 13-16x106 cells were aliquoted and pelleted per 
tube to be used in an antibody -dependent manner.  
 
3.3. Bacterial Strains 
 Escherichia coli (E. coli) strain TOP10 was used in the production of all plasmid 
vectors. Transformed E. coli cells were grown at 37°C in shaking incubator in Luria-
Bertani (LB, 1% tryptone (w/v), 0.5% yeast extract (w/v), 1% sodium chloride (w/v), 
BD) broth supplemented with 100 µg/mL ampicillin or 34 µg/mL kanomycin (Fisher). 
LB-agar plates selective for transformed E. coli colonies were made with LB broth 
supplemented with 1.5% (w/v) agar and appropriate antibiotic. Plates were incubated 
overnight in a 37°C incubator. 
 
3.4. General Molecular Biology Techniques 
 The majority of techniques used in this study are based on those outlined by 
Sambrook (Sambrook et al, 1989). 
3.4.1. Molecular Cloning 
3.4.1.1. Restriction Enzyme Digestion 
 All restriction enzymes used were obtained from New England Biolabs. 
Generally, digestions were performed with DNA at a concentration of 1 µg/µL and 
appropriate volumes of enzyme such that 1 µg DNA was incubated with 1 Unit of 
enzyme. The buffer used in these studies was One-Phor-All Buffer Plus (OPA, 
Amersham Biosciences) at appropriate concentrations as suggested by the 
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manufacturer. Reactions requiring complete digestion, were placed in 37°C incubator 
for a minimum of two hours, whereas, those requiring partial digestion were incubated 
at 37°C for a maximum of fifteen minutes. Partial digestion reactions were stopped with 
6x loading dye (0.25% (v/v) bromophenol blue, 0.25% (v/v) xylene cyanol FF, 30% 
glycerol (v/v) and 10 mM ethylenediamine tetracetic acid (EDTA)). 
3.4.1.2. Polymerase Chain Reaction 
 Polymerase chain reactions (PCR) were performed with either Taq (Qiagen) or 
Pfu DNA polymerase (Stratagene), the buffers supplied with the enzymes, dNTPs 
(Amersham Biosciences) and specifically designed forward and reverse primers 
(Invitrogen). Concentrations of reaction components were determined by following 
manufacture instructions. Primers were designed using either MacVector or Vector NTI 
Advance 10 software inputed with target sequences; annealing temperatures were
derived at time of primer design using the above software. Generally, sequences of 
interest were amplified by 30 cycles in the thermocycler (GeneAmp 2700, Applied 
Biosystems), with a melting temperature of 95°C and an extension temperature of either 
68°C (Pfu) or 72°C (Taq). Extension times varied based on the size of the expected 
product and enzyme used; Taq driven extensions were determined using a 2 kb/min. 
rule and Pfu driven extensions determined using a 0.5 kb/min. rule.
3.4.1.3. Removal of 5’ Terminal Phosphate 
 In order to dephosphorylate the 5’ terminal ends of vector DNA prior to ligation, 
1 Unit of calf intestinal alkaline phosphatase (Pharmacia Biotech) was added to 
restriction enzyme digests and incubated at room temperature for one hour. 
3.4.1.4. Agarose Gel Electrophoresis 
 Agarose gels consisted of 0.75-2% agarose (w/v) (EMD) in TAE buffer (40 mM 
Tris-acetate, 1mM EDTA, pH. 8.0) or TBE buffer (45 mM Tris-borate, 1 mM EDTA, 
pH. 8.0). DNA fragments were loaded with 6X gel loading buffer into wells of agarose 
gel. Electrophoresis was performed for at least 45 minutes at 90 volts in either TAE or 
TBE buffer.  
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3.4.1.5. Purification of DNA Fragments 
 DNA separated by agarose gel electrophoresis for ligation reactions was cut out 
of the agarose gel and then isolated from the agarose using the MiniElute Gel Extraction 
Kit, the QIAquick Gel Extraction Kit or QIAEX II Gel Extraction Kit as per 
manufacture instructions (all kits available from Qiagen). 
3.4.1.6. DNA Ligation 
 DNA ligations were performed using Quick T4 DNA ligase (New England 
Biolabs) and supplied buffer. Ligation reactions were generally performed using equal 
concentrations of purified dephosphorylated vector and purified insert (50 ng of vector 
and 50 ng of insert) in a final volume of 21 µL including supplied ligation buffer and 
enzyme. Reactions proceeded at room temperature for 13 minutes.      
3.4.2. Site Directed Mutagenesis 
 All mutated constructs were obtained by using the QuickChange (Stratagene) 
site directed mutagenesis protocol with specifically designed primers that overlapped 
the site of mutation. Primers were designed using MacVector software. 
3.4.3. DNA Sequencing 
 Automated DNA sequencing was performed either by Annette Kerviche at the 
Saskatchewan Cancer Agency using an ABI Prism 310 Genetic Analyser or by Inge 
Roewer at the PBI/NRC DNA Sequencing Lab using a 96-capillary AB 3730x/DNA 
sequence analyser.  
3.4.4. Preparation and Transformation of Competent Cells 
 E. coli TOP10 cells were rendered competent for transformation prepared using 
a protocol described by Hanahan (Hananhan, 1983). Similarly, competent cells were 
transformed as described (Hananhan, 1983), plated onto LB plates supplemented with 
appropriate selective antibiotic and incubated overnight at 37°C. 
3.4.5. Isolation of Plasmid DNA from Bacterial Cells 
3.4.5.1. Small Scale Plasmid Purification 
 Isolated, transformed, bacterial colonies were picked from LB-agar plates, 
placed in 3 mL of LB-ampicillin/kanamycin culture media. Cultures were allowed to 
grow overnight at 37°C in the shaking incubator. The isolation of small quantities of 
plasmid DNA (<20 µg) from the cultures was performed by using either the 
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FastPlasmid Mini Kit (Eppendorf, VWR) or the QIAprep Spin Miniprep Kit (Qiagen) 
as per manufacturer’s instructions.  
3.4.5.2. Medium Scale Plasmid Purification 
 The isolation of moderate quantities of plasmid DNA (<100 µg) was performed 
by using the Plasmid Midi Kit (Qiagen). The isolation of plasmid DNA using this kit 
was performed as per manufacturer’s instructions with the following exceptions: One 
mL of Buffer ER was added to the lysate after filtration of the lysate through the 
QIAfilter cartridge. Lysate was incubated on ice for 30 min. prior to filtration. All 
buffers used were of Endofree quality thus resulting in transfection quality plasmid 
DNA. 
3.4.5.3. Large Scale Plasmid Purification 
 The isolation of large quantities of plasmid DNA (<500 µg) was performed 
using the Endofree Plasmid Maxi Kit (Qiagen) as per manufacturer’s instructions. This 
kit provided plasmid DNA sufficiently pure to be utilized in mammalian transient 
transfection. 
 
3.4.6. Isolation of RNA from Eukaryotic cells 
 RNA was isolated from dividing mammalian cultured cells as outlined by the 
guanidinium thiocyanate protocol reported by Chomczynski and Sacchi (Chomczynski 
and Sacchi, 1987). Purified RNA pellets were resuspended in RNA storage buffer (0.1 
mM EDTA, 0.1% (v/v) diethyl pyrocarbonate (DEPC)). Concentration and quality of 
isolated RNA was assessed by A260/A280. RNA with an A260/A280 ratio of above 1.7 was 
considered acceptable for analysis. 
 
3.4.7. Isolation of protein from Eukaryotic cells 
 Cultured mammalian cells were washed once in ice cold PBS and lysed directly 
in SDS loading buffer (65 mM Tris-HCL (pH. 7.0), 2% (w/v) SDS, 5 % β-
mercaptoethanol, 10% (v/v) glycerol and 0.5% (w/v) bromophenol blue). Samples were 
processed by the movement of the samples through a 27.5 gauge syringe until no longer 
viscous. Samples were subsequently stored at -80°C. 
 
 68
3.4.8. Generation of radioactively labelled DNA Probes 
Uniformly [P32]-labelled radioactive probes suitable for Northern blot analysis 
were labelled through the random labelling of DNA fragments by the Ready-To-Go 
Labelled Beads (dCTP) kit (Amersham Biosciences) as per kit instructions. 
 
3.4.9. Protein Concentration Determination 
3.4.9.1. Bradford Method 
 The Bradford method was used to determine the protein concentration in cell 
lysates obtained from transient transfection studies. The assay required the addition of 
10-15 µL cell lysate into 500 µL diluted Bradford reagent (Biorad). The reaction was 
incubated for ten minutes and then samples were read at A595. Serial dilutions of bovine 
serum albumin (BSA) were assayed as protein standards. 
3.4.9.2. Lowry Method 
 The Lowry method of protein quantification was used to assess the protein 
concentration of lysates obtained through cell lysis by SDS sample buffer. The protocol 
used was as outlined by manufacturer’s instructions for the Total Protein Kit, Micro 
Lowry (Sigma, Peterson’s modification). 
 
3.5. Plasmid Construction 
3.5.1. Expression Constructs  
 The CMV β-galactosidase (β-Gal) expression construct was a gift from 
Dr. W. Roesler (Biochemistry, University of Saskatchewan). The pBluescript II SK(+) 
was obtained from Fermentas. The Drosophila specific β-galactosidase (p97b) 
expression construct was a gift from Dr. L. Lania (University of Naples "Federico II," 
Naples, Italy). The SuPr-1 construct was a generous gift from Dr. L. Zon (Boston 
Children’s Hospital, Boston, Massachusetts). HDAC (Histone deacetylase) 1 and 2 
expression constructs were gifts from Dr. J. Davie (Manitoba Institute of Cell Biology, 
University of Manitoba). HDAC3 and 8 expression constructs were gifts from Dr. E. 
Seto (Moffit Cancer Centre, Tampa Bay, Florida). The HDAC5 expression vector was a 
gift from Dr. S. Khochobin (Institute Albert Bonniot, Grenoble, France). The HDAC6 
and 10 expression vectors were kind gifts from Dr. Xiang-Jiao Yang (University of 
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McGill, Montreal, Quebec). The HDAC7 expression construct was a gift from Dr. E. 
Verdin (University of California, San Francisco, California).  
3.5.2. CAT Reporter Constructs 
 The 0.38 SRC1A-CAT, 0.38 SRC1AGC1mut-CAT and 0.38 
SRC1AGA2mut-CAT (CAT- chloramphenicol transferase) reporter constructs have 
been previously described (Bonham et al., 2000). The SRC1A∆GC1/GA2-GAL4-CAT 
has also been previously described (Dehm et al., 2004). The SRC1AGA2mut∆GC1-
GAL4-CAT construct has been previously described (Ellis et al., 2006). 
3.5.3. GAL4 Expression Constructs 
             All Sp1 and Sp3 expression vectors used in this study are depicted in Fig. 3.1. 
The pSG4-Sp3(GAL4Sp3∆N(SG4)) and the pSG4-
Sp3K539R(GAL4Sp3∆NRmut(SG4)) were kind gifts from Dr. G. Gill (Harvard 
Medical School, Boston, Massachusetts). The pSG424(DNA binding domain (DBD) 
construct used in SG4 transfections) construct was obtained from Dr. R. O’Brien 
(Vanderbuilt University, Nashville, Tennessee). Plasmids pM(DBD construct used in all 
pM vector experiments), GAL4/Sp3(GAL4Sp3∆N(pM)) and GAL4Sp1  were gifts from 
Dr. T. Sakai (Kyoto University, Kyoto, Japan). GAL4Sp3li was constructed by 
digesting both the pM vector and pPacSp3FL-NEW with BamHI. The subsequent 
fragment was inserted into the pM plasmid. GAL4Sp3liRmut and GAL4Sp3liQmut 
were produced by site-directed mutagenesis and the mutagenic primers specific for 
arginine (R) and glutamine (Q), respectively, as outlined above. The GAL4Sp3M1 
construct was made by producing a PCR fragment with the following primers: sense 
(5’GGAATTCGCTATGGATAGTTCAGAC, EcoRI site inserted into primer) and anti-
sense (5’ATGGATCCGCAGCTTCCACAGATGCCAG, BamHI site inserted into 
primer). The resulting PCR fragment and pM vector were digested with EcoRI and 
BamHI. The PCR fragment was then inserted into the vector. The GALSp3M2 construct 
was produced via PCR with the following primers: sense 
(5’GGATTCCAGACAATGACTGCAGGC, EcoRI site contained) and anti-sense 
(5’ATGGATCCGCAGCTTCCACAGATGCCAG, BamHI site contained). The product  
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Figure 3.1. Sp1 and Sp3 constructs used in these studies. (A) The structure of Sp1
and Sp3. The black bands indicate the DNA binding domain, AD the activation
domain, ID the inhibitory domain, N the amino terminal and C the carboxy terminal.
The critical lysine residue present in all Sp3 isoforms is in bold with adjacent amino
acids. The arrows indicate the translational start sites of Sp3. (B) The GAL4 expression
constructs used to study Sp1 and Sp3 in human cells. All of the GAL4 Sp3 expression
constructs were produced with a common pM vector backbone and fused to a GAL4
DNA binding domain unless otherwise noted. GAL4Sp3li construct produces one full
length construct but is representative of both full length isoforms that are nearly equal
in size and functionally identical. GAL4Sp3 N(SG4) expresses the Sp3 N isoform
that is N-terminally truncated by ~100 amino acids and fused to the GAL4 DNA
binding domain (DBD) of the SG424 construct. GAL4Sp3 N(pM) expresses the
Sp3 N isoform (see above) but is fused to the GAL4 DBD of the pM construct.
GAL4Sp3M1 and M2 are the shortest Sp3 isoforms derived from the GAL4 internal
translation start sites and fused to GAL4 DBD of the pM construct. (C) The pPac
expression constructs used for Sp1 and Sp3 analysis in SL2 cells.
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and plasmid pM were digested with EcoRI and BamHI and the resulting fragment 
inserted into vector pM. The GAL4Sp3M1R and Q mutants and GAL4Sp3M2R and Q 
mutants were produced by site-directed mutagenesis with the indicated primers as 
described above. 
3.5.4. pPac Expression Constructs 
The Drosophila specific pPacSp3(pPacSp3M), pPacUSp3(pPacSp3∆N), 
pPacUSp3-K-mut(pPacSp3∆NRmut), pPacSp3FL-NEW(pPacSp3li), and pPacSp3FL-
NEW-K/R(pPacSp3MRmut) constructs were very generous gifts from Dr. G. Suske 
(Marburg University, Germany). pPacSp1 was a donation from Dr. R. Tijan (Howard 
Hughes Medical Institute, University of California). pPacSp3Rmut (arginine mutation) 
was created through site-directed mutagenesis using the following mutagenic primers: 
sense (5’GGATCAGAGAAGAAGAACCTGATCC) and  
anti-sense (5’ GGATCAGGTTCTTCTTCTCTGATCC). 
pPacSp3MQmut and pPacSp3∆NQmut (glutamine mutation) were made with the 
following mutagenic primers: sense (5’GGATCCAGGAAGAAGAACCTGATCC) and 
anti-sense (5’ GGATCAGGTTCTTCTTCTCTGATCC).  
 
3.6. Transient Transfection of Eukaryotic Cell Lines 
3.6.1. Transfection with Reporter Constructs 
 All transfections were performed with plasmid DNA isolated from Qiagen’s 
EndoFree Plasmid Maxi kit or the Plasmid Midi kit (Qiagen) modified to produce 
endofree plasmids and thus all transfected plasmids were endotoxin free. 
3.6.1.1. Mammalian Cells 
 Generally, a typical co-transfection reaction consisted of 0.5-0.75 µg reporter 
(CAT) DNA, 0.5 µg CMV β-gal and 0-1 µg of plasmid DNA expressing the activator or 
repressor under study. The final concentration of DNA transfected into the cells was 
maintained at 2.0 µg by the addition of pBluescript. The DNA was mixed together in 85 
µL serum free media; 10 µL of Superfect Transfection Reagent (Qiagen) was added and 
the reaction was incubated at room temperature for 20 minutes. During this incubation 
period, cells seeded at various confluencies the day before, were rinsed once in ice cold 
PBS. Subsequent to DNA complex incubation, 0.6 mL of serum-containing media was 
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added to the complexes, vortexed and added to cells. The transfections were allowed to 
proceed for 2.5 hours at which time 3 mL of serum-containing media was added to the 
cells. Cells were allowed to grow for an additional 48 hours prior to harvesting cell 
lysates. Specifically, in the GAL4 studies, 0.75 µg CAT-reporter DNA and 0.047-0.75 
µg of GAL4DBD, GAL4Sp1 or GAL4Sp3 DNA was used. For the HDAC 
overexpression transfections, 0.5 µg reporter DNA and 0.25-1.0 µg HDAC DNA was 
used. Cells seeded 24 hours prior to transfection were seeded at the following 
confluencies: HepG2 cells at 2.5x105/35 mm plate and SW480 cells at 5.0x105/35 mm 
plate.   
3.6.1.2. Insect Cells 
 All transfections into Drosophila SL2 cells were performed using Effectine 
reagent (Qiagen) at room temperature. Transfection mixtures were composed of 0.55 µg 
CAT reporter construct, 0.43 µg of p97b (β-galactosidase vector) and up to 85 ng of 
pPac expression construct. The final concentration of DNA transfected into the cell was 
maintained at 1 µg by the addition of pBluescript. In a typical transfection, 1 µg DNA 
was mixed with Buffer EC to a final volume of 100 µl, 8 µl Enhancer was added and 
mixtures were incubated at room temperature for 5 minutes. Following the incubation, 
10 µl Effectine reagent was added to the mixture and incubated for a further 10 minutes. 
During this incubation period, cells seeded the previous day at 6x105 per 35 mm plate 
were aspirated of media and 0.8 mL of new media was added per plate. Following the 
incubation, 0.6ml of media was added to the DNA/BufferEC/Enhancer/Reagent 
complexes, mixed and added to each well. The cells were grown for 48 hours at which 
time they were lysed. 
 
3.6.2. Transfection with siRNA  
 All class I HDAC siRNA SMARTpools were obtained from Dharmacon RNA 
technologies (#M-003494-00-05, M-003495-00, M-003496-00-05, M-003500-00). 
HDAC 5, 6 and 10 siRNA was obtained from Ambion and HDAC 7 siRNA was 
obtained from Qiagen (#16708, 51320, 16708 and #S102777726). All siRNA specific 
for class II HDACs were specific for the HDAC in question and we were not given the 
target sequence. HT29 cells were seeded at 3x105/ 35 mm plate and HepG2 cells were 
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seeded at 2.5x105/ 35 mm plate 24 hours prior to transfection. In a typical siRNA 
transfection, 10 µL Lipofectamine 2000 (Invitrogen) was added to 0.5 mL OptiMEM 
(GibcoBRL) and incubated at room temperature for 15 minutes. After the incubation, 
200 pmol of siRNA (final siRNA concentration of 100 nM) mixed with 0.5 mL 
OptiMEM was added to the reagent/media mixture and incubated for a further 15 
minutes at room temperature. During this incubation, previously seeded cells were 
rinsed once with ice cold PBS and 1 mL of fresh complete media was added. Following 
the incubation, the siRNA/reagent complexes were added directly to the cells. 
Transfection was allowed to proceed for 6 hours at which time 2 mL of fresh complete 
media was added to the cells. Cells were harvested 48, 72 or 96 hours post-transfection. 
All transfection sets included mock (no siRNA) and scrambled siRNA (Dharmacon, 
Ambion) reaction.
 
3.7. Analysis of Reporter Gene Activity 
 Transiently transfected cells were rinsed once in ice-cold PBS 48 hours post-
transfection and harvested in 500 µL 1 X lysis buffer available from Roche Applied 
Science.   
3.7.1. β-Galactosidase Assay 
 A colorimetric assay described by Hall (Hall et al., 1983) was used to identify 
the uniformity of transfection efficiency among samples prior to performing CAT-
ELISA studies. The reaction mixtures were placed at 37°C until a yellow colour 
developed. Colour development was halted by the addition of 120 µL of 1M Sodium 
Carbonate (NaCO3, EMD Chemicals) stop solution. The sample absorbance was 
measured at a wavelength of 415 nm with a microplate reader. 
3.7.2. Chloramphenicol Acetyltransferase Enzyme Linked Immunosorbant Assay 
(CAT ELIZA)  
 Levels of CAT expression in 200 µL of lysate were assayed using CAT-ELISA 
kit as per manufacturer’s instructions (Roche Applied Sciences).  
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3.8. Western Blot Analysis 
3.8.1. Western Procedure 
 Equal amounts of protein were resolved on a 10% SDS-polyacrylamide gels and 
transferred to a nitrocellulose membrane (PALL Life Sciences). Protein amounts 
resolved per well/gel varied depending on the experiment; 15 µg of protein isolated 
from siRNA transfected cells and 30 µg of protein isolated from transiently transfected 
cells.  
3.8.2. Analysis of Western Blot with Chemiluminescence 
Membranes were washed in TBST buffer (10 mM Tris, 15 mM NaCl, 0.5% 
(v/v) Tween-20) and blocked either at room temperature for 1 hour or at 4°C overnight 
in blocking buffer (5% (w/v) fat-free skim milk powder (Carnation) in TBST). 
Membranes were incubated for a minimum of one hour at room temperature in primary 
antibody diluted in blocking buffer. After incubation, membranes were washed thrice 
with TBST buffer and then incubated for a minimum of one hour at room temperature 
in secondary antibody (horsedradish peroxidase conjugate) diluted in blocking buffer. 
Subsequently, membranes were washed thrice in TBST buffer and incubated in 
chemiluminescent reagent (Pierce) at room temperature for one minute. Signal detection 
was achieved through exposure to Kodak X-Omat Blue XB-1 film. Primary antibodies 
used include: Sp3 (Santa Cruz Biotechnology, sc-644), HDAC 1 (05-614, Upstate), 
HDAC 2 (05-814, Upstate), Src (05-184, Upstate) and actin (Ab-1, Calbiochem). Host 
appropriate secondary antibodies were all obtained from Santa Cruz Biotechnology.   
3.8.3. Analysis of Western Blot with LICOR Technology 
 Membranes were treated as recommended by LICOR Technologies (Western 
Blot Analysis Protocol). Host specific secondary antibodies were diluted 1:15,000 into 
Odyssey Blocking Buffer (LICOR Technologies) and were specifically obtained from 
LICOR Technologies. Primary antibodies used in these studies were identical to those 
used for Western Blotting with chemiluminesent detection. 
 
3.9. Reverse Transcriptase Polymerase Chain Reaction (RT-PCR) 
 Total RNA was isolated as described above and subjected to RT-PCR using 
Qiagen’s One Step RT-PCR Kit as per manufacturer’s instructions. RT-PCR primers 
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were designed using MacVector or Vector NTI Advance 10 software. The primers used 
in these studies were as follows:  
 
 
Table 3.5. RT-PCR Primers 
HDAC1 FOR: 5’-AAGGGGTGGCTGGGTCTTCAAGGA 
REV: 5’-ACAGAGGGCAGGCAGTGTTTCTTG 
HDAC2 
 
FOR: 5’-GCCACTGCCGAAGAAATG 
REV: 5’-ATGATGTAATCCTCCAGCCC 
HDAC3 FOR: 5’-GAGTGGCTTGGGATGCTGTG 
REV: 5’-GGAGGAAGTCAGAGGCAATCTCAG 
HDAC4 FOR: 5’-CCCCCACCAAGCCGAGGT 
REV: 5’-CGTCCGCGGATGCACTCG 
HDAC5 FOR: 5’-ACAGGTGTGGTCTACGAC 
REV: 5’-TTTGCGACCTCGGATCCG 
HDAC6 FOR: 5’-GGGCAGTCCCCTGAGGAGCGG 
REV: 5’-GCCTTCCGGGAAGCTGTC 
HDAC7 FOR: 5’-GCAGCGCTCGGTGGAGCCCA 
REV: 5’-CGGGCGTGCTGCTACTAC 
HDAC8 FOR: 5’-TTATGTGCTGGAAATCACGCC 
REV: 5’-CCTCCTGCCTACAAACTGGTG 
HDAC9 FOR: 5’-TTAATTCAGTTGCAATTACCGCCAAATAC 
REV: 5’-TCAAACTCTTTGGCCACA 
HDAC10 FOR: 5’-CCGGCTGCTCTGGGACGACC 
REV: 5’-CCGCGCGCAGTGAAAGGT 
SRC FOR: 5’-GGCTACATCCCCAGCAACTACG 
REV: 5’-CCCTTGAGAAAGTCCAGCAAACTC 
RPL13A FOR: 5’-CAAGGTGTTTGACGGCATCC 
REV: 5’-GCTTTCTCTTTCCTCTTCTCCTCC 
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The majority of the primers were designed to span intronic sequences to ensure that the 
amplified product of desired size was derived from mRNA transcript and not genomic 
DNA. Products were visualized using agarose gel electrophoresis.                              
 
3.10. Chromatin Immunoprecipitation (ChIP) Assays 
 Cell pellets isolated during ChIP tissue culture were subjected to ChIP analysis 
using Upstate’s ChIP Assay Kit as per manufacturer’s instructions. The following 
modifications were made to the kit protocol. Cell pellets were lysed in either 350 µL 
(for pellets containing 5X106 cells) or 1 mL (for pellets containing 13-16X106 cells) 
SDS Sample Buffer (Upstate) diluted with protease inhibitors (1 X PIM, 1 µM pepstatin 
A, 1M Sodium Vanadate and 1 M Sodium Fluoride). Genomic DNA was sheared for 35 
seconds using a Branson Sonifier 450 sonicator (output control of 1.5, 60% duty cycle) 
to an average size of 300-800 bp. Cleared lysates were split into three fractions; input 
fraction, positive antibody fraction and negative antibody fraction. Subsequent to ChIP 
protocol, resultant genomic DNA was subjected to PCR analysis to identify factor 
enrichment at specific genomic loci. PCR products were analysed by agarose gel 
electrophoresis. The PCR primers used in these studies are described below:  
Table 3.6. ChIP PCR Primers   
SRC1alpha FOR: 5’-GACAAGTCGATCAGCTTCC 
REV: 5’-GCAAGTAGGTAAGGGCCAG 
SRC1A FOR: 5’-AGGCGGATCTGGGGCGTAG 
REV: 5’-ATTCCGGGCCGGGAGAGAC 
p21(#1) FOR: 5’-GGGCGGGGCGGTTGTATATCAG 
REV:5’-GTCTGCCGCCGCTCTCTCACCT 
p21(#2) FOR: 5’-CGCACCAACGCAGGCGAGGG 
REV: 5’-ACGCTTGGCTCGGCTCTGGG 
RPL13A FOR: 5’-TCAGTCGCTTGAAGGGGTAATG 
REV: 5’-AAGGAGGAGGTTTTGTCGCAGG 
Exon1A/1B FOR: 5’-TCAGTGTGGCTTCAGTGAGGTG 
REV: 5’-CCTGGTGAGGTTTACCCAAAAAG 
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Exon1B/1C FOR: 5’-CCATTGACTTGTCCCTCAGGAG 
REV: 5’-GGCAGGTTCCGATTATTCTTTGG 
Exon4/5(#1) FOR: 5’-TCCTACTCACCCTCCCATTC 
REV: 5’-CCTCCACCTGCCAGATAACTTCAC
Exon4/5(#2) FOR: 5’-TGCTGAGTGCTTGAAGTTGCG 
REV: 5’-CCAGGTGAAAAAGGCAGAACC 
3’UTR FOR: 5’-TCAAACCCTGCCCTCCTTAGAC 
REV: 5’-CATCACCCACAAGCCGATTG 
   
The antibodies used in these studies include: Sp3 (Santa Cruz Biotechnology, sc-644 
and Upstate, 07-107), Sp1 (Santa Cruz Biotechnology, sc-420 and Upstate, 07-645), 
hnRNP K (a kind gift from Dr. Gideon Dreyfuss, Howard Hughes Medical Institute, 
Philadelphia, Pennsylvania), HDAC1 (05-614, Upstate), RNA Polymerase II (Upstate, 
05-623 clone CTD4H8), RNA Polymerase II CTD Serine 2 Phospho-specific (Bethyl 
Laboratories Inc., BL2894),  RNA Polymerase II CTD Serine 2 Phospho-specific 
(Bethyl Laboratories Inc., BL2896), Acetylated Histone H3 (Upstate, 06-599), 
Acetylated Histone H4 (Upstate, 06-866), Trimethylated Histone H3K9 (Upstate, 07-
442), Acetylated Histone H3K9 (Upstate, 07-352), Acetylated Histone H3K14 (Upstate, 
07-353), Acetylated Histone H4K5 (Upstate, 07-327), Acetylated Histone H4K8 
(Upstate, 07-328), Acetylated Histone H4K12 (Upstate, 07-595) and Acetylated Histone 
H4K16 (Upstate, 07-329). 
 
3.11. Real-Time PCR 
 All Real-Time PCR reactions were performed using the MiniOpticon System 
(Bio-Rad). Real-Time PCR was performed with the QuantiTect Multiplex No-ROX 
PCR Kit (Qiagen), which included buffers, enzymes and dNTPs. All suggested reaction 
conditions were followed including a set annealing temperature of 60°C and 50 cycles/ 
run. The forward and reverse primers (Invitrogen) and TaqMan Major Groove Binding 
(MGB) probes (Applied Biosystems) used were designed using either MacVector or 
Vector NTI Advance 10 software inputed with target sequences. The primers used in 
these reactions are listed below: 
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Table 3.7. Real-Time PCR Primers 
SRC1A FOR: 5’-AGGCGGATCTGGGGCGTAG 
REV: 5’-ATTCCGGGCCGGGAGAGAC 
SRC1alpha FOR: 5’-GACAAGTCGATCAGCTTCC 
REV: 5’-GCAAGTAGGTAAGGGCCAG 
p21 FOR: 5’-GGGCGGGGCGGTTGTATATCAG 
REV:5’-GTCTGCCGCCGCTCTCTCACCT 
RPL13A FOR: 5’-TCAGTCGCTTGAAGGGGTAATG 
REV: 5’-AAGGAGGAGGTTTTGTCGCAGG
3’UTR FOR: 5’-TCAAACCCTGCCCTCCTTAGAC 
REV: 5’-CATCACCCACAAGCCGATTG 
 
The Taqman probes and probe specific fluorophore used in this study are included in 
the following table. 
 
Table 3.8. Taqman Probes  
SRC1A TGCGGCGCCCTGGCGGAGTG FAM 
SRC1alpha CAGGCTGGCTTCTGCTGTTGACTGGC FAM 
p21 CACGCGAGGTTCCGGGACCGGC TET 
RPL13A TTCCACTCACAAACATGGCGGACAGAGCG TET 
3’UTR TGAGGGACCCTTCGAGATCATCACTTCCTTGC FAM 
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4. RESULTS AND DISCUSSION 
4.1 REGULATION OF THE SRC1A PROMOTER BY Sp1 AND Sp3 
4.1.1. Role of Sp1 and Sp3 in SRC Transcriptional Activation 
 In previous studies performed with the SRC1A promoter and the Sp family of 
transcription factors, Sp1 was described as a potent activator of the SRC1A promoter. 
Conversely, Sp3 was identified as being unable to activate SRC1A and could repress 
Sp1 -mediated SRC1A activation, presumably through competition for binding sites 
(Ritchie, et al., 2000). In a subsequent study, Sp1 was still identified as an activator of 
SRC1A activity; however, Sp3 was also able to potently activate SRC1A. As opposed 
to the first Sp3 study, the second study utilized a GAL4Sp3 fusion construct that 
allowed the analysis of Sp3 in mammalian cells (Dehm, et al., 2004). Due to obvious 
disparities between the Sp3 results, the regulation of the SRC1A promoter by the Sp 
family of factors was revisited. To identify if Sp1 and Sp3 interact in vivo with the 
SRC1A promoter, chromatin immunopreciptation assays (ChIPs) were performed in the 
colon cancer cell line HT29 with antibodies specific for Sp1, Sp3 and hnRNP K (Fig. 
4.1.). To ensure the specificity of the antibody used for the factor in question, PCR was 
also performed with primers specific to the SRC1α promoter (not shown). Sp1, Sp3 and 
hnRNP K were all found to bind to the SRC1A promoter, and not the SRC1α promoter, 
in HT29 cells. These results suggest that all three factors are important in SRC 
regulation.  
Both Sp1 and Sp3 are abundant within the mammalian cell. Therefore to identify 
the effect of Sp1 and Sp3 on SRC1A activity, in a dose -dependent manner, the 
interference of endogenous levels of Sp1 and Sp3 needed to be eliminated. To that end, 
a SRC1A promoter construct was generated where the GC1 and GA2 Sp binding sites 
were replaced with GAL4 recognition sequences (Fig. 4.2B). The hepatocarcinoma cell 
line, HepG2, and the colon cancer cell line, SW480, were then co-transfected with Sp1 
and Sp3 GAL4 fusion constructs (Fig. 3.1) and the SRC1A GAL4 binding site modified 
reporter construct. As expected, GAL4Sp1 was a very potent activator of SRC1A as 
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Figure 4.1. Sp1, Sp3 and hnRNP K bind the SRC1A promoter. (A) ChIP analysis
was performed in HT29 cells with antibodies specific for Sp1, Sp3 and hnRNP K.
Following immunoprecipitation and de-crosslinking, DNA was amplified with
primers specific for the SRC1A promoter. This is representative of experiments
performed at least three times (B) Graphical depiction of the primers
used in the ChIP PCR analysis. A control PCR reaction was performed with primers
specific to the SRC1 promoter (not shown).
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compared to co-transfection with the DNA binding domain (DBD) alone (Fig. 4.2 A). 
However, GAL4Sp3li, which is equivalent to the newly discovered, physiologically 
relevant longest Sp3 isoforms, was a more modest activator of SRC1A (Sapetschnig, et 
al., 2004). Conversely, the non-physiological GAL4Sp3∆N(pM) construct was a far 
more potent activator of SRC1A than GAL4Sp3li, especially in HepG2 cells. This 
expression vector encodes a Sp3GAL4 fusion lacking approximately 100 amino acids 
from its N-terminal region. This non-physiological form of Sp3 has historically been 
considered as the full-length Sp3 and has been used in numerous studies (Sowa, et al., 
1999; Ross, et al., 2002; Sapetschnig, et al., 2002; Tang, et al., 2004). 
In contrast, the two shorter Sp3 isoforms, GAL4Sp3M1 and GAL4Sp3M2, were 
unable to activate the SRC1A promoter (Fig, 4.2. A). Though not shown, all of these 
constructs could impart a dose responsive effect, similar to what is shown in figure 4.2., 
on the SRC1A reporter construct in these cell lines. These results suggest that both Sp1 
and Sp3∆N are potent activators of SRC, whereas, Sp3li is a modest activator of SRC. 
In contrast, both short Sp3 isoforms are unable to activate SRC in mammalian cells. 
 
4.1.2. Role of Binding Site and Cell Line in Sp Factor SRC1A Activation 
 The SRC1A promoter has two Sp binding sites, GC1 and GA2 (Ritchie, et al., 
2000). In order to determine if the effect of Sp1 and Sp3 on SRC1A activity is 
dependent on which binding site the factor is bound to, mutated reporter constructs were 
generated. To accomplish this, a SRC1A reporter construct was designed where the 
GC1 site was mutated and the GA2 site was replaced with a GAL4 recognition site (Fig. 
4.3 B). In both HepG2 and SW480 cells, Sp1 was a potent activator of SRC1A via the 
GA2 site (Fig. 4.3 A). Both Sp3li and Sp3∆N could activate SRC1A in both HepG2 and 
SW480 cells at the GA2 site. However, again, Sp3∆N was a far more potent activator 
than full-length Sp3li.   
 To identify how Sp1 and Sp3 interacted with the GC1 site of SRC1A, a SRC1A 
reporter construct was modified such that the GA2 site was mutated and the GC1 site 
was replaced with the GAL4 recognition sequence (Fig. 4.4 B). In SW480 cells, Sp1, 
Sp3li and Sp3∆N activated SRC via this site in a fashion similar to what was observed 
when the GA2 site was isolated (Fig. 4.4 A). However, the fold activation was  
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Figure 4.3. Role of binding site and cell line in Sp factor activation. (A) The
SRC1AGC1mut GA2-GAL4-CAT was transactivated by Sp1 and long Sp3 isoform
GAL4 fusion constructs in HepG2 and SW480 cells. (B)The 0.38GC1mutSRC1A-CAT
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significantly reduced when activation via the GA2 site versus the GC1 site was 
compared. Similarly, in HepG2 cells, both Sp3li and Sp3∆N activated SRC at the GC1 
site. Again, Sp3∆N was a more effective activator than Sp3li. Interestingly, Sp1 was 
unable to activate SRC via the GC1 site in HepG2 cells. Taken together, these results 
suggest that promoter activation by Sp1 or Sp3 is -dependent on both the architecture of 
the promoter and the cell line used. Furthermore, Sp1 is a potent activator of the 
SRC1A promoter via the GA2 and GC1 sites in SW480 cells but only via the GA2 site 
in HepG2 cells.  
 
4.1.3. Sp1 and Sp3 -mediated SRC1A activation in Drosophila SL2 cells  
 To support the results observed with the GAL4 system in human cells, a series 
of transfections were performed in Drosophila SL2 cells. These cells are ideal for Sp 
factor studies as these cells do not express Sp1 and Sp3. Therefore, the endogenous 
abundance of Sp1 and Sp3 does not interfere with transient co-transfection studies and 
the effect of these factors on the native SRC1A promoter can be studied. Sp1 and 
Sp3∆N were strong activators of SRC1A through binding at either the GC1 or GA2 Sp 
sites (Fig. 4.5). Sp3li was a comparatively modest activator of SRC1A activity, 
especially through the GC1 site. These results are consistent with the observations 
obtained from mammalian cells with the GAL4 system (Fig. 4.2 A, 4.3 A, 4.4 A). In 
contrast, Sp3M, which expresses the two shortest Sp3 isoforms, did not activate SRC1A 
at either binding site in SL2 cells, which is also consistent with observations using the 
mammalian GAL4 system (Fig.4.2 A). 
 
4.1.4. Impact of Sp3 Modifications on SRC1A Activity in Mammalian Cells 
 A critical lysine residue (K551) within the inhibitory domain of Sp3 has been 
reported to be post-translationally modified by acetylation or SUMOylation. These 
studies have suggested that modification of this residue alters Sp3 -mediated activity, 
either through the recruitment of co-activators or co-repressors or the alteration of 
cellular localization  (Braun, et al., 2001; Ross, et al., 2002; Verger, et al., 2004). In the 
interest of identifying how these modifications affect Sp3 -mediated SRC1A activation,  
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Figure 4.5. Sp1 and Sp3 SRC1A activation in SL2 cells. (A) The effect of the
Sp1 and Sp3 isoforms was assayed using a wildtype 0.38SRC1A-CAT reporter
construct in Drosophila SL2 cells. (B) The effect of the Sp1 and Sp3 isoforms was
assayed using a 0.38GC1mutSRC1A-CAT reporter construct in Drosophila SL2 cells.
(C)The effect of the Sp1 and Sp3 isoforms was assayed using a 0.38GA2mutSRC1A-
CAT reporter construct in Drosophila SL2 cells. The Sp3M construct expresses both
forms of the shortest Sp3 isoforms. The error bars are representative of the standard
deviation between two experiments each performed in duplicate.
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the GAL4 system was again utilized in mammalian cells (Fig. 4.6 A). SW480 and 
HepG2 cells were co-transfected with the GAL4 reporter construct and K551 modified 
versions of GAL4Sp3li. The first modification tested was a lysine to arginine 
substitution at residue 551 (K551R). This modification has been reported to prevent 
both acetylation and SUMOylation at this pertinent residue (Ross, et al., 2002) 
Interestingly, Sp3liRmut SRC1A activation was no different to wildtype Sp3li SRC1A 
activation in mammalian cells (Fig. 4.6. B). However, upon Sp3∆NRmut transfection 
into SW480 cells, a two-fold increase in SRC1A activation was observed as compared 
to the wild type Sp3∆N control (Fig. 4.6 C).  
The effect of histone deacetylase inhibitors (HDI) treatment on Sp3∆N -
mediated SRC1A activation was also studied. HDIs repress SRC expression through an 
unknown mechanism (Kostyniuk, et al., 2002). Furthermore, the identification of Sp3 as 
an activator of SRC1A combined with the observation that upon Sp3 acetylation Sp3 is 
no longer an effective transcriptional activator suggests a potential mechanism for HDI 
-mediated SRC repression through Sp3 acetylation (Braun, et al., 2001). If the 
acetylation of Sp3 did cause HDI -mediated SRC1A repression, it would be expected 
that SRC1A activation by the mutated form of Sp3∆N would not change upon TSA 
treatment. Upon treatment with TSA, however, Sp3∆NRmut activated SRC1A was not 
immune to HDI treatment and reporter activity decreased (Fig. 4.6 C). These results 
indicate that HDI -mediated SRC1A repression is not achieved through Sp3 acetylation. 
The key lysine residue within the shortest GAL4Sp3 constructs were also 
modified to encode an arginine residue (GAL4Sp3M1Rmut and GAL4Sp3M2Rmut) 
and co-transfected into mammalian cells with the SRC1AGAL4 reporter construct. 
Interestingly, the results from the use of the shorter constructs were dramatically 
different from the results obtained with the longer constructs (Fig. 4.7. B, C). Both of 
the short Sp3 isoforms (Sp3M1, Sp3M2) were converted into very potent activators of 
SRC1A when both acetylation and SUMOylation were prevented (Sp3M1Rmut, 
Sp3M2Rmut). These results suggest that the modification of the shortest Sp3 isoforms 
by either SUMOylation or acetylation dampens the activating potential of these 
isoforms. 
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Figure 4.6. Role of SUMOylation and/or acetylation on Sp3 mediated SRC1A
activation in mammalian cells. (A) The wildtype 0.38SRC1A promoter was
mutated to replace the endogenous Sp binding sites with GAL4 binding sites
(SRC1AGC1/GA2-GAL4-CAT). (B) The differences in GAL4Sp3li mediated
SRC1A transactivation when comparing wild-type GAL4Sp3li, GAL4Sp3liRmut
and GAL4Sp3liQmut in HepG2 and SW480 cells. (C) The differences in GAL4-
Sp3N(SG4) and GAL4Sp3NRmut mediated SRC1A transactivation in
SW480 cells with treament of 1M TSA.The error bars are representative of the
standard deviation between two experiments each performed in duplicate.
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Figure 4.7. Role of SUMOylation and/or acetylation on Sp3 mediated SRC1A
activation in mammalian cells. (A) The wildtype 0.38SRC1A promoter was
mutated to replace the endogenous Sp binding sites with GAL4 binding sites
(SRC1AGC1/GA2-GAL4-CAT). (B) The differences in GAL4Sp3M1,
GAL4Sp3M1Rmut and GAL4Sp3M1Qmut mediated SRC1A transactivation in
HepG2 cells. (C) The differences in GAL4Sp3M2, GAL4Sp3M2Rmut and
GAL4Sp3M2Qmut mediated SRC1A transactivation in HepG2 cells.The error
bars are representative of the standard deviation between two experiments each
performed in duplicate.
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To identify which modification was dampening the activational activity of 
Sp3M1/M2, the critical lysine residue was mutated to a glutamine residue (K551Q).   
A modification of this kind serves to mimic an acetylated lysine residue thus aiding in 
identifying which modification is affecting activational ability (De Nadal, et al., 2004). 
The longer Sp3 isoform was also similarly modified to act as a negative control. In 
agreement with previous Sp3liRmut results, Sp3liQmut demonstrated no difference in 
SRC1A activation as compared to the wildtype Sp3li in mammalian cells (Fig. 4.6. B). 
Significantly, the Sp3M1 and Sp3M2 constructs bearing the Q mutation were equally 
potent activators as the constructs bearing the R mutation thus suggesting that 
acetylation of Sp3M1/M2 has little impact on the potential for these factors to activate 
SRC1A.  
Taken together, these results suggest that the modification of the longer forms of 
Sp3 have little effect on the ability of Sp3 to activate SRC1A in mammalian cells. 
Conversely, the modification of the shorter Sp3 isoforms by SUMOylation has a 
negative impact on the ability of these shorter isoforms to activate SRC1A in 
mammalian cells. Furthermore, Sp3 acetylation does not account for HDI -mediated 
SRC repression. 
 
4.1.5. Role of SUMOylation on Sp3 -mediated SRC1A Activation in SL2 Cells     
 To complement the GAL4Sp3 SUMOylation and acetylation studies performed 
in mammalian cells, the effect of SUMOylation and acetylation on Sp3 activation 
potential was also studied using the Drosophila SL2 system.  In SL2 cells, both the 
Sp3liRmut and wild-type Sp3li constructs modestly activated the SRC1A promoter 
(Fig. 4.8. B). Similarly, Sp3∆N, Sp3∆NRmut and Sp3∆NQmut also activated SRC1A 
equally in SL2 cells. In contrast, Sp3MRmut and Sp3MQmut were significantly 
stronger SRC1A activators as compared to the wild-type Sp3M in SL2 cells. These 
results are consistent with that which was observed in mammalian cells, whereby 
modification of the longer forms of Sp3 had no affect on activation potential, however, 
modification of the shorter forms substantially increased the ability of Sp3M to activate 
the SRC1A promoter. To ensure equal expression of the Sp3 constructs, Western blots 
were performed with cell lysates obtained from SL2 cells transfected with the Sp3  
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Figure 4.8. Role of modification on Sp3 mediated SRC1A activation in SL2
cells. (A) The wildtype 0.38SRC1A-CAT reporter construct used in the experiments
in B and C. (B) Differences in Sp3 mediated SRC1A activation when comparing all
wild-type Sp3 constructs and modified counterparts. The error bars are representative
of the standard deviation between two experiments each performed in duplicate. (C)
Western Blot analysis of all Sp3 isoforms and corresponding mutants from co-
transfected SL2 cell lysates using an antibody specific for Sp3. Star represents wild-
type Sp3 population that has been modified by SUMOylation.
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constructs and an antibody specific to all isoforms of Sp3 (Fig. 4.8. C). These control 
experiments also served to confirm that the wild-type Sp3 constructs were indeed being 
modified by SUMO-1. The SUMOylated form of Sp3 can be seen migrating ~20 KDa 
above the non-SUMOylated forms of Sp3. The absence of the slower migrating Sp3 
band in the lanes containing only mutated forms of Sp3 confirmed that the mutated 
forms of Sp3 were not SUMOylated. 
 These results are consistent with the results obtained from mammalian cells 
using the GAL4 expression constructs. Taken together, these results suggest that neither 
the SUMOylation or acetylation status of the long Sp3 isoforms affects the activation of 
SRC1A by Sp3li. In contrast, the SUMOylation, but not acetylation, of the shortest Sp3 
isoforms cripples the activation potential of these isoforms. Furthermore, preventing the 
SUMO-1 modification of the shortest isoforms converts these factors into powerful 
activators of the SRC1A promoter.      
 
4.1.6. SUMOylation of the Short Sp3 Isoforms Prevents SRC1A Activation 
To further investigate if the SUMOylation of the shorter Sp3 isoforms was 
negatively impacting the ability of these isoforms to activate SRC1A, a construct 
expressing SUMO protease 1 (SuPr-1) was obtained. SuPr-1 specifically cleaves the 
SUMO-1 moiety from a target lysine residue (Splenger, et al., 2005; Ross, et al., 2002). 
Co-transfection experiments in HepG2 cells were again performed, using the SRC1A 
GAL4 construct, GAL4Sp3M1, GAL4Sp3M2, and increasing levels of the SUMO-1 
protease expression construct. The expression of SuPr-1 led to an increase in both 
Sp3M1 and Sp3M2 -mediated SRC1A activation (Fig. 4.9. B, C).  
 These studies further support that the role of the shorter Sp3 isoforms in the 
activation of SRC1A is directly -dependent on the SUMOylation status of the inhibitory 
domain. While SUMOylated Sp3M1 and Sp3M2 are ineffective activators of SRC1A, 
non-SUMOylated Sp3M1 and Sp3M2 are powerful SRC1A activators.  
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Figure 4.9. SUMOylation of the inhibitory domain of the short Sp3 isoforms
prevents activation of SRC1A. (A) The wildtype 0.38SRC1A promoter was mutated
to replace the endogenous Sp binding sites with GAL4 binding sites
(SRC1AGC1/GA2-GAL4-CAT). (B) Activation of SRC1AGC1/GA2-GAL4-CAT
reporter construct by GAL4Sp3M1 with and without co-transfection of SuPr-1 in
HepG2 cells. (C) Activation of SRC1AGC1/GA2-GAL4-CAT reporter construct by
GAL4Sp3M2 with and without co-transfection of SuPr-1 in HepG2 cells. The error
bars are representative of the standard deviation between two experiments each
performed in duplicate.
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4.1.7. Discussion 
4.1.7.1. Sp3 -mediated SRC1A Transactivation is Isoform -dependent 
 SRC is overexpressed in numerous cancer cell lines, including both colon cancer 
and hepatocellular carcinoma cell lines (Dehm and Bonham, 2004). In addition, SRC 
overexpression correlates strongly with increases in both c-Src protein and kinase 
activity. Furthermore, the increased levels of SRC mRNA transcripts have been shown 
to be the result of SRC transcriptional activation (Dehm, et al., 2001). These studies 
identify that the activation of the SRC gene in cancer cell lines is a legitimate 
contribution to increased c-Src kinase activity. Therefore, the mechanism of SRC 
transcriptional activation is a significant concern in discerning the role of c-Src 
deregulation in human cancer. To that end, the ubiquitously expressed SRC1A promoter 
has been characterized as being regulated by the Sp family of transcription factors and 
hnRNP K (Ritchie, et al., 2000; Ritchie, et al., 2003).  
 Original analysis of the impact of the Sp family on SRC expression suggested 
that Sp1, but not Sp3, was an important mediator of SRC1A activity, however, these 
experiments were performed in SL2 cells with the pPacSp3M construct that expresses 
only the shortest Sp3 isoforms (Ritchie, et al., 2000). In addition, recent discoveries 
prompted the re-examination of the effects -mediated by Sp3 with respect to SRC 
expression. For instance, until recently, an accurate clone of full length Sp3 was not 
available. The frequently cited, Sp3 clone that was formerly thought to be full length 
was not in reality a physiological form of Sp3, as a significant section was missing from 
the N-terminal region (Sapetschnig et al., 2004). In addition, the effects of Sp3 
appeared to be promoter context -dependent; thus the actual role of a particular Sp3 
isoform at a physiologically relevant promoter was impaired by the observations of 
other groups using artificial promoter systems and ill-defined Sp3 constructs. Finally, 
during the course of unrelated experiments, a member of the Bonham laboratory 
identified a potential role for Sp3 in SRC1A activation (Dehm, et al., 2004). Clearly, 
the capacity by which Sp3 exerts its effects on the SRC1A promoter needed to be re-
evaluated.  
 To this end, a series of SRC reporter constructs were generated in which the Sp 
binding sites were replaced with GAL4 sequences, and a systematic examination of 
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each physiologically relevant isoform in mammalian cells was carried out. In addition, 
the N-terminally deleted form of Sp3, which had previously been thought to represent 
full-length Sp3 was examined. In parallel, a similar study in SL2 cells using the wild-
type human promoter was carried out. From these experiments several significant 
observations were made. As expected, Sp1 was an impressive activator of the SRC1A 
promoter in both mammalian and insect cells. In contrast, whereas the physiologically 
relevant full length Sp3li was a modest activator of SRC1A, the two shortest Sp3 
isoforms, Sp3M1/M2, were unable to activate the SRC1A promoter in either 
mammalian or insect cells. Significantly, the N-terminally truncated form of Sp3, 
Sp3∆N, was able to activate the SRC1A promoter at least as effectively as Sp1 in all 
cell lines tested. Moreover, Sp3∆N activated the SRC1A promoter 2-3 fold more 
effectively than Sp3li in mammalian cells and at least 5 fold more effectively in SL2 
cells. These observations suggest that there may be a negative inhibitory region within 
the N-terminal region of Sp3.  
The existence of a negative regulatory region within the N-terminus of Sp3 is 
quite plausible as the 100 residues missing from the N-terminal truncated form of Sp3 
include hydrophobic residues, such as alanine and glycine-rich tracts, as well as several 
glutamine residues. These residues could mediate differences in the folding of full 
length Sp3 that might alter protein architecture and associations with co-activators to 
render the protein a far less potent activator. Similarly, the activation potential of Sp3 
may also be hindered by a yet unidentified N-terminal post-translational modification. 
As discussed in the literature review, the phosphorylation of both Sp1 and Sp3 has 
alternate affects depending on the system being studied (Chu, et al., 2003: Arinze and 
Kawai, 2003). However, to date, nothing has been published suggesting that a discreet 
residue within the N-terminal domain of Sp3 is responsible for the disparities in 
activation potential between the true full length and truncated forms of Sp3. Aside from 
structural differences, the functional differences between Sp3li and Sp3∆N are 
extremely important if the number of publications describing results obtained using the 
non-physiological Sp3∆N are considered. Many groups, including the Bonham 
laboratory, used the non-physiological form of Sp3 or shorter forms of Sp3 in the 
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characterization of promoter regulation. As such, the true role of Sp3 in the 
transcriptional regulation of the SRC1A promoter is only now being revealed.   
4.1.7.2. Transactivation of SRC1A by the Sp Family is Binding Site and Cell  
             Line -dependent 
 Through the use of GAL4 reporter constructs, the effect of Sp1 and Sp3 at 
discreet SRC1A binding sites was measured. These results suggested that Sp1 was 
unable to activate the SRC1A promoter via the GC1 binding site, in HepG2 cells. 
Curiously, Sp1 was an activator of this site in SW480 cells, as well as in the insect cell 
line. Moreover, both of the longer Sp3 isoforms, Sp3li and Sp3∆N, were able to activate 
SRC1A through the GC1 site in all cell lines analysed. Due to the utilization of GAL4 
constructs, an important conclusion can be drawn from these observations. Since in the 
GAL4 system all of the fusion constructs contained the same GAL4 DNA binding 
domain, the inability of Sp1 to activate the GC1 site of SRC1A was not a result of 
impeded binding. As compromised binding of Sp1 to its DNA target is therefore ruled 
out as a potential deterrent to Sp1 -mediated SRC1A activation via this site, only a few 
alternatives remain. One possibility is that Sp1 -mediated activation could be 
compromised by a post-translational modification such as glycosylation and/or 
phosphorylation in this cell line (Li, et al., 2004). However, although the selective 
modification of Sp1 is possible within a particular cell line, one would expect that Sp1 -
mediated activation via the alternative site would also be precluded if this were indeed 
the case. The fact that SRC1A is still activated by Sp1 via the GA2 site in this cell line 
suggests that this possibility is unlikely. Another potential impairment to Sp1-mediated 
activation via the GC1 site is the distance of the GC1 site from the SRC1A core 
promoter region. It is possible that the association of Sp1 with critical co-activators is 
impeded within this cell line at this distance from the core promoter elements. In this 
scenario, Sp1 bound to the GA2 site may be sufficiently proximal to the core promoter 
elements that an interaction with supplementary factors is either facilitated or 
unnecessary. Furthermore, it is known that Sp1 forms homotetramers to amplify 
activation, as well as associates with the co-activator CRSP to enhance PIC assembly 
(Suske, 1999; Ryu, et al., 1999). Indeed, experiments with the human Ha-ras promoter 
have identified a key role for the most proximal Sp1 binding site in transcription start 
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site selection and enhanced activation, likely through interactions with co-activators 
(Lu, et al., 1994). This scenario is plausible considering that the activation of the 
SRC1A promoter via both GC1 and GA2 by Sp1 has the same fold value as activation 
through the GA2 site alone in HepG2 cells (~0.6), suggesting that the GC1 site is not 
contributing to enhanced SRC1A activation. Despite the unique perspective gained by 
the equalized binding of the GAL4 fusion constructs, further studies will be needed to 
elucidate the role of binding sites on Sp1-mediated activation of the SRC1A promoter 
in different cell lines.       
 
4.1.7.3. SUMOylation of the Inhibitory Domain of Sp3 Isoforms Mediates    
  Differential Activation of the SRC1A Promoter 
 The post-translational modification of regulatory proteins is an effective 
mechanism to rapidly and radically alter the effect of a protein in a particular system. 
Sp3 has been reported to be modified by both acetylation and SUMOylation  (Braun, et 
al., 2001; Ross, et al., 2002; Ammanamanchi, et al., 2003; Splenger, et al., 2005). 
Though modification by either moiety is targeted to an identical lysine residue within 
the inhibitory domain of Sp3, the ramifications of each modification are remarkably 
opposite.  
The acetylation of Sp3 is frequently associated with increased activational 
activity but has also been implicated in the repression of Sp3 -mediated activation. In a 
recent study, ceramide treatment of a human lung adenomacarcinoma cell line reduced 
Sp3 -mediated activation of the hTERT promoter through a decrease in the acetylation 
of Sp3 (Wooten and Ogretmen, 2006). Similarly, in MCF-7L breast cancer cells, Sp3 
was shown to mediate the activation of the transforming growth factor-beta receptor 
type II (RII) promoter following acetylation induced by TSA treatment 
(Ammanamanchi, et al., 2003). Conversely, Sp3 acetylation prevented transcriptional 
activation of two artificial promoters in mammalian and insect cells (Braun, et al., 
2001) In contrast, the SUMOylation of the key lysine residue within the inhibitory 
domain of Sp3 is exclusively associated with reduced Sp3 -mediated activation. Two 
studies, published at approximately the same time, highlight the repression of two 
promoter systems by SUMOylation of Sp3 in both mammalian and insect cells (Ross, et 
 98
al., 2002; Sapetschnig, et al., 2002). Another study, published after the isolation of the 
physiologically relevant full length Sp3 isoform, also found SUMOylation of Sp3 to be 
detrimental to Sp3 -mediated activation (Sapetschnig, et al., 2004). Although the 
majority of studies suggest that acetylated Sp3 is a more potent activator of 
transcription, it is not known if acetylation itself plays a role in increasing Sp3  
-mediated activation or if the prevention of SUMOylation, by acetylation, increases Sp3 
-mediated activation. Clearly, there is a great deal of confusion surrounding the role of 
post-translational modifications of Sp3 in Sp3 activation or repression potential.  
 The finding that acetylation may impede the activation potential of Sp3 was 
particularly interesting within the context of SRC expression. A recurring topic 
throughout this thesis is the repression of SRC activity by HDIs. HDIs disrupt the 
balance between HAT and HDAC activity, ultimately tipping the scale towards 
increased acetylation of histones and other important factors. If HDI-mediated 
acetylation of Sp3 dampened the ability of Sp3 to activate the SRC1A promoter, this 
could be a possible mechanism by which HDIs repress SRC expression. Consistent with 
this idea, several groups have identified HDI-responsive Sp binding sites within the 
promoter regions of genes transcriptionally activated by HDIs (Xiao, et al., 2000; 
Ferguson, et al., 2003). Furthermore, at least one group has reported that HDI-mediated 
activation was associated with the acetylation of Sp1 followed by the recruitment of co-
activators to the Sp1 binding site (Huang, et al., 2005). As a logical extension of these 
studies, it is not difficult to imagine that acetylated Sp3 could recruit factors, in this case 
co-repressors, to the SRC1A promoter to hinder SRC expression, thereby providing a 
link between acetylation of Sp3 and repressed SRC1A activation. However, the 
mutation of the critical N-terminal lysine residue of Sp3li had little effect on Sp3li -
mediated SRC1A activation in either mammalian or insect cells. Interestingly, in 
mammalian cells, mutating the critical lysine residue of Sp3∆N resulted in a modest 2-
fold increase in SRC activity. Moreover, upon treatment of mammalian cells with TSA, 
SRC1A activity was repressed, however, this repression was observed regardless of 
which Sp3∆N construct was used. These results indicate that the modification of Sp3 by 
acetylation is not responsible for HDI-mediated SRC1A repression. Furthermore, the 
increased activation of SRC1A by the mutated Sp3∆N was not observed in insect cells, 
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suggesting that the modest increase in Sp3∆NK551R activation potential observed in 
mammalian cells is cell line specific.  
The results obtained from the Sp3li and Sp3∆N lysine to arginine and lysine to 
glutamine studies conflict with the observations of other groups that suggest that the 
prevention of SUMOylation, and in at least one case acetylation, dramatically increases 
the activation potential of Sp3. One possible explanation for this phenomenon may 
involve promoter context and the ability of Sp3 to modulate transcriptional activation. 
For example, initial studies of Sp3 SUMOylation utilized artificial or viral promoter 
systems and initial experiments were performed with Sp3∆N. In these studies, 
Sp3∆NK551R was an extremely strong activator of both the artificial G5-luc and 
BCAT-2 reporter constructs as compared to wild-type Sp3∆N in both mammalian and 
insect cells (Ross, et al., 2002; Sapetschnig, et al., 2002). Furthermore, a more recent 
study suggested that the full length Sp3liK551R was a more potent activator of the 
artificial BCAT-2 promoter than wild-type full length Sp3 in insect cells. However, 
within this same study, in SL2 cells, Sp3liK551R managed only a modest 3 fold 
activation of the SV40-driven reporter construct, pGL3, as compared to wild-type 
(Sapetschnig, et al., 2004). Interestingly, the sole investigation identifying Sp3 
acetylation as a detriment to Sp3 activation potential also utilized the artificial BCAT-2 
and SV40-promoter driven pGL3 (Braun, et al., 2001). Taken together, these results 
suggest that the effect -mediated by Sp3 post-translational modifications may be 
promoter context -dependent. 
 Most surprisingly, the mutation of the critical lysine residue within the shortest 
inactive Sp3 isoforms, Sp3M1/M2, transformed these weak factors into potent 
activators of SRC expression in both insect and mammalian cell lines. Indeed, mutating 
the critical lysine residue to mimic an acetylated residue combined with SUMO 
protease 1 experiments confirms an important and significant role for SUMOylation in 
regulating the activity of Sp3M1/M2. The mechanisms of Sp3 regulation by SUMO-1 
have not yet been elucidated, however, some suggest that SUMOylation prevents the 
association of the shortest Sp3 isoforms with co-activators, thus preventing Sp3M1/M2 
-mediated activation (Splenger, et al., 2005). SUMO-1 -mediated interruptions of Sp3 
co-activator associations may not be as apparent with the longer Sp3 isoforms as they 
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contain two activation domains as opposed to the single activation domain adjacent to 
the inhibitory domain in Sp3M1/M2 (Fig. 3.1). As such, SUMOylation of these longer 
Sp3 isoforms would not abrogate activation to the degree observed with the shorter Sp3 
isoforms. Similarly, SUMO-1 quenching may involve the recruitment of co-repressors, 
which would alter the assembly of transcriptional complexes at the core promoter 
regions and repress transcription. In agreement with this idea, SUMO-1 interacts with 
the CHD3/ZFH zinc-finger-containing helicase present in histone deacetylase 
complexes (Verger, et al., 2004). However, while this mechanism may occur with other 
factors it is unlikely that SUMO-1 -mediated Sp3M1/M2 silencing is a result of the 
recruitment of co-repressors. The recruitment of co-repressors by SUMO-1 to Sp3 
would result in similar consequences regardless of which Sp3 isoform was bound. As a 
result, one would expect that the activity of all Sp3 isoforms would be affected, which 
is not the case. Finally, SUMOylation is reported as modifying the subcellular 
localization of transcription factors, such as p53, thus influencing their ability to 
activate or repress transcription (Verger, et al., 2004). Again, this scenario is unlikely in 
the case of Sp3. The conjugation of SUMO-1 to the critical lysine residue within Sp3 is 
a global phenomenon, as observed in Western blots performed with SL2 cell lysates. 
However, the effect -mediated by SUMO-1 is observed exclusively through the shortest 
Sp3 isoforms. Whatever the mechanism, SUMOylation significantly alters the ability of 
Sp3M1/M2 to enhance SRC1A activity.        
4.1.7.4. Scope and Significance 
 The Sp family of transcription factors is relatively well characterized in their 
ability to modulate transcription. The opposing regulation of the SRC1A promoter by 
Sp1 and Sp3 has been previously described in both mammalian cancer cell lines and 
insect cell lines. However, recent developments concerning the multiplicitous nature of 
Sp3 have forced the re-evaluation of the role these factors exert within the context of 
the SRC1A promoter. The work described herein suggests that while the physiological 
isoforms of Sp3 (Sp3li) are modest SRC1A activators, the shortest isoforms 
(Sp3M1/M2) are incapable of activating SRC1A. However, although the ability of 
Sp3M1/M2 to activate SRC1A transcription is directly related to SUMOylation, 
SUMOylation of Sp3li had little effect on SRC1A activation. Interestingly, these results 
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suggest that activation by Sp3 is promoter context, binding site, cell line and 
modification -dependent, and therefore provide important clues in delineating the role 
of Sp1 and Sp3 in the regulation of SRC1A and other physiological promoters.  
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4.2. MODIFICATIONS AT SRC AND p21WAF1 PROMOTER LOCI IN 
RESPONSE TO HISTONE DEACETYLASE INHIBITORS  
 4.2.1. TSA Induced Acetylation Changes At SRC and p21WAF1 Promoters 
 The SRC1A and SRC1α promoters are both directly repressed by histone 
deacetylase inhibitors (HDIs), such as TSA and Sodium Butyrate. Previous work 
demonstrated that this repression did not require new protein synthesis and discrete HDI 
responsive elements could not be identified (Kostyniuk, et al., 2002; Dehm, et al., 
2004). Historically, it was believed that HDIs act at the histone level to alter chromatin 
dynamics through the inactivation of HDACs to result in histone hyperacetylation and 
increased transcriptional activation (Santos-Rosa and Caldas, 2005). However, this 
model does not explain transcriptional repression of gene expression by these agents. 
Indeed, changes in the acetylation status of histones associated with genes repressed by 
HDAC inhibitors, such as SRC, have not been reported. Therefore, a systematic 
investigation of the changes in histone H3 and H4 acetylation status at the promoter 
regions of two genes differentially affected by HDAC inhibitors was carried out. For 
this study, the histones proximal to both SRC promoters were analysed, as they are both 
transcriptionally repressed by HDIs. In addition, the acetylation of histones proximal to 
the p21WAF1 promoter was also studied as p21WAF1 is transcriptionally activated by HDIs 
and should demonstrate high levels of histone acetylation (Rosato and Grant, 2003).  
  As transcriptional activation usually corresponds with increased histone 
acetylation, it would be expected that an increase in acetylation at the p21WAF1 promoter 
and a decrease in histone acetylation at the SRC promoter regions would be observed in 
response to TSA treatment. To test this model and identify changes in histone 
acetylation at promoter proximal regions, chromatin immunoprecipitation (ChIP) assays 
were performed with antibodies specific for histone H3 acetylated residues 9 and 14 
(H3Ac9/14) and histone H4 acetylated residues 5, 8, 12 and 16 (H4Ac5/8/12/16). The 
acetylation of these residues was analysed, as histone acetylation of these residues is 
commonly associated with transcriptionally active genes (Santos-Rosa and Caldas, 
2005). ChIPs were performed with HT29 cells that had been treated at various time 
points with 1µM TSA (Fig. 4.10). HT29 cells were used in this study due to previous 
findings from the Bonham laboratory suggesting that SRC transcription is initiated  
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Figure 4.10. Effect of TSA on acetylation of Histone H3 and Histone H4 at the
SRC and p21WAF1 promoters. ChIP assays were performed on HT29cells that had
been treated for various time points with 1 M TSA. Proteins bound to DNA were
cross-linked and immunoprecipitations were performed on cell lysates with antibodies
specific to histone H3 acetylated lysines 9and 14, histone H4 lysines 5, 8, 12 and 16
and an antibody specific to integrin (negative control antibody, not shown). Following
reversal of cross-links, immunoprecipitates underwent PCR with primers specific for
the SRC1A (A), SRC1 (B) and p21WAF1 (C) promoters. These are representatives
of experiments performed at least three times in each cell line.
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equally from the SRC1A and SRC1α promoter regions in this cell line (Dehm, et al., 
2001). Likewise, the p21WAF1 promoter is also active in this cell line (Dehm, et al., 
2004). PCR primers were designed that were specific for the SRC1A, SRC1α and 
p21WAF1 promoter regions and used to amplify the DNA obtained from the ChIP assays 
(Fig. 4.10.). Interestingly, at all three promoter loci analysed, an increase in histone H3 
and H4 acetylation was observed. It is important to note that although increases in 
SRC1α histone acetylation were more dramatic than that observed at the SRC1A 
promoter locus in HT29 cells, the pattern of change in histone acetylation was similar at 
both loci. 
 This experiment was repeated in HepG2 cells (Fig. 4.11.). This cell line was 
analysed as a result of previous studies suggesting, as with HT29 cells, SRC 
transcription is initiated equally from both the SRC1A and SRC1α promoter (Dehm, et 
al., 2001). Unfortunately, the changes in histone acetylation at the p21WAF1 promoter 
was not analysed alongside the SRC promoters as previous studies have suggested that 
the increased p21WAF1 expression -mediated by HDIs is not a result of transcriptional 
activation in this cell line (Hirsch and Bonham, 2004). Similar to that which was 
observed in HT29 cells, the SRC1A and SRC1α promoter regions displayed an 
enrichment of acetylated histone residues upon TSA treatment. However, in HepG2 
cells the increase in TSA -mediated acetylation was dramatic and immediate at both 
histone H3 and H4 residues. Compared to HT29 cells, however, H3K9/14 acetylation 
increased strikingly at the SRC1α promoter and only slightly at the SRC1A promoter. 
Likewise, H4K5/8/12/16 acetylation increased in a less obvious fashion in HT29 cells 
than the increase observed in HepG2 cells. Overall, histone acetylation increases at the 
SRC promoter regions and p21WAF1 promoter region in response to TSA treatment. 
Therefore, these results suggest that histone acetylation status may not be indicative of 
the transcriptional activity of a particular promoter in response to TSA treatment.   
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Figure 4.11. Effect of TSA on acetylation of Histones H3 and H4 at the
SRC promoters. ChIP assays were performed on HepG2 cells that had been treated
for various time points with 1 M TSA. Proteins bound to DNA were cross-linked
and immunoprecipitations were performed on cell lysates with antibodies specific to
histone H3 acetylated lysines 9and 14, histone H4 lysines 5, 8, 12 and 16 and an
antibody specific to integrin (negative control antibody, not shown). Following
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4.2.2. TSA -mediated Changes in Acetylation of Lysine Residues 9 and 14 on    
          Histone H3 
 To further explore the results observed with histone H3Ac9/14 antibodies, a 
ChIP approach was again utilized to identify exactly what changes in acetylation were 
occurring at specific histone H3 lysine residues. This experiment was important because 
the histone H3Ac9/14 antibody can recognize acetylated H3K9 and/or acetylated 
H3K14. As a result, antibodies specific for acetylated H3K9 (H3Ac9) and acetylated 
H3K14 (H3Ac14) were obtained and ChIP assays were performed in HepG2 and HT29 
cells treated with 1µM TSA. Primers specific for the SRC1A, SRC1α and p21WAF1 
amplicons were again used in these studies (Fig. 4.12). In HepG2 cells, TSA treatment 
resulted in an increase in H3K14 acetylation at both the SRC1A and SRC1α promoters. 
Conversely, TSA treatment caused a decrease in H3K9 acetylation at the SRC1A 
promoter and a very slight increase in acetylation at the SRC1α promoter. As before, 
the p21WAF1 promoter region was not analysed in HepG2 cells. In HT29 cells, H3K9 
acetylation increased at all promoter regions analyzed. However, while H3K9 
acetylation at the p21WAF1 promoter increased very gradually over the time course of 
TSA treatment, the increase in acetylation was more impressive at the SRC promoter 
regions. H3K9 acetylation is frequently associated with transcriptionally active 
chromatin regions, whereas H3K9 methylation is associated with transcriptionally silent 
heterochromatin regions (Eskeland, et al., 2007). As a result of the observed decrease in 
H3K9 acetylation at the SRC1A promoter in HepG2 cells, ChIPs were performed with 
an antibody specific to trimethylated H3K9. The purpose of this experiment was to 
observe if the decrease in H3K9 acetylation correlated with an increase of H3K9 
trimethylation, which would signify a transition form a transcriptionally active 
chromatin region to a transcriptionally silent chromatin region. However, H3K9 
trimethylation could not be seen at any point before or after TSA treatment suggesting 
that despite the loss of H3K9 acetylation, H3K9 trimethylation was not occurring (data 
not shown). Moreover, although TSA led to an increase in H3K14 acetylation at the 
SRC1A, SRC1α and p21WAF1 promoters, the increase in acetylation at this residue was 
more dramatic at the p21WAF1 promoter as compared with the SRC promoters.  In 
summary, in HepG2 cells, the SRC1A promoter displayed a decrease in H3K9  
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Figure 4.12. Effect of TSA on acetylation of Histone H3 lysines 9 and 14 at the
SRC and p21WAF1 promoters. ChIP assays were performed on HepG2 and HT29
cells that had been treated for various time points with 1 M TSA. Proteins bound to
DNA were cross-linked and immunoprecipitations were performed on cell lysates
with antibodies specific to histone H3 acetylated lysine 9, histone H3 acetylated
lysine 14 an antibody specific to integrin (negative control antibody, integrin).
Following reversal of cross-links, immunoprecipitates underwent PCR with primers
specific for the SRC1A(A), SRC1 (B) and p21 (C) promoters.
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acetylation but an increase in H3K14 acetylation upon TSA treatment, whereas, the 
SRC1α promoter showed an increase in acetylation at both H3 lysine residues. In HT29 
cells, all three promoter regions analyzed demonstrated increased H3K9 and H3K14 
acetylation in response to TSA. With the exception of decreased H3K9 acetylation at 
the SRC1A promoter in HepG2 cells, these findings correlate well with the results 
obtained with ChIP assays using the pan acetylated histone H3 antibodies.  
 
4.2.3. TSA -mediated Changes in Acetylation of Lysine Residues 5, 8, 12 and 16 on   
           Histone H4 
 Similar to the histone H3Ac9/14 antibody (4.2.2.), the histone H4Ac5/8/12/16 
antibody was capable of recognizing the epitope of any or all of the pertinent histone H4 
acetylated lysine residues (K5, 8, 12, 16). In order to fully characterize the impact of 
TSA on the acetylation of histone H4 lysine residues, individual ChIP assays were 
necessary with antibodies specific for the acetylated form of each of the lysine residues 
(Fig.4.13.).  In HepG2 cells, SRC1A and SRC1α promoters showed increased histone 
H4K12 and histone H4K16 acetylation upon TSA treatment. However, it should be 
noted that acetylation of these histone residues at the SRC1α promoter was marginal 
and, therefore, difficult to detect. Histone H4K8 acetylation either increased slightly or 
remained unchanged at both SRC promoter regions in response to TSA. Similarly, 
histone H4K5 acetylation increased very slightly or not at all at the SRC1A promoter, 
however, an increase in acetylation at H4K5 was observed at the SRC1α region.  
 In HT29 cells, histone H4K5 acetylation increased at the p21 and SRC promoter 
regions in response to TSA treatment. However, enrichment of histone H4K5 
acetylation was marginal at the SRC1A promoter as compared to the other two regions 
analyzed. Histone H4K8 acetylation decreased at all three promoter regions studied. 
Histone H4K12 acetylation increased slightly at the SRC1A promoter but decreased at 
the SRC1α and p21 promoter regions. Conversely, histone H4K16 acetylation 
decreased at the SRC1A promoter but increased slightly at the SRC1α and p21 
promoters.  
 Overall, these observations correlate well with the pan acetylated histone H4 
ChIP data. In HepG2 cells, at residues where there was a change in acetylation, there  
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Figure 4.13. Effect of TSA on acetylation of Histone H4 lysine 5, 8, 12 and 16 at
the SRC and p21WAF1 promoters. ChIP assays were performed on HepG2 and
HT29 cells treated for various time points with 1 M TSA. Proteins bound to DNA
were cross-linked and immunoprecipitations were performed on cell lysates with
antibodies specific to histone H4 acetylated lysine residues 5, 8, 12 and 16. Following
reversal of cross-links, immunoprecipitates underwent PCR with primers specific for
the SRC1A (A), SRC1 (B) and p21WAF1 (C) promoters.
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was an increase in acetylation upon TSA treatment. In HT29 cells, at each promoter 
studied, at least one residue displayed a dramatic increase in acetylation in response to 
TSA. Due to the ambiguity of antibody/epitope binding of the pan acetylated histone H3 
and H4 antibodies, it was difficult to identify what epitope the antibody was recognizing 
and these studies aided in identifying the histone lysine residues affected by HDI 
treatment. 
 
4.2.4. Trends in TSA -mediated Changes in Histone Acetylation at the SRC and    
           p21WAF1 Promoters 
 In order to gain an appreciation for the global changes in histone acetylation 
occurring at these promoter regions in response to TSA, a summary chart has been 
included (Table 4.1.). In general, the three promoter regions appear to be very similar in 
the promoter specific changes in acetylation. An obvious difference in HepG2 treated 
cells is that H3K9 is deacetylated at the SRC1A promoter but increased acetylation is 
observed at the SRC1α promoter. An important observation in HT29 cells, is that the 
SRC1α and p21WAF1 promoter regions demonstrated greater similarity in histone 
acetylation changes as compared to the SRC1A promoter. This is of particular interest 
considering that both SRC promoters are transcriptionally repressed by HDIs whereas 
p21WAF1 is transcriptionally activated by HDIs. These findings again contribute to the 
idea that the histone acetylation pattern is not an accurate predictor of promoter activity 
in response to TSA treatment.     
 
4.2.5. Transcription Factor Occupancy on the SRC1A Promoter in Response to    
           TSA Treatment 
 Previous experiments failed to identify discrete HDI response elements 
at either of the SRC1A or SRC1α promoters (Dehm, et al., 2004). In addition, the 
acetylation of histone residues at SRC promoter proximal regions was not indicative of 
HDI -mediated transcriptional activation or repression. As a result of these findings, the 
binding of gene-specific transcription factors, as well as an essential component of the 
pre-initiation complex (PIC) were analysed. It would be expected that if HDIs were 
indeed detrimental to the binding of activators, there would be a decrease in promoter  
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SRC1A SRC1 p21WAF1 SRC1A SRC1
HT29 cells HepG2 cells
Table 4.1. Summary chart of acetylation specific ChIP analysis results.
Promoter specific increased histone acetylation during the time course is indicated
by the ( ) symbol. Promoter specific decreased histone acetylation during the
time course is indicated by the ( ) symbol. No change or a marginal increase in
histone acetylation is indicated by the ( ) symbol.
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occupancy of these factors upon TSA treatment. Therefore, to identify if promoter 
occupancy of known SRC1A activators was abrogated by TSA treatment, thereby 
impeding SRC activity, ChIP assays were performed.  
Previous results (Fig. 4.1) suggested that in untreated HT29 cells Sp1 is bound 
to the SRC1A promoter. Similarly, we used HT29 and HepG2 cells that had been 
treated at various time points with TSA and performed ChIP analysis with antibodies 
specific for Sp1 (Fig. 4.14.). PCR was performed with primers specific for the SRC1A 
promoter and it was found that Sp1 remained at the SRC1A promoter upon treatment 
with TSA. One problem with these particular Sp1 studies was that the antibody used in 
these experiments was not from the same lot that was used to previously identify the 
presence of Sp1 at the SRC1A promoter (Fig. 4.1). As a result, the positive antibody 
bands were very faint and difficult to interpret. To confirm these PCR results, real-time 
PCR with taqman probes was implemented to identify fold changes in Sp1 occupancy at 
the SRC promoters with ChIP samples derived from TSA treated HT29 cells. The 
benefit of adopting a real-time PCR strategy in the analysis of transcription factor 
binding to the SRC1A promoter is due to the quantitative nature of real-time PCR. 
Other ChIP results were obtained through the use of a thermocycler and analysed by 
agarose gel electrophoresis. Unfortunately, this method is semi-quantitative at best as 
often many cycles are necessary to identify DNA enriched in the positive antibody 
samples, as high number of PCR cycles can result in less accurate results and the linear 
range of product amplification may be exceeded due to limiting reagents. Real-time 
PCR overcomes this obstacle by analysing the product after every cycle, thus allowing 
for quantitative analysis within the linear range of amplification. To analyze the 
Taqman results, values were determined by standardizing the samples to input C(T), 
converting C(T) values into DNA concentrations and then graphing as fold changes 
between the negative and positive antibody samples. This method resulted in the fold 
enrichment of Sp1 occupancy at the SRC promoters as compared to the negative control 
antibody, integrin. These results suggest that there is approximately a 30 fold difference 
in Sp1 occupancy at the SRC1A promoter as compared to the negative antibody and this 
enrichment did not change over the three hour time course (Fig.4.14. B.). As an  
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Figure 4.14. Effect of TSA on Sp1 binding to the SRC1A promoter. (A) ChIP
assays were performed on HepG2 and HT29 cells, treated at various time points with
TSA, with an antibody specific to Sp1. Following immunoprecipitation and
de-crosslinking, DNA was amplified using primers specific for the SRC1A promoter.
Samples were resolved on an agarose gel. The input samples are non-
immunoprecipitated samples. The negative antibody control ( -Integrin) samples are
not shown. These results are representative of three independent experiments per-
formed in each cell line. (B)Real-time PCR of two averaged HT29 ChIP assays per-
formed with probes and primers specific for the SRC1A promoter. (C)
Both B and C values were determined by standardizing the
samples to input C(T), converting C(T) values into DNA concentrations and then
graphing as fold changes between the negative and positive antibody samples.

Real-time PCR
of two averaged HT29 ChIP assays performed with probes and primers specific for
the SRC1 promoter.
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additional control, real-time PCR was performed with a probe and primers specific to 
the SRC1α promoter, which does not bind Sp1 (Fig. 4.14. C). As expected, these results 
showed no difference between Sp1 and integrin occupancy at this region, thus 
confirming the specificity of the SRC1A findings.  
 Similar experiments were performed to identify if Sp3 binding to SRC1A was 
affected by TSA treatment. ChIP assays with antibodies specific to Sp3 were performed 
with TSA treated HT29 and HepG2 cells. Again, the lot of Sp3 antibody that had been 
used in previous studies (Fig. 4.1.) could not be purchased and the results obtained from 
traditional PCR were difficult to interpret (Fig. 4.15. A). Real-time PCR, with a probe 
and primers specific to SRC1A, demonstrated that Sp3 was present at approximately a 
10 fold enrichment as compared to the negative control antibody (Fig. 4.15. B). 
Significantly, these results demonstrated that Sp3 occupancy at the SRC1A promoter 
was not changed upon TSA treatment. As with the Sp1 studies, the SRC1α promoter 
region was used as a ChIP assay specificity control and again it was found that Sp3 does 
not bind to this region of the SRC locus (Fig. 14.5. C).  
 Taken together, these results show that Sp1 and Sp3 continue to bind the 
SRC1A promoter despite TSA treatment. This suggests that the effects exerted by TSA 
are not -mediated by either of these factors at the SRC1A promoter in either HepG2 or 
HT29 cells. Notably, promoter occupancy studies of the SRC1α specific transcription 
factor, HNF-1α, were not performed. Unfortunately, a HNF-1α specific antibody 
amenable to ChIP analysis was unavailable and as such the effect of TSA treatment on 
the HNF-1α promoter occupancy could not be measured by ChIP analysis.  
 
4.2.6. RNA Polymerase II Occupancy on SRC Gene in Response to TSA Treatment   
 The binding of Sp1 and Sp3 to proximal promoter elements was not affected by 
TSA treatment. Furthermore, studies have shown that HDIs can attenuate transcriptional 
initiation by preventing the binding of basal transcription factors and RNA polymerase 
II (Svejstrup, 2004). In keeping with the model whereby HDIs mediate SRC repression 
through the abrogated binding of key factors to the SRC promoter regions, the 
occupancy of RNA polymerase II (RNA Pol. II) at the SRC core promoter regions in  
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Figure 4.15. Effect of TSA on Sp3 binding to the SRC1A promoter. (A) ChIP
assays were performed on HepG2 and HT29 cells, treated at various time points
with TSA, with an antibody specific to Sp3. Following immunoprecipitation and
de-crosslinking, DNA was amplified using primers specific for the SRC1A
promoter. Samples were resolved on an agarose gel. The input samples are non-
immunoprecipitated samples. The negative antibody control ( -Integrin) samples
are not shown. These results are representative of three independent experiments
performed in each cell line.

(B)Real-time PCR of two averaged HT29 ChIP assays
performed with probes and primers specific for the SRC1A promoter. (C) Real-time
PCR of two averaged HT29 ChIP assays performed with probes and primers specific
for the SRC1 promoter. Both B and C values were determined by standardizing the
samples to input C(T), converting C(T) values into DNA concentrations and then
graphing as fold changes between the negative and positive antibody samples.
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response to TSA treatment was analysed. If TSA treatment modifies RNA Pol. II 
binding to the SRC core promoter regions, SRC transcriptional activation would be 
severely crippled. Therefore, ChIP analysis was performed with an antibody specific for 
RNA Pol. II with HepG2 and HT29 cells treated for various times with TSA (Fig. 
4.16.).  
 RNA Pol. II occupancy was not affected at the SRC1A and SRC1α promoters 
following TSA treatment. Therefore TSA -mediated SRC repression is not a result of 
the absence of this essential component of transcription. However, despite the presence 
of this factor at the promoters, the possibility of faulty transcriptional initiation 
and/or elongation could not be discounted. To address this issue, PCR was performed 
with the RNA Pol. II ChIP samples from the TSA treated cells using primers specific to 
several regions downstream of the SRC promoters. The first two regions analysed for 
changes in RNA Pol. II occupancy were regions between the SRC1A exon and SRC1B 
exon and a region between SRC1B and SRC1C exons (Fig. 4.17. A.). The times above 
the stars in the figure give the range of time necessary for the effects of TSA on RNA 
Pol. II entrapment at the promoter regions to be identified. The times were calculated 
assuming that RNA Pol. II transcribes DNA at a rate of 1-1.5 Kb per minute 
(Neugebauer, 2002; Mason and Struhl, 2005). PCR of the first amplicon did not yield 
any information to suggest that RNA Pol. II was ever bound to this region, before or 
after treatment (Fig. 4.17. B). Amplification of the genomic region between exons 
1B/1C suggested that RNA Pol. II continued to be associated with this region following 
TSA treatment. Notably, amplification of this region was not as efficient as that of 
either of the promoter regions and the occupancy of RNA Pol. II at this region could be 
changing.  
 The next SRC genomic amplicons analyzed included two regions spanned by 
exons 4 and 5 and the 3’ untranslated region (3’UTR) (Fig. 4.18. A). Importantly, the 
first exon 4/5 amplicon showed a definite decrease in RNA Pol. association after 
approximately 30 minutes, with detection being completely abrogated by the three 
hours time point (Fig. 4.18. B.). This phenomenon was especially apparent in HT29 
TSA treated samples. Significantly, 30-45 minutes is the expected amount of time that it 
would take to actually be able to record a loss in RNA Pol. II at this region of the SRC  
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Figure 4.16. RNA polymerase II occupancy at the SRC promoters is not
affected by TSA treatement. (A) SRC genomic architecture. Dark boxes indicate in
the SRC untranslated regions and lighter boxes indicate exons that are translated.
The time required for RNA polymerase II transcription from either the SRC1A or
SRC1 promoters to the amplicon is indicated above the star. Time required was
determined assuming a polymerase II rate of transcription of 1 or 1.5 Kb/minute.
(B) ChIP assays were performed on HepG2 and HT29 cells, treated at various time
points with TSA, with an antibody specific for RNA polymerase II. Following
immunoprecipitation and de-crosslinking, DNA was amplified using primers
specific for SRC1 and SRC1A promoters.

 Samples were resolved on an agarose
gel. The input samples are non-immunoprecipitated samples. The negative antibody
control ( -Integrin) samples are not shown. These results are representative of three
independent experiments performed in each cell line.

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Figure 4.17. RNA polymerase II occupancy at SRC exons is not
affected by TSA treatement. (A) SRC genomic architecture. Dark boxes indicate in
the SRC untranslated regions and lighter boxes indicate exons that are translated.
The stars indicate the regions amplified in the ChIP analysis. The time required for
RNA polymerase II transcription from either the SRC1A or SRC1 promoters to the
amplicon is indicated above the star. Time required was determined assuming a
polymerase II rate of transcription of 1 or 1.5 Kb/minute. (B) ChIP assays were
performed on HepG2 and HT29 cells, treated at various time points with TSA, with
an antibody specific for RNA polymerase II. Following immunoprecipitation and
de-crosslinking, DNA was amplified using primers specific for the regions between
exon 1A/1B and exons 1B/1C.

Samples were resolved on an agarose gel. The input
samples are non-immunoprecipitated samples. The negative antibody control
( -Integrin) samples are not shown. These results are representative of three
independent experiments performed in each cell line.

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Figure 4.18. RNA polymerase II occupancy at the SRC 3'UTR is affected by
TSA treatement. (A) SRC genomic architecture. Dark boxes indicate in the SRC
untranslated regions and lighter boxes indicate exons that are translated. The stars
indicate the regions amplified in the ChIP analysis. The time required for RNA
polymerase II transcription from either the SRC1A or SRC1 promoters to the
amplicon is indicated above the star. Time required was determined assuming a
polymerase II rate of transcription of 1 or 1.5 Kb/minute. (B) ChIP assays were
performed on HepG2 and HT29 cells, treated at various time points with TSA, with
an antibody specific for RNA polymerase II. Following immunoprecipitation and
de-crosslinking, DNA was amplified using primers specific for two regions between
exons 4/5 and the 3' untranslated region (3' UTR).

Samples were resolved on an
agarose gel. The input samples are non-immunoprecipitated samples. The negative
antibody control ( -Integrin) samples are not shown. These results are representative
of three independent experiments performed in each cell line.

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gene if RNA Pol. II was sequestered at the promoter regions upon treatment. 
Conversely, the second amplicon between exons 4 and 5 showed continued detection of  
RNA Pol. II by the three hours time point, despite a subtle decrease in overall 
occupancy. Finally, there was an obvious loss of RNA Pol. II at the 3’UTR by the 30 
minutes time point with an almost complete loss of Pol. II by the three hours time point 
in both cell lines studied.  
 In summary, RNA Pol. II remains present at both SRC promoters in HepG2 and 
HT29 cells after TSA treatment. A definite decrease in RNA Pol. II occupancy at the 
3’UTR was observed by the 30 minutes time point, with an almost complete loss 
observed by three hours post treatment. These results suggest that RNA Pol. II may be 
confined to the promoter regions in response to TSA treatment.  
 
4.2.7. Phosphorylation of RNA Polymerase II on SRC Gene in Response to TSA 
Treatment  
 An RNA Pol. II signal was present at the SRC promoter regions and yet was lost 
at regions downstream in response to TSA treatment. RNA Pol. II function is dictated 
by the phosphorylation of two key residues within its carboxy-terminal domain (CTD) 
(Meinhart, et al., 2005). The Human RNA Pol. II CTD is characterized as having 52 
heptad repeats, with the phosphorylation of the second and fifth serine residues being 
key in RNA Pol. II function (Phatnani and Greenleaf, 2006). RNA Pol. II is 
characteristically phosphorylated at the fifth serine residue of the CTD heptad when 
RNA Pol. II is within the 5’ region of a gene (Phatnani and Greenleaf, 2006). Typically, 
the phosphorylation of serine five decreases as the polymerase transverses the gene. The 
RNA Pol. II antibody used in the previous experiments was not phospho-specific. 
Therefore, to identify if TSA induced changes may occur via RNA Pol. II at the 
promoter regions, changes in the phosphorylation of both residues in response to TSA 
were addressed.  
 To identify if aberrant CTD phosphorylation was occurring in response to TSA, 
ChIPs were performed with an antibody specific to RNA Pol. II CTD phosphorylated 
serine 5 (RNA Pol. II (S5)) with TSA treated HeG2 and HT29 cells (4.19.). S5 of RNA 
Pol. II CTD was phosphorylated at the promoter regions of SRC. This phosphorylated  
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Figure 4.19. Effect of TSA on the serine 5 phosphorylated form of RNA
Polymerase II binding to the SRC promoters and SRC 3'UTR. ChIP assays were
performed on HepG2 and HT29 cells, treated at various time points with TSA, with
an antibody specific to the serine 5 phosphorylated form of RNA Polymerase II.
Following immunoprecipitation and de-crosslinking, DNA was amplified using
primers specific for the SRC1A promoter (A), SRC1 promoter (B) or SRC 3'UTR
(C). Samples were resolved on an agarose gel. The input samples are non-
immunoprecipitated samples. The negative antibody control ( -Integrin) samples are
not shown. These results are representative of three independent experiments
performed in each cell line. Real-time PCR of two averaged HT29 ChIP assays
performed with probes and primers specific for the SRC1A promoter (D), SRC1
promoter (E) and 3'UTR (F).



Both B and C values were determined by standardizing the
samples to input C(T), converting C(T) values into DNA concentrations and then
graphing as fold changes between the negative and positive antibody samples.
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form of Pol. II was maintained at the promoter regions despite TSA treatment (Fig.4.19. 
A, B.). Conversely, S5 CTD phosphorylation appeared to decrease at the 3’ UTR of  
SRC in response to TSA (Fig. 4.19. C.). This observation was in agreement with 
previous RNA Pol. II results, whereas an overall decrease in RNA Pol. II occupancy at 
this locus had been previously observed (Fig.4.18.). These experiments were supported 
by real-time PCR data performed with samples from HT29 cells and graphed as 
indicated in a previous section (Fig. 4.19. D, E, F.). The real-time data suggests that 
there is a greater population of serine 5 phosphorylated RNA Pol. II at the SRC1A 
promoter as compared to the SRC1α promoter (nearly five fold difference in occupancy 
between the two promoters). Although RNA Pol. II (S5) is not commonly associated 
with the 3’ distal regions of a gene, there was approximately a 14 fold enrichment at this 
region in untreated cells that rapidly decreased upon TSA treatment as compared to the 
negative control (α-integrin).  
 Conversely, the serine 2 phosphorylated CTD form of RNA Pol. II (RNA Pol. II 
(S2)) is under-represented at the promoter and is commonly most abundant at regions 
downstream of the promoter (Phatnani and Greenleaf, 2006). To identify where this 
form of RNA Pol. II was most abundant along the SRC gene, we performed ChIP with 
an antibody specific for RNA Pol. II (S2) in TSA treated HT29 and HepG2 cells (Fig. 
4.20.). Interestingly, RNA Pol. II (S2) could be detected at both SRC promoter regions 
and these levels did not change upon TSA treatment. However, real-time results 
indicate that though RNA Pol. II (S2) can be found at the SRC promoter regions, it is at 
very low levels as compared to RNA Pol II (S5) enrichment at these regions. Whereby, 
RNA Pol. (S2) can only be found at two-fold the levels of the negative control antibody 
at the SRC1α promoter and four-fold the levels of the negative control at the SRC1A 
promoter. These levels were dramatically lower than what was observed with the 
antibody specific for RNA Pol. II (S5) at the SRC1α and SRC1A promoter regions (4 
and 17-fold, respectively). In contrast, RNA Pol. II (S2) occupation at the 3’UTR is 
significantly higher than what was observed with the RNA Pol. II (S5) experiments (40-
fold versus 17-fold enrichment) but the presence of this phospho-specific RNA Pol. II 
moiety also decreased in response to TSA. 
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Figure 4.20. Effect of TSA on the serine 2 phosphorylated form of RNA
Polymerase II binding to the SRC promoters and SRC 3'UTR. ChIP assays were
performed on HepG2 and HT29 cells, treated at various time points with TSA, with
an antibody specific to the serine 2 phosphorylated form of RNA Polymerase II.
Following immunoprecipitation and de-crosslinking, DNA was amplified using
primers specific for the SRC1A promoter (A), SRC1 promoter (B) or SRC 3'UTR
(C). Samples were resolved on an agarose gel. The input samples are non-
immunoprecipitated samples. The negative antibody control ( -Integrin) samples are
not shown. These results are representative of three independent experiments
performed in each cell line. Real-time PCR of two averaged HT29 ChIP assays
performed with probes and primers specific for the SRC1A promoter (D), SRC1
promoter (E) and 3'UTR (F).



Both B and C values were determined by standardizing the
samples to input C(T), converting C(T) values into DNA concentrations and then
graphing as fold changes between the negative and positive antibody samples.
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Taken together, these results confirm that regardless of the form of RNA Pol. II 
studied, RNA Pol. II remained associated with the SRC promoter regions and decreased 
at the 3’UTR in response to TSA treatment. These findings further confirm that TSA  
treatment may be interrupting transcription at a point after the binding of RNA Pol. II to 
the promoter regions, thus diminishing the ability of RNA Pol. II to reach the 3’ UTR of 
the SRC gene.   
 
4.2.8. Discussion 
4.2.8.1. Histone Acetylation is Not a Simple Predictor of Gene Activity 
 The transcriptional activation and/or repression -mediated by HDIs can result in 
apoptosis and cell cycle arrest in numerous neoplasms (Dokmanovic and Marks, 2005). 
HDI -mediated apoptosis can be achieved through the transcriptional upregulation or 
downregulation of key factors involved in either the caspase--dependent apoptosis 
pathway and/or the death receptor apoptosis pathway (Johnstone, 2002). Similarly, HDI 
induced cell cycle arrest has been suggested to occur through the transcriptional 
upregulation of the cyclin -dependent kinase p21WAF1 combined with the transcriptional 
downregulation of Cyclin A and D1 (Sandor, et al., 2000). While HDIs mediate their 
effects in a variety of manners, the mechanism responsible for HDI -mediated 
transcriptional activation and/or repression remains unknown (Chen, et al., 2005; Li, et 
al., 2006). 
 Classically, it has been suggested that HDIs act at the chromatin level to 
modulate transcriptional activation. This hypothesis was established primarily based on 
the functions attributed to HDACs. HDACs act, in part, to relieve the acetylation of 
histone tail lysine residues thereby restoring a positive charge to the lysine residues 
contained within the histone tail. This increase in positive charge results in increased 
DNA-histone tail or histone tail-histone interactions, which lead to the condensation of 
the chromatin. The “closed” conformation marked by condensed chromatin prevents the 
interactions of gene specific activators and general transcription factors with their 
cognate DNA sequences thus preventing transcriptional activation (Santos-Rosa and 
Caldas, 2005). As a result, HDIs are frequently associated with transcriptional 
activation due to their ability to inhibit HDACs and presumably the repressive activities 
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of HDACs. In agreement with a role for HDI -mediated acetylation in transcriptional 
activation, numerous groups have reported increases in histone H3/H4 acetylation at the 
promoter regions of genes transcriptionally activated by HDIs, most notably at the 
p21WAF1 promoter (Richon, et al., 2000; Zhao, et al., 2006; Pan, et al., 2007).  The 
above hypothesis addresses the mechanism of HDI -mediated transcriptional 
deregulation at genes whose expression is enhanced by HDIs but fails to identify what 
is occurring at the promoter regions of genes repressed by HDIs.  
Previous studies attempting to identify the mechanisms behind HDI -mediated 
repression of SRC activity were unsuccessful. Moreover, discrete HDI response 
elements could not be identified at either promoter region and protein neosynthesis was 
not required to mediate SRC repression (Kostynuik, et al., 2002; Dehm, et al., 2004). 
As a result of these findings, a comparison of the changes of histone acetylation at the 
promoter regions of two genes differentially affected by HDIs was undertaken. The goal 
was to identify if there were indeed opposing changes in histone acetylation at the two 
genes in response to HDIs in order to determine if differential promoter regulation could 
be explained by differential chromatin modifications.  
Surprisingly, it was discovered that regardless of the effect -mediated by HDIs, 
acetylation of both histones H3 and H4 increased at both SRC promoters and the 
p21WAF1 promoter loci in response to TSA. Although increased histone acetylation was 
expected at the p21WAF1 promoter locus, according to the HDI-chromatin model, 
acetylation changes at the SRC promoters should have demonstrated an opposite affect. 
These results suggest that histone acetylation is not an accurate predictor of 
transcriptional activation as the SRC promoter regions should have demonstrated 
decreased or unchanged histone acetylation upon HDI treatment.  In HepG2 cells, TSA 
induced increased acetylation at the SRC promoter regions as rapidly as 15 minutes post 
treatment. The short amount of time elapsed between treatment and an observable 
change in acetylation is significant as it suggests that effects -mediated by HDIs at the 
SRC and p21WAF1 promoter regions are immediate and likely occurring directly at or 
within close proximity to the promoter regions.  
Further analysis into the discrete residues affected by HDIs resulted in several 
interesting observations. Specifically, while all three promoters demonstrate similar 
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overall trends in HDI induced histone acetylation changes in HT29 cells, there were two 
notable exceptions. The SRC1A and SRC1α promoters are both repressed by HDIs; 
however, upon treatment with TSA, acetylation at histone H4K12 increased slightly at 
the SRC1A promoter but decreased at the SRC1α promoter. Moreover, the marginal 
acetylation of histone H4K12 at the p21WAF1 promoter also decreased. These results 
suggest that the acetylation status of this residue was more similar at the SRC1α and 
p21WAF1 promoter regions, which are differentially affected by HDIs, than at the two 
SRC promoter regions, which are both repressed by HDIs. Similarly, the same 
phenomenon was observed with histone H4K16 acetylation; H4K16 acetylation 
decreased at the SRC1A promoter and increased at the SRC1α and p21WAF1 promoter 
regions. Again, these results suggest greater similarities in histone acetylation patterns 
between the differentially affected SRC1α and p21WAF1 promoter regions. The 
observation that H4K16 acetylation decreases at the SRC1A promoter is particularly 
interesting within the context of HDI -mediated transcriptional repression. H4K16 
acetylation is reported to prevent the condensation of chromatin by the remodelling 
enzyme ISWF (Shia, et al., 2006). The decrease in H4K16 acetylation at the SRC1A 
promoter is therefore significant as it provides a possible mechanism by which SRC1A 
transcription could be repressed through chromatin compaction. However, the increase 
in H4K16 acetylation at the SRC1α promoter upon treatment suggests that HDI -
mediated repression by this mechanism is unlikely. Furthermore, in HepG2 cells 
H4K16 acetylation increases at both the SRC1A and SRC1α promoter regions. 
Interestingly, H4K8 acetylation gradually decreased at all three promoter regions 
studied in HT29 cells. Acetylation of H4K8 has been reported to be required for the 
recruitment of the chromatin-remodelling enzyme SWI/SNF to contribute to 
transcriptional initiation at the INF-β locus in vitro (Agalioti, et al., 2002). Despite 
compelling studies highlighting unique roles for the acetylation of histone H4 lysine 
residues in transcriptional activation, a recent study performed in budding yeast 
suggested that the effects of histone H4K5, K8, and K12 acetylation are cumulative and 
do not have discreet roles in transcriptional regulation. Conversely, histone H4K16 
acetylation was suggested to be required for the transcriptional activation of many genes 
(Dion, et al., 2005), The disparities reported in the consequences -mediated by the 
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acetylation of histone H4 residues, and the results presented herein, suggest that while 
acetylation status is changeable, a particular effect -mediated by a change in acetylation 
is not guaranteed.    
The only notable difference in HDI -mediated acetylation changes at the SRC1A 
and SRC1α promoter regions in HepG2 cells was observed at histone H3K9. H3K9 
acetylation increases marginally at the SRC1α promoter but immediately decreases at 
the SRC1A promoter. This finding is particularly interesting considering that H3K9 
acetylation is frequently associated with transcriptionally active genomic regions. In 
particular, acetylation of both H3K9 and H3K14 mediates the binding of TAF1 via 
TAF1’s double bromodomains and therefore contributes to PIC assembly in vitro 
(Agalioti, et al., 2002). The gradual increase of H3K9 and H3K14 acetylation at all 
three promoter loci upon TSA treatment in HT29 cells suggests that while it is possible 
that H3K9 and H3K14 acetylation mediates TAF1 binding, the acetylation of these 
residues does not guarantee subsequent transcriptional activation. Furthermore, in 
HepG2 cells, H3K14 acetylation increases at both SRC promoters in response to TSA 
whereas H3K9 acetylation changes are different between the two promoter regions 
studied. This suggests TAF1 binding is not occurring via these two histone residues in 
this cell line. Aside from participating in TAF1 binding, however, H3K9 acetylation is 
mutually exclusive to the methylation of H3K9, which is commonly found in 
transcriptionally repressed or heterochromatin regions (Eskeland, et al., 2007; 
Wissmann, et al., 2007). However, H3K9 trimethylation could not be detected at any of 
the three promoter regions studied thus suggesting that the chromatin was not 
condensing into heterochromatin in response to TSA.  
Similar to that observed in HT29 cells, the decreased acetylation of H3K9 at the 
SRC1A promoter did not correlate with the H3K9 acetylation change at the SRC1α 
promoter in HepG2 cells. This observation, combined with differences in histone H4 
acetylation at both SRC promoters in HT29 cells, could suggest a differential 
mechanism for HDI -mediated repression between the two promoter regions. However, 
this is unlikely considering the overall histone acetylation status at all three promoter 
regions studied alters in a similar fashion regardless of HDI -mediated transcriptional 
events. Therefore, taken together, these studies into the post-translational modifications 
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of histone residues in response to HDI treatment have shown that changes in histone 
acetylation are not accurate indicators of transcriptional activation or repression 
following HDI treatment. Indeed, residue specific alterations in histone acetylation at 
differentially affected promoter regions did not correlate with transcriptional activation 
or repression -mediated by HDIs. As a result, the changes in histone acetylation at the 
SRC promoter regions may simply be an artifact of HDI treatment. Conversely, the 
increased acetylation may be indicative of the recruitment of co-activators to the SRC 
promoter regions following HDI treatment. However, in this scenario, HDI -mediated 
SRC repression would negate the effect of the recruited co-activators by repressing SRC 
expression at a later stage in transcription.     
 
4.2.8.2. Transcription Factor Binding and RNA Polymerase II Binding to SRC   
              Promoters is Unaffected by TSA Treatment 
 As HDI -mediated global chromatin deacetylation was not observed at either 
SRC promoter region, the role of gene specific regulators of transcriptional repression 
were addressed. Previous studies into HDI-mediated transcriptional activation of 
p21WAF1 suggested a role for the Sp family of factors in HDI induced activation (Xiao, 
et al., 1999; Huang, et al., 2000; Xiao, et al., 2000; Sun, et al., 2002). Furthermore, 
other groups have identified HDI response elements that require Sp factor binding sites 
for HDI-mediated transcriptional deregulation (Choi, et al., 2002; Steiner, et al., 2004; 
Yokota, et al., 2004; Huang, et al., 2005). These studies all suggest a major role for Sp 
factor binding in mediating HDI specific effects. However, other studies have suggested 
HDI -mediated transcriptional repression is the result of abrogated transcriptional 
initiation through the impeded binding of basal transcription factors such as TBP and 
RNA Pol. II (Rascle, et al., 2003). Similarly, HDI treatment inhibits selected interferon 
beta (IFNbeta)-stimulated immediate early genes by preventing RNA Polymerase II 
from binding to promoter regions (Sakamoto, et al., 2004). Taken together, these 
studies suggest that HDI -mediated activation or repression may be mediated through 
the deregulation of transcriptional initiation. Deregulation could be achieved through 
either the abrogation, or enhancement of initiation-mediated by sequence specific 
 129
transcriptional regulators such as the Sp family, or through the loss of RNA Pol. II 
binding.  
Previous work failed to identify an HDI responsive element at either the SRC1A 
or SRC1α promoter regions, including at the Sp factor binding sites. However, this 
same study identified a potential role for general promoter architecture, including both 
proximal promoter elements and core promoter elements, in HDI-mediated repression 
(Dehm, et al. 2004). In this current study, Sp1, Sp3 and RNA Pol. II occupancy of both 
the SRC promoters was unchanged in response to TSA treatment. These findings have 
several interesting implications for HDI -mediated SRC repression. 
 Despite the well-established involvement of the Sp family of transcription 
factors in HDI -mediated transcriptional activation, these factors are not involved in 
HDI -mediated SRC repression. Evidence for this conclusion is drawn from several 
sources. Firstly, previous studies did not identify an HDI response element at the 
SRC1A promoter. If HDIs were mediating repression of SRC exclusively through the 
binding or activity of these factors, mutating the binding sites would diminish the 
effects of HDI -mediated repression. However, this was not the case (Dehm, et al., 
2004). Secondly, the Sp family of factors could not be responsible for HDI-mediated 
repression of the SRC1α promoter, as this family of transcription factors does not 
activate the SRC1α promoter. Finally, the binding of distal promoter elements by 
factors such as Sp1 are reported to enhance or disrupt PIC assembly prior to RNA Pol. 
II binding (Ryu, et al., 1999). The finding that RNA Pol. II occupancy at the SRC1A 
and SRC1α promoter regions was not abrogated by HDI treatment suggests that the 
majority of the PIC assembles despite TSA treatment. Therefore, maintained RNA Pol. 
II promoter occupancy suggests that the effects imposed by Sp factor binding, whether 
positive or negative, have already occurred and were not detrimental to the PIC 
assembly. 
These results are unlike those observed for HDI -mediated repression of both 
cytokine and interferon induced gene expression (Rascle, et al., 2003; Sakamoto, et al., 
2004). Both cytokine and interferon targeted genes are activated as a result of 
transcriptional induction. Therefore, RNA Pol. II occupancy at affected promoter 
regions can be followed prior to induction, when RNA Pol. II should not be present, all 
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the way through induction and transcriptional activation, when RNA Pol. II should be 
present. Furthermore, these studies have suggested that the abrogated binding of 
transcriptional activators STAT5 or interferon regulatory factor 9 (IFR9) are responsible 
for impeded RNA Pol. II binding to these promoter regions. As evidenced by Sp1/Sp3 
ChIP results, however, the binding of transcriptional activators to the SRC1A promoter 
was not abrogated upon HDI treatment. 
Continued RNA Pol. II binding at both SRC promoter regions, despite HDI 
treatment, suggests that HDIs are affecting either transcriptional initiation or elongation. 
The presence of RNA Pol. II at the promoter region does not, however, identify if TFIIE 
and/or TFIIH is(are) binding to the partially assembled PIC to mediate transcription 
initiation. These studies have, however, shown that RNA Pol. II occupation at the SRC 
promoter regions was not abolished upon treatment with TSA, which suggests that 
HDIs affect SRC expression downstream of RNA Pol. II binding.  
 
4.2.8.3. Reduction in RNA Polymerase II Occupancy at Regions 3’of the SRC    
             Promoters in Response to TSA Treatment 
 Regions downstream of the SRC1A promoter were analysed for RNA Pol. II 
occupancy. Overall, these results suggest that RNA Pol. II was sequestered at the SRC 
promoter regions upon TSA treatment as a definite decrease in RNA Pol. II occupancy 
at the 3’ UTR was detected as soon as 30 minutes post-treatment in both HepG2 and 
HT29 cells. Furthermore, the amount of time required to observe a change in RNA Pol. 
II occupancy at the SRC 3’UTR was in agreement with the amount of time elapsed 
before TSA promoter specific effects would be observed at the distal ends of the gene 
(Neugebauer, 2002; Mason and Struhl, 2005). However, at several regions between the 
promoter and 3’UTR there were unexpected disparities in RNA Pol. II enrichment at 
almost adjacent amplicons.  
In discussing these discrepancies it is important to note that although HDI -
mediated effects are being measured, the differences in RNA Pol. II occupancy at 
adjacent regions is apparent in untreated cells. This suggests that treatment with HDIs is 
unrelated to the observed differences. For example, RNA Pol. II occupancy is almost 
undetectable throughout the time course at the amplicon between exon 1A and 1B. 
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Whereas, downstream at the amplicon between exon 1B and 1C, RNA Pol. II 
occupancy was detected at the 0 time point in both cell lines. A similar phenomenon 
was observed at adjacent amplicons between exon 4 and exon 5. It would be expected 
that if RNA Pol. II could not be detected upstream at a particular region, that RNA Pol. 
II would not be detected at an amplicon downstream. This is clearly not the case. The 
most obvious reason for the observed disparities may reside in differences in PCR 
efficiency between amplicons. The region between exon 1A and 1B is very GC rich 
and, as a result, amplification of this region is much more difficult. Moreover, while the 
adjacent amplicons between exon 4 and exon 5 demonstrate similar decreases in RNA 
Pol. II occupancy upon HDI treatment PCR products obtained from the second 
amplicon were clearer. Aside from experimental difficulties, the duration of RNA Pol. 
II occupancy was not consistent along a gene. An in vitro study into RNA Pol. II pause 
sites within the c- and N-myc gene suggested that a pause in RNA Pol. II transcription 
frequently occurs in three distinct gene regions. In particular these regions included 
regions directly downstream of T-rich regions which yield U-rich mRNA, regions that 
were U- or C-rich and finally, sites following RNA hairpins (Keene, et al., 1999). If one 
or more of the SRC amplicons analysed encompassed an RNA Pol. II pause site, RNA 
Pol. II ChIP results would be enriched at this particular region as RNA Pol. II would be 
present at this particular site for a longer period of time. Moreover, assuming that 
transcription initiation by RNA Pol. II was consistently occurring prior to treatment, and 
by logical extension, that productive elongation was occurring, a relative backlog of 
RNA Pol. II moieties would be present at regions upstream from the site of 
transcriptional pausing. This scenario may explain why RNA Pol. II occupancy at 
particular regions along the SRC gene may be better represented by ChIP analysis than 
RNA Pol. II occupancy at other regions.  
4.2.8.4. No Change in RNA Polymerase II Phosphorylation at SRC 
  Promoters upon TSA Treatment  
Experiments measuring RNA Pol. II occupancy at the SRC promoter regions 
and more distal regions of the gene show transcriptional initiation or elongation by 
RNA Pol. II was impeded upon HDI treatment. Moreover, studies utilizing antibodies 
specific for the phosphorylated forms of RNA Pol. II demonstrated that transcriptional 
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initiation was likely occurring, which suggests that productive transcriptional elongation 
was likely abrogated by HDIs. 
The logic used in the derivation of these conclusions stems from the observation 
that the occupancy of RNA Pol. II CTD phosphorylated at serine 5 (S5) is maintained at 
the SRC promoter regions despite treatment with TSA. RNA Pol. II S5 phosphorylation 
is -mediated exclusively through the kinase activity of TFIIH (Svejstrup, 2003; Thomas 
and Chiang, 2006). The phosphorylation of S5 suggests that TFIIH and TFIIE are 
present within the PIC as TFIIE is responsible for stimulating the ATPase, CTD kinase 
and helicase activities of TFIIH to initiate RNA Pol. II -mediated transcription (Thomas 
and Chiang, 2006). Moreover, the phosphorylation of S5 within the CTD of RNA Pol. 
II is frequently associated with and required for initiated transcription (Komarnitski, et 
al., 2000; Svejstrup, 2003; Meinhart, et al., 2005). Therefore, the lack of change in the 
occupancy of S5 phosphorylated RNA Pol. II, upon HDI treatment, suggests that TSA 
was not repressing SRC expression via inhibition of transcriptional initiation. If 
transcriptional initiation was abrogated by HDI treatment, a decrease in RNA Pol. II S5 
phosphorylation would be observed as soon as 15 minutes post-treatment. This was not 
the case.  
As expected, the detection of the S2 phosphorylated form of RNA Pol. II at 
either SRC promoter regions was difficult.  S2 phosphorylated RNA Pol. II is more 
frequently observed at regions downstream of the promoter as S2 phosphorylation 
occurs after the addition of the methylated guanosine cap to the nascent mRNA 
(Saunders, et al., 2006). The requirement of such co-transcriptional processes in the 
phosphorylation of S2 RNA Pol. II, have led to the acceptance that S2 phosphorylated 
RNA Pol. II is indicative and required for transcriptional elongation (Komarnitski, et 
al., 2000; Svejstrup, 2003; Meinhart, et al., 2005). However, by performing quantitative 
PCR it was demonstrated that S2 phosphorylated RNA Pol. II was present at SRC 
promoter proximal regions, although at a very low abundance. Upon treatment with 
TSA the occupancy of this form of RNA Pol. II did not change. The lack of change in 
distribution of this form of RNA Pol. II following TSA treatment would generally 
indicate that elongation was not impeded by TSA. However, the use of changes in S2 
phosphorylated RNA Pol. II occupancy at promoter regions as an indicator of deviated 
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transcriptional elongation was not ideal, as the levels of S2 phosphorylated Pol. II were 
already very low in these regions. Therefore, subsequent decreases in phosphorylation 
were difficult to gauge. Indeed, work with the inducible MAP kinase phosphatase-1 
(MKP-1) gene has suggested that the induced phosphorylation of S2 RNA Pol. II was 
best observed at regions far downstream of the promoter (Fujita, et al., 2007). As 
expected, the S2 phosphorylated form of RNA Pol. II was abundant at the 3’UTR of 
SRC prior to TSA treatment. However, in agreement with previous RNA Pol. II 
occupancy ChIP results, the distribution pattern of the S5 phosphorylated form of RNA 
Pol. II and S2 phosphorylated from of RNA Pol. II decreased at the distal 3’ regions of 
the gene upon TSA treatment. These results suggest a model whereby transcriptional 
elongation, not initiation, is attenuated by these drugs.  
In agreement with a role for impeded transcriptional elongation in HDI -
mediated SRC repression, previous transient transfection experiments performed with 
SRC reporter constructs were susceptible to HDI -mediated repression (Kostyniuk, et 
al., 2002; Dehm, et al., 2004). If HDIs were repressing SRC transcriptional activity via 
chromatin remodelling, the transiently transfected reporter constructs would likely be 
immune to the effects -mediated by HDIs as these would target chromatin packaged 
endogenous SRC. In addition, these SRC reporter constructs are composed of a 
relatively small region of the SRC promoter DNA. Therefore the effect imposed by 
HDIs could be -mediated at only this small region of the SRC promoter locus. 
Interestingly, the segment of the SRC locus contained within these reporter constructs 
encompasses the region upstream of the transcriptional start site, which is required for 
the binding of transcription factors, the Inr element, as well as the region downstream of 
the transcriptional start site. As these experiments have already eliminated the abrogated 
binding of transcription factors and/or RNA Pol. II as a mechanism for SRC repression 
by HDI treatment, only one region and the processes associated with this region remains 
as a target for HDI -mediated SRC repression. Therefore by process of elimination, the 
only remaining step that could be deregulated to result in abrogated SRC promoter 
activity following TSA treatment is elongation.      
HDIs could be attenuating transcriptional elongation at any of several critical 
stages in elongation. A key rate-limiting step in the transition from transcriptional 
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initiation to the formation of the early elongation complex revolves around the 
stabilization of the 4-5 nucleotide nascent transcript by TFIIB (Chen and Hampsey, 
2004; Saunders, et al., 2006). Conversely, prolonged TFIIB association with the very 
early elongation complex can impede the “bubble” collapse necessary to produce 
energy required for productive elongation thus preventing promoter escape. Indeed, in 
vitro assays have suggested that “bubble” collapse and elongation between nucleotide 
+7 and +9 is attenuated by the presence of TFIIB (Pal, et al., 2005). Clearly, the 
association of TFIIB with the initiation and elongation complexes must be finely 
regulated to ensure proper associations at appropriate phases of transcription. 
Interestingly, the autoacetylation of TFIIB, which enhances the stability of TFIIB/TFIIF 
interactions, potentially contributes to transcriptional activation (Choi, et al., 2003). 
HDI treatment could prevent the deacetylation of TFIIB, thereby prolonging an 
interaction with TFIIF, which could eventually prevent promoter escape by the 
elongation complex. While possible, this scenario is unlikely as it has been suggested 
that the deacetylation of TFIIB occurs without the aid of a deacetylase (Choi, et al., 
2003).  
A more likely mechanism for HDI -mediated repression of SRC transcriptional 
elongation involves deregulation of promoter-proximal pausing (Figure 4.21.). DRB 
sensitivity-inducing factor (DSIF) and negative elongation factor (NELF) bind to the 
early elongation complex (EEC) thus pausing the complex to facilitate the recruitment 
of the capping enzyme (CE) to the S5 phosphorylated CTD of RNA Pol. II (Sims III, et 
al., 2004). Elongation continues as a result of the association of positive transcription- 
elongation factor-b (P-TEFb) with the stalled elongation complex, which mediates the 
phosphorylation of S2 residue within the CTD as well as DSIF and NELF (Saunders, et 
al., 2006). The phosphorylation of NELF causes its disassociation from the paused 
complex and the phosphorylation of DSIF converts DSIF into a positive elongation 
factor (Peterlin and Price, 2006). Concomitantly, the small CTD phosphatase (SCP) 
dephosphorylates the S5 residue within the CTD. These alterations in the elongator 
complex recruit TFIIS to contribute to the re-initiation of elongation (Sims III, et al., 
2004). The elegant interplay of enzymatic functions culminating in the formation of the 
mature elongation complex could be easily undone through the deregulation of one key  
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Figure 4.21. Model of TSA mediated abrogation of transcriptional elongation.
A. Pre-initiation complex (PIC) fully assembled for transcription initiation.
B. Promoter-proximal pausing of RNA Pol. II by DSIF and NELF to accommodate
the entry of the capping enzymes to the S5 phosphorylated CTD. C. TSA inhibits
HDAC activity and disrupts phosphatase/HDAC complex formation. Phosphatase
dephosphorylates P-TEFb to inactivate P-TEFb kinase domain to prevent
subsequent P-TEFb kinase activity thus preventing RNA Pol. II release form
promoter-proximal pausing. Conversely, phosphatase aberrantly dephosphorylates
another key elongation dependent factor.
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B Promoter-proximal pausing
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135
 136
enzyme. For example, the association of P-TEFb with the paused elongation complex 
and subsequent kinase functions of P-TEFb strongly depends on the phosphorylation of 
the CDK9 subunit of P-TEFb. If the phosphorylation of P-TEFb is compromised, full 
enzymatic activity is lost and the early elongation complex is not released from the  
pause site (Peterlin and Price, 2006). Significantly, it has recently been demonstrated 
that HDI treatment disrupts protein phosphatase 1 (PP1)/HDAC complexes resulting in 
the dephosphorylation of effectors (Chen, et al., 2005; Alao, et al., 2006). Interestingly, 
the CDK9 subunit of P-TEFb is a substrate for PP1 -mediated dephosphorylation 
(Ammosova, et al., 2005). It is therefore not difficult to imagine that HDI treatment 
could release PP1 from HDAC complexes, to dephosphorylate P-TEFb thus preventing 
re-initiation of the stalled elongation complex and ultimately, abrogate SRC expression. 
Similarly, PP1 also dephosphorylates the S2 CTD residue of RNA Pol. II in vitro, 
providing another potential target for HDI -mediated repression via curtailed elongation 
(Washington, et al., 2002). The premature dephosphorylation of any of the components 
of the stalled elongation complex could result in aberrant expression. Interestingly, 
other studies have suggested a role for kinases in HDI -mediated transcriptional 
activation of p21WAF1, NF-κβ and gelsolin (Han, et al., 2001; Kim, et al., 2006; Eun, et 
al., 2007). The observations that kinases are involved in mediating transcriptional 
activation by HDIs further supports an argument for a role for phosphatases in 
mediating HDI repression. Moreover, it is important to consider that the interaction 
between elongation factors and phosphatases is only one example of a potential 
mechanism by which HDIs could repress expression through reduced transcriptional 
elongation. There are likely many such interactions that could be deregulated or 
interrupted by HDI treatment.  
4.2.8.5. Scope and Significance 
HDIs are a powerful and exciting class of chemotherapeutic agents credited with 
inducing apoptosis, cell cycle arrest and terminal differentiation in cancer cells. The 
mechanisms behind these effects are only beginning to emerge, however, the 
mechanism behind the transcriptional activation or repression by HDIs remains 
unknown. Classically, HDI -mediated histone modifications, such as acetylation, were 
credited with altering chromatin condensation to enhance transcriptional activation. 
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However, current studies suggest that HDI -mediated histone modifications are not 
necessarily indicative of the subsequent transcriptional activity of a particular gene. 
Furthermore, studies of inducible genes have suggested a role for abrogated RNA Pol. II 
binding in mediating transcriptional repression by HDIs, as a result of impeded 
transcription initiation. As an equal number of genes are repressed by HDIs as activated 
by these agents, the utility in discovering the mechanism for HDI -mediated repression 
cannot be emphasized enough. This current work suggests that transcription elongation, 
not initiation, may be responsible for HDI -mediated curtailed SRC transcriptional 
expression. Furthermore, as many pertinent genes are repressed by HDIs, such as cyclin 
A and cyclin D1, these findings could provide powerful clues in deciphering the general 
mechanism of HDI -mediated transcriptional repression.       
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4.3. REQUIREMENT OF HDAC ACTIVITY FOR SRC TRANSCRIPTIONAL 
ACTIVATION 
4.3.1. Effect of Class I HDACs on the Promoter Activity of SRC and p21WAF1 
 Recent studies have suggested that in some cases an HDAC may be required for 
transcriptional activity (Rascle, et al., 2003; Klampfer, et al., 2004). This finding 
correlates well with observations that SRC is repressed by HDIs. Indeed, if an HDAC is 
required for SRC transcription, and HDIs are inhibiting the essential HDAC, an 
abrogation of transcriptional activation would be expected. Therefore in an attempt to 
identify if HDACs are required for the transcriptional activation of SRC, a series of 
knockdown and overexpression experiments were performed with HDACs. 
 Class I HDACs are ubiquitously expressed, inhibited by HDIs and frequently 
associated with transcriptional regulation (Yang and Seto, 2003). In an attempt to 
identify if any of the class I HDACs were responsible for the TSA-mediated effects on 
SRC, all of the class I HDACs were individually overexpressed in SW480 and HepG2 
cells. These experiments were performed in an effort to identify what effect, if any, 
these factors have on SRC transcriptional activity. Furthermore, if a class I HDAC is 
required for SRC promoter activity, the overexpression of each individual class I HDAC 
should result in increased SRC promoter activity. As described in a previous section, 
p21WAF1 is transcriptionally activated by TSA. Furthermore, HDAC2 has been reported 
to directly repress p21WAF1 promoter activity (Huang, et al., 2005). Therefore as a proof 
of principle experiment, class I HDACs were co-transfected with the p21 reporter 
construct into SW480 cells (Fig. 4.22.). While HDAC2 and 8 could repress p21WAF1 
promoter activation, HDAC3 overexpression had little effect and surprisingly, HDAC1 
could modestly activate p21WAF1. These experiments confirmed that the overexpression 
of a class I HDAC was capable of regulating promoter activity. Co-transfection of 
SW480 cells with the SRC reporter constructs and each HDAC had differing effects 
(Fig. 4.23. A.). HDAC1, 2, 3 and 8 all decreased SRC1A promoter activity in SW480 
cells, whereas, SRC1α activity remained the same or decreased slightly upon co-
transfection with the class I HDACs in this cell line. In contrast, none of the class I 
HDACs had any effect on SRC activation, from either promoter, in HepG2 cells (Fig. 
4.23. B.).  
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Figure 4.22. Effect of the overexpression of Class I HDACs on the p21WAF1
promoter. (A) Class I HDACs (HDAC1, 2, 3 and 8) and p21WAF1-CAT were
co-transfected into SW480 cells.(B) The p21WAF1-CAT reporter construct used in A.
These results are representative of experiments performed at least three times in
duplicate. The standard deviation was calculated from two experiments each
performed in duplicate.
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Figure 4.23. Effect of the overexpression of Class I HDACs on the SRC1A and
SRC1 promoters. (


A) Class I HDACs (HDAC1, 2, 3 and 8) and SRC1A-CAT or
SRC1 -CAT were co-transfected into SW480 cells.(B)
The SRC1A-CAT and SRC1 -CAT reporter constructs used in A and B.
Class I HDACs (HDAC1, 2,
3 and 8) and SRC1A-CAT or SRC1 -CAT were co-transfected into HepG2 cells.
(c) These
results are representative of experiments performed at least three times in
duplicate. The standard deviation was calculated from two experiments each
performed in duplicate.
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4.3.2. Effect of Class I HDACs Knockdown on SRC Expression Levels  
 To complement the class I HDAC transfection studies, siRNA -mediated 
knockdowns of all of the class I HDACs were performed in HepG2 and HT29 cells 
(Fig. 4.24.). siRNA transfected cells were harvested and total RNA was extracted from 
the samples. RT-PCR was performed with primers specific for the HDAC being 
knocked down, SRC and a positive loading control (RPL13A). The knockdown of all 
four class I HDACs resulted in increased SRC expression in both cell lines studied, 
although the effect was clearest in HepG2 cells. Notably, an increase in SRC message 
was most apparent when HDAC8 was knocked down. This observation may be 
particularly significant as HDAC8 was not abundant prior to knockdown, suggesting 
that only a slight decrease in HDAC8 may result in dramatic increases in SRC 
activation. 
 Taken together, these results suggest that none of the class I HDACs are 
involved in SRC transcriptional activation. Moreover, it appears that all four of the class 
I HDACs may have a negative role in SRC regulation.  
 
4.3.3. Effect of Class II HDACs Knockdown on SRC Expression 
 Class II HDACs are also inhibited by HDIs and, though not as well studied, are 
also reported as having a role in transcriptional regulation (Fischle, et al., 2001). To 
characterize what role class II HDACs exerted on SRC expression, siRNA -mediated 
knockdowns of HDAC 5, 6, 7 and 10 were performed in HepG2 and HT29 cell lines 
followed by RT-PCR (Fig. 4. 25.). HDAC4, 5, 6, 7, 9 and 10 are all described as class II 
HDACs but as preliminary RT-PCR analysis failed to produce a discernable signal for 
HDAC4 and 9 in the cell lines studied, these two representatives were omitted from 
further investigation. Interestingly, in HepG2 cells, the knockdowns of all four class II 
HDACs studied eventually resulted in decreased SRC mRNA. This was not as apparent 
in HT29 cells, however, although the decrease in SRC mRNA could still be observed if 
the scrambled and 96 hours time points were directly compared.  
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Figure 4.24. Class I HDACs may repress SRC transcriptional activity. HepG2
cells (A) and HT29 cells (B) were transfected with 100 nM of siRNA specific for each
class I HDAC (HDAC1, 2, 3 and 8). Transfected cells were harvested at 48, 72 and
96 hours time points, RNA was extracted and RT-PCR was performed with primers
specific for the HDAC in question, SRC and RPL13A (positive control). All results
were compared to the scrambled (Scr.) siRNA transfected samples. The negative
RT-PCR control was distilled water. These are representative of experiments
performed at least three times in each cell line.
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Figure 4.25. Class II HDACs may be neccessary for SRC expression. HepG2
cells (A) and HT29 cells (B) were transfected with 100 nM of siRNA specific for each
class II HDAC (HDAC5, 6, 7 and 10) expressed in the above cell lines. Transfected
cells were harvested at 48, 72 and 96 hours time points, RNA was extracted and RT-
PCR was performed with primers specific for the HDAC in question, SRC and
RPL13A (positive control). All results were compared to the scrambled (Scr.) siRNA
transfected samples. The negative RT-PCR control was distilled water. These are
representative of experiments performed at least three times in each cell line.
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4.3.4. Effect of Class II HDAC on SRC Promoter Activity 
 The siRNA -mediated knockdown of select class II HDACs resulted in 
decreased SRC mRNA thus suggesting a role for any or all of these HDACs in the 
positive regulation of SRC. To identify if these class II HDACs were capable of acting 
directly at the SRC promoter regions to increase transcript level, co-transfection studies 
similar to the class I HDAC studies were performed in HepG2 and SW480 cells (Fig. 4. 
26.). In SW480 cells, HDAC5 and 7 did not change the activity of either promoter. 
However, in the same cell line, HDAC6 and 10 overexpression resulted in decreased 
SRC transcriptional activation via both SRC promoters. Conversely, in HepG2 cells, 
HDAC5, 7 and 10 overexpression all resulted in decreased SRC promoter activity. 
HDAC6 overexpression caused no change in SRC transcriptional activity at either 
promoter in either the cell lines studied.  
The overexpression results indicate that a class II HDAC may not be required 
for SRC transcriptional activation. However, the RT-PCR data suggests that the class II 
HDACs may have an indirect role in maintaining the SRC transcript levels.   
 
4.3.5. Discussion 
 Several recent studies have described a role for histone deacetylases (HDACs) in 
transcriptional activation in both human and yeast cells (Vidal, et al., 1991; Rascle, et 
al., 2003; Xu, et al., 2003; Chang, et al., 2004; Kato, et al., 2004; Klampfer, et al., 
2004; Sakamoto, et al., 2004; Nusinzon and Horvath, 2006; Sharma, et al., 2007). For 
example, in STAT 5 activated expression, HDAC activity was required for the 
recruitment of the basal transcription factors TBP and RNA Pol. II to promoter regions 
upon cytokine stimulation. Indeed, treatment with HDIs impeded STAT5 activated 
transcription in all genes analysed (Rascle, et al., 2003). Similarly, STAT5 induced 
expression of the Id-1 gene required HDAC1 activity to deacetylate transcription factor 
C/EBPβ (CCAAT/enhancer binding protein-α) to promote activation (Xu, et al., 2003). 
A general role for HDACs in mediating the activation of interferon-stimulated genes 
has also been established, however, the precise mechanism has yet to be determined. 
One study suggests that HDAC activity is required for RNA Pol. II binding to the  
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Figure 4.26. Effect of the overexpression of Class II HDACs on the SRC1A and
SRC1 promoters. (


A) Class II HDACs (HDAC5, 6, 7 and 10) and SRC1A-CAT or
SRC1 -CAT were co-transfected into SW480 cells.(B)
The SRC1A-CAT and SRC1 -CAT reporter constructs used in A and B.
Class II HDACs (HDAC5, 6,
7 and 10) and SRC1A-CAT or SRC1 -CAT were co-transfected into HepG2 cells.
(c)
These results are representative of experiments performed at least three times in
duplicate. The standard deviation was calculated from two experiments each
performed in duplicate.
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ISG54 promoter to activate transcription (Sakamoto, et al., 2004). In another study, a 
role for HDAC 6 in the activation of INF-β gene expression has been suggested 
(Nusinzon and Horvath, 2006). Furthermore, HDIs have also been shown to inhibit 
INFγ-induced STAT1--dependent transcription through decreased HDAC1, 2 and 3 
activity, thereby suggesting a requirement for these HDACs in STAT-1 -dependent 
transcription (Klampfer, et al., 2004). Finally, HDAC 7 has been shown to co-localize 
with HIF-1α in the nucleus under hypoxic conditions to promote the transcriptional 
activation of HIF-1α responsive genes (Kato, et al., 2004). These studies conflict with 
the general paradigm of a repressive role for HDACs in transcriptional activation, as 
well as provide a potential mechanism for HDI-mediated repression.  
 The studies described in the previous sections have suggested that HDI -
mediated repression of SRC is not achieved though impaired transcription factor 
binding, histone specific changes in acetylation, or impeded transcription initiation. 
Furthermore, despite identifying a potential role for attenuated transcriptional 
elongation in HDI -mediated SRC repression, the actual mechanism(s) behind SRC 
transcriptional repression by HDIs has not been determined. Though initially counter-
intuitive, the requirement of an HDAC for SRC transcriptional activation may explain 
how HDIs are able to repress SRC mRNA expression. In agreement with this 
hypothesis, p21WAF1 transcriptional activation has been shown to be repressed by 
HDAC1, 2 and/or 3 (Wilson, et al., 2006). As discussed in previous sections, p21WAF1 is 
the classical example of a gene that is transcriptionally activated by HDIs and, as such, 
a role for HDACs in transcriptional activation provide a potential mechanism for HDI -
mediated repression in gene expression.     
4.3.5.1. Class I HDACs do not Activate SRC Promoters 
 When studies examining the overexpression of all four class I HDACs were 
carried out it was found that none of the class I HDACs were able to activate SRC from 
either promoter region. Furthermore, that the SRC promoters were affected differently 
by overexpression of the class I HDACs suggests that a class I HDAC is not required 
for SRC activation, much less responsible for HDI -mediated repression. Interestingly, 
in SW480 cells, the SRC1A promoter is repressed by the overexpression of all four 
class I HDACs. The SRC1A selective decrease in activity could be explained by the Sp 
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family -mediated regulation of the SRC1A promoter. The abrogated interaction between 
Sp1 and class I HDACs is a frequent finding at genes that are transcriptionally activated 
by HDIs, suggesting that HDAC/Sp1 interactions are generally repressive to these genes 
(Xiao, et al., 1999; Huang, et al., 2000; Xiao, et al., 2000; Yokota, et al., 2004; Huang, 
et al., 2005). As such, the overexpression of HDACs in SW480 cells may have led to 
increased associations between Sp1/Sp3 and the class I HDACs at the SRC1A 
promoter, resulting in transcriptional repression. Previous findings suggesting that 
Sp1/Sp3 do not contribute to HDI -mediated repression of SRC do not preclude these 
factors from interactions that mediate SRC1A repression in-dependent of HDIs. In 
agreement with a role for Sp/HDAC interactions repressing SRC1A activity, the SRC1α 
promoter, which is not regulated by Sp1/Sp3, is unaffected by the overexpression of 
class I HDACs in this cell line. Surprisingly, siRNA -mediated knockdown of the class I 
HDACs resulted in increased SRC message 48 hours post-transfection, which further 
suggests that class I HDACs are repressive to SRC expression. Although the HDAC 
knockdown -mediated increase in SRC transcript levels was observed in both cell lines 
studied, it was easier to observe in HepG2 cells due to the ease with which these cells 
respond to transfection. If both the level of HDAC knockdown and increase in SRC 
message are analysed in HT29 cells, proportional changes in message can be observed. 
These results suggest that while SRC is repressed by HDIs, it is not due to a 
requirement of class I HDACs for transcriptional activation. In fact, class I HDACs 
appear to have a negative influence on SRC expression. 
4.3.5.2. Class II HDACs do not Activate SRC Promoters but may be Required for  
              the Maintenance of SRC mRNA Levels 
 HDIs, in particular TSA, also repress class II HDACs (Bolden, et al., 2006). To 
fully examine the potential role of HDACs in SRC transcriptional regulation, class II 
HDAC activity was also addressed. In contrast to results obtained from class I HDAC 
knockdown studies, siRNA -mediated knockdown of class II HDACs eventually 
resulted in a decrease in SRC expression. This was especially apparent when HDAC6 is 
knocked down in both cell lines analyzed. To identify if class II HDACs directly 
affected SRC transcriptional activation, overexpression studies were again performed. If 
class II HDACs were involved in SRC transcriptional activation, an increase in SRC 
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activity might be expected upon class II overexpression. This was not the case, 
suggesting that while this class of HDAC may be involved in maintaining SRC 
expression, as suggested by the decrease in SRC mRNA following class II knockdown, 
they are not involved in the transcriptional activation of SRC. Conversely, an HDAC 
may be required for promoter activity, however, the overexpression of an HDAC in 
transient transfections may be insufficient for defining the role of the particular HDAC 
in SRC promoter activity. Overexpressing a particular HDAC may be problematic as 
the HDAC in question may already be present at the SRC promoter regions and 
therefore the presence of more HDAC protein would be redundant. Furthermore, 
HDACs often function in complex with other proteins and as such the overexpression of 
an HDAC alone may also be insufficient to achieve a promoter specific effect. As a 
result of these differing scenarios, the knockdown studies of the class II HDACs were 
far more informative about what role these HDACs may mediate in SRC promoter 
activity.   
 A role for both class I and II HDACs in mediating gene activation has been 
observed in several interferon, viral and hypoxia induced genes (Rascle, et al., 2003; 
Xu, et al., 2003; Chang, et al., 2004; Kato, et al., 2004; Klampfer, et al., 2004; 
Sakamoto, et al., 2004; Nusinzon and Horvath, 2006). The same cannot be applied to 
SRC transcriptional activation, however, as the studies outlined herein have 
demonstrated that although HDIs mediate the repression of SRC expression, the 
overexpression of either class I or II HDACs did not activate SRC expression from 
either the SRC1A or SRC1α promoters. The most plausible explanation for this 
phenomenon involves the nature of the genes activated by HDACs. Indeed, without 
exception, all of the genes activated by HDACs are inducible by interferon, viral 
activity or hypoxic conditions, SRC is not. 
 Several important conclusions can be drawn from these studies. Firstly, SRC 
expression appears to be negatively impacted by class I HDACs, as evidenced by 
increased SRC message upon class I knockdown. Secondly, class II HDACs, in 
particular HDAC6, have an essential role in the maintenance of SRC expression. 
Finally, SRC promoter activity is not activated in response to class II HDAC 
overexpression, thus suggesting that the role of class II HDACs in SRC expression is  
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Figure 4.27. Model for HDI mediated SRC repression. Treatment of cells with
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not direct. The most obvious implication of these findings is that HDIs may be 
inhibiting essential class II HDAC processes to attenuate SRC expression. These  
findings fit well with a model for HDI -mediated repression of SRC whereby HDIs 
abrogate HDAC/phosphatase complexes to result in the aberrant dephosphorylation of 
factors critical to transcriptional elongation (Fig. 4.27.). Though a decrease in SRC 
transcript is not observed until 96 hours post Class II HDAC knockdown, the effect on 
SRC mRNA may not be observed until the existing class II HDAC protein levels 
decrease and the implications of class II HDAC loss on SRC expression can be realised. 
It is also significant that HDAC6 knockdown was most effective in decreasing SRC  
message in both cell lines tested as HDAC6 has been reported to exist in complex with 
PP1. Moreover, the HDAC6/PP1 complex is reported to be disrupted by HDI treatment,  
further supporting a role for both HDAC6 and PP1 in SRC repression via abrogated 
transcriptional elongation (Chen, et al., 2005; Alao, et al., 2006). 
4.3.5.3. Scope and Significance 
 The full extent of effects -mediated by HDACs are only now being realised. 
Originally only considered within the context of chromatin remodelling -mediated by 
histone specific modifications, HDACs are now known to be involved in transcriptional 
activation and repression, as well as in a variety of signalling cascades independent of 
histone modifications. This new found wealth of knowledge concerning HDACs is 
mostly the result of studies involving the use of the powerful chemotherapeutic known 
as histone deacetylase inhibitors. Significantly, the relationship between SRC 
expression and class II HDACs may be essential in delineating the mechanism of 
repression -mediated by HDIs. As it has been suggested that the expression of up to 
22% of all genes may be affected by HDIs, elucidating the mechanism(s) behind the 
transcriptional activation or repression -mediated by these agents will be invaluable.   
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5. CONCLUSIONS AND FUTURE STUDIES 
 
The activation and/or overexpression of c-Src has been a consistent finding in a 
variety of cancers; most notably, cancer of the colon, breast, liver, and pancreas 
(Biscardi, et al., 1999). Previous work from the Bonham laboratory has demonstrated 
that increased c-Src activity can, in part, be explained by the transcriptional 
overexpression of SRC in several colon cancer and breast cell lines (Dehm, et al., 2001; 
Dehm and Bonham, 2004). In an effort to determine the mechanisms responsible for 
SRC transcriptional overexpression in cancer cells, the regulation of the SRC promoter 
regions is of considerable significance. Similarly, of particular interest, SRC mRNA 
expression is powerfully repressed by the potent chemotherapeutic drugs, histone 
deacetylase inhibitors (HDIs), by a currently unknown mechanism (Kostynuik, et al., 
2002; Dehm, et al., 2004).    
 Two disparate promoters, SRC1α and SRC1A, regulate SRC expression. The 
SRC1α promoter is regulated by HNF-1α and as a result is expressed primarily in 
tissues such as the stomach, liver, and kidney (Bonham, et al., 2000). The 
housekeeping-like SRC1A promoter is approximately 1 kb downstream of the SRC1α 
promoter. The SRC1A promoter is ubiquitously expressed, GC-rich and regulated by 
the Sp family of transcription factors and hnRNP K. 
5.1. The Role of Sp3 on SRC Activity 
 Until recently, the Sp family factor, Sp3, was thought to be unable to activate the 
SRC1A promoter, however, a similar factor, Sp1, was a powerful activator of the 
SRC1A promoter. Recent information concerning the role of Sp3 resulted in the re-
characterization of the effect of this factor on SRC expression. Through the course of 
these studies it was determined that the longest physiological forms of Sp3 were indeed 
activators of SRC1A, however, not to the same extent as Sp1. Furthermore, previous 
studies were utilizing Sp3 constructs that were expressing the non-physiological, N-
terminal truncated form of Sp3. As such, the actual role of Sp3 within these systems 
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studied is circumspect due to the differing activating potential between the 
physiological and truncated forms of Sp3. As a result of these findings, and those of 
others, the true roles of the longest forms of Sp3 in transcriptional regulation are only 
now being realized. Moreover, comparative analyses of the putative and authentic long 
forms of Sp3 have identified a potential regulatory region in the N-terminal region of 
Sp3 that is missing in the non-physiological form of Sp3. The characterization of this 
region will be necessary in gleaning the complete role of the longest Sp3 isoforms in 
transcriptional regulation.  
Aside from the importance of the longest Sp3 isoform in transcriptional 
regulation, the shortest isoforms have a newly identified role as potential activators of 
transcription. This stems from the identification of SUMOylation as an inhibitor of the 
short Sp3 isoforms’ activation potential. Curtailing SUMOylation, either through 
mutation or the overexpression of a SUMO-1 protease, converted these ineffective 
transcription factors into potent activators. Interestingly, the same experiments to 
eliminate SUMOylation had little effect on the transcriptional activation by the longer 
isoforms of Sp3. Taken together, these results suggest that the SUMOylation of the 
shortest Sp3 isoforms may impede transcriptional activation, by these isoforms, through 
a mechanism that blocks the function of the sole activation domain present within the 
shortest Sp3 isoforms. A similar effect was not observed upon SUMOylation of the long 
isoforms potentially due to the presence of a second activation domain a significant 
distance away from the SUMO-1 binding site. To completely characterize the role of 
Sp3 on SRC activity, the proportion of which Sp3 isoforms are bound in vivo to the 
SRC1A promoter will need to be determined as well as the modification status of the 
isoform bound. Unfortunately, at this time, the antibodies necessary to undertake such a 
study are not available and only a general population of Sp3 can be identified as binding 
to the SRC1A promoter in vivo. Considering that a recent analysis of Sp factor binding 
sites on chromosome 21 and 22 listed a minimum of 12,000 binding sites specific for 
this family of factors on these chromosomes alone, suggests that theses factors are 
highly involved in gene regulation and essential in the characterization of promoter 
activity (Cawley, et al., 2004). Furthermore, it is through the characterization of 
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promoter regulation by factors such as these that the mechanism of enhanced SRC 
promoter activity in cancer cells may be ascertained. 
5.2. HDIs repress SRC Expression 
Despite the obvious dissimilarities between both SRC promoters, they have 
several qualities in common. Transcription is initiated from both promoters via an Inr 
element, and they are both repressed by the promising class of chemotherapeutic agent, 
histone deacetylase inhibitors (HDIs). HDIs are a particularly exciting class of 
chemotherapeutics due to their abilities to induce apoptosis, cell cycle arrest and 
terminal differentiation in neoplasms (Dokmanovic and Marks, 2005).  These effects are 
-mediated, in part, through transcriptional upregulation and downregulation of gene 
expression. Historically, this differential gene expression was attributed to altered 
histone modifications resulting in chromatin remodelling. As HDIs inhibit the activity 
of histone deacetylases, a greater number of histone residues are acetylated upon 
treatment. Traditionally, histone acetylation is associated with transcriptionally active 
genomic regions due to a more relaxed chromatin conformation at these regions; 
therefore treatment with HDIs would increase histone acetylation leading to an “open” 
chromatin conformation and increased transcriptional activity. While this model is 
suggestive of how genes are transcriptionally activated by HDIs, it fails to address 
genes transcriptionally repressed by HDIs, such as SRC.  
5.3. HDI Treatment Results in Similar Changes in Acetylation Status at SRC and 
p21WAF1 Promoters 
 As a result of this model, the acetylation status of the promoter regions of two 
genes differentially affected by HDIs was undertaken. The p21WAF1 promoter was used 
in this study as a classical example of a gene transcriptionally activated by HDIs 
whereas both SRC promoters were used as examples of a gene transcriptionally 
repressed by HDIs. Strikingly, the acetylation of histone residues at both SRC 
promoters and the p21WAF1 promoter increased in response to treatment with the HDI, 
Trichostain A (TSA). Upon closer analysis of changes in acetylation at particular 
histone residues, it was identified that despite a shared repression upon TSA treatment, 
the SRC1α promoter exhibited changes in acetylation at discreet residues more similar 
to the transcriptionally activated p21WAF1 promoter as compared to the transcriptionally 
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repressed SRC1A promoter. These results suggest that histone acetylation status is not 
an accurate predictor of transcriptional activity. Moreover, as a result of the increased 
histone acetylation at the SRC promoters in response to TSA, it is unlikely that 
chromatin remodelling is responsible for the repressive effects of HDIs at the SRC 
gene. Despite this compelling evidence suggesting that HDIs do not repress SRC 
through chromatin remodelling, to completely exclude the possibility, in vitro 
nucleosomal remodelling studies may be necessary.  
5.4. SRC Transcriptional Elongation Abrogated Following TSA Treatment   
As a result of findings such as those outlined above, the mechanisms behind 
HDI-mediated repression and activation are currently under intense study. While many 
suggest roles for transcription factors and HDI-responsive elements in HDI-mediated 
transcriptional activation, the mechanisms behind HDI-mediated repression remain 
elusive. HDI -mediated repression of SRC is not a result of HDI-responsive elements or 
protein neosynthesis, however, previous studies were able to identify potential roles for 
both core and proximal promoter elements in HDI-mediated SRC repression 
(Kostynuik, et al., 2002; Dehm, et al., 2004).  
 Upon closer examination, it was shown that transcription factor binding was 
maintained in vivo upon treatment with TSA. RNA Polymerase II (RNA Pol. II) 
occupancy was also maintained at both SRC promoter regions despite TSA treatment. 
Upon tracking RNA Pol. II occupancy along the SRC gene, however, RNA Pol. II 
occupancy at the 3’ UTR decreased in response to TSA treatment. Interestingly, the 
amount of time that elapsed before a decrease in Pol. II occupancy could be observed at 
the 3’UTR correlated well with the amount of time required to observe TSA -mediated 
effects on RNA Pol. II occupancy at the promoter region at the most distal ends of the 
gene. Essentially, it appeared as though RNA Pol. II was sequestered to the SRC 
promoter regions. To identify if TSA was abrogating transcriptional initiation or 
elongation, the phosphorylation status of RNA Pol. II upon TSA treatment was 
identified. The phosphorylation of RNA Pol. II suggested that while transcription 
initiation was occurring, a mature transcript was not formed due to the absence of RNA 
Pol II at the 3’ UTR. As such, a role for abrogated transcriptional elongation in HDI -
mediated SRC repression was identified. In support of these observations, transient 
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transfection analysis of SRC reporter constructs were also susceptible to HDI -mediated 
repression. Again, taken together, these results all suggest that a region encompassed in 
the reporter construct, downstream of the transcriptional start site is responsive to HDI -
mediated repression of SRC.  
5.5. Class II HDACs May be Required to Maintain SRC mRNA Levels 
 In contrast to HDI -mediated repression of SRC via abrogated transcriptional 
elongation, other groups have identified that an HDAC is required for transcriptional 
activation at several promoters that are interferon, virus or hypoxia induced. Therefore, 
in these systems, HDIs mediate transcriptional repression through the inhibition of the 
HDAC essential to transcriptional activation (Rascle, et al., 2003; Xu, et al., 2003; 
Chang, et al., 2004; Kato, et al., 2004; Klampfer, et al., 2004; Sakamoto, et al., 2004; 
Nusinzon and Horvath, 2006). Despite innate differences between SRC and these 
systems requiring an HDAC, it was discovered that SRC expression is also dependent 
on a class II HDAC. In contrast to that observed with induced genes, SRC 
transcriptional activation was not enhanced by the presence of an HDAC. Indeed, the 
overexpression of an individual class I or II HDAC often resulted in decreased, not 
enhanced, SRC promoter activity. However, siRNA -mediated knockdowns of HDAC5, 
6, 7 or 10 resulted in an eventual decrease in SRC transcript levels. Recent studies have 
identified that HDIs are capable of disrupting phosphatase/HDAC complexes, resulting 
in aberrant phosphatase activity throughout the cell (Chen, et al., 2005; Alao, et al., 
2006). One example is the disruption of the HDAC6/PP1 complex. Interestingly, both 
the positive elongation factor P-TEFb and the CTD of RNA Pol. II are among the many 
targets of PP1 (Washington, et al., 2002; Ammosova, et al., 2005). The phosphorylation 
of either of these targets is critical in maintaining productive transcriptional elongation 
to yield a mature mRNA transcript. Therefore if HDI treatment inhibited HDAC6 thus 
resulting in aberrant PP1 phosphatase activity targeting either or both of these critical 
components of elongation, expression would be repressed, as a mature transcript could 
not be produced. Interestingly, these events could be easily be occurring downstream of 
the SRC promoters to impede transcriptional elongation.  
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5.6. Future Studies 
 Ideally, to validate this model several studies are required. To identify what role 
if any the above factors have in HDI -mediated repression there are a host of inhibitors 
available including: an inhibitor specific for HDAC6, tubacin, an inhibitor specific for 
P-TEFb, DRB, and a whole arsenal of PP1 inhibitors. In the case of P-TEFb, it would 
be expected that if P-TEFb is inhibited thus preventing SRC transcriptional elongation, 
treatment with DRB would result in SRC repression in a manner similar to what is 
observed with HDI--mediated repression. If tubacin is used to inhibit HDAC6 and SRC 
is still repressed than we have identified that the repression of HDAC6 activity is 
responsible for HDI -mediated SRC repression. Moreover, with the exception of TSA 
and SAHA, many HDIs are specific for one class of HDAC versus another therefore the 
potential involvement of a particular HDAC could be elucidated through the systematic 
investigation of which HDI is capable of repressing SRC.  Finally, if PP1 is mediating 
the elongation abrogating effects on SRC expression, the treatment of cells with a PP1 
inhibitor after treatment of cells with TSA should rescue SRC expression. Regardless, 
of the actual outcome of the inhibitor studies, the information gleaned would be 
invaluable in further characterizing HDI -mediated SRC repression. 
 Unfortunately, there are not ample methods for studying transcriptional 
elongation in vivo. ChIP assays are one method that is frequently utilized, however, 
with this technique it is difficult to identify the precise sequence where elongation is 
attenuated. Despite these difficulties, a great deal could be determined through this 
technique. Many groups have had success with antibodies specific for P-TEFb, NELF 
and DSIF. Moreover, if an amplicon downstream of the SRC promoters was analysed, it 
may be possible to observe greater enrichment in serine 2 CTD RNA Pol. II 
phosphorylation and any changes in this phosphorylation -mediated by HDI treatment 
could be quantified. Alternate techniques, such as RNAse protection assays (RPAs) and 
RT-PCR at particular regions of the transcript, are also possible; however, these 
techniques could prove to be overly problematic depending on where along the 
transcript elongation is terminated. For example, if elongation is curtailed within 100 
bases of the promoter region, the transcript may be too short for identification as well as 
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may degrade too quickly due to a lack of stabilizing co-transcriptional processing such 
as 5’ methyl-guanine capping.  
Despite the technical difficulties that must be addressed, the role of 
transcriptional elongation and class II HDAC(s) in HDI -mediated repression of SRC 
should be clarified. In doing so, the mechanism of repression of the SRC proto-
oncogene by the powerful chemotherapeutics, HDIs, may be determined. Given that 
approximately half of all genes affected by HDIs are repressed, a mechanism for this 
repression is of extreme importance in the development of future chemotherapeutics.              
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